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The serine protease C1s which exists physiologically as C1 complex (C1qr2s2) 
is responsible for the first enzymatic amplification step of the classical 
complement pathway. As a complex, C1q functions as a pattern recognition 
molecule directing C1s to sites where complement activation are required such 
as IgG/IgM bound pathogens and surfaces of apoptotic cells. Activation of the 
classical complement pathway will lead to the eventual clearance of these 
‘waste’.  
 
Of clinical significance is the strong association of congenital complete C1s 
deficiency and juvenile onset systemic lupus erythematosus (SLE), a complex 
autoimmune disease typified by the presence of autoantibodies directed 
against mainly intracellular nuclear components (such as DNA/nucleosomes). 
Two immunological hallmarks of this disease are the formation of pathogenic 
immune complexes and the presence of interferon-α genes response. The 
mechanism of how C1s protects against autoimmunity is not easily explained 
by its traditional role in cleaving complement proteins C4 and C2 which will 
form C3 convertase (C4bC2a) which is responsible for the next enzymatic 
amplification step of the cascade.  
 
In this study, C1s has been found to cleave a novel substrate, high mobility 
group box 1 (HMGB1), a danger associated molecular pattern (DAMP) that 
has important roles in both infective and sterile inflammation. HMGB1 in 
complex with nucleosomes is able to induce a SLE phenotype in mice with the 
formation of autoantibodies. In addition, its presence in SLE immune 
xiii 
 
complexes is necessary for its ability to induce IFN-α production. Cleavage of 
HMGB1 by C1s leads to the loss of its synergistic pro-inflammatory cytokines 
response (TNF-α and IL-6) with LPS on monocytes, macrophages and 
dendritic cells. Of greater significance is the ability of C1 complex to cleave 
HMGB1 that is released from late apoptotic cells. Treatment of the 
interferogenic immune complexes formed from SLE autoantibodies and 
autoantigens derived from apoptotic cells supernatant with C1 complex leads 
to both cleavage of HMGB1 and reduction of its ability to induce IFN-α 
production from peripheral blood mononuclear cells.       
 
This result is significant as accumulation of apoptotic cells can lead to its 
necrosis with release of pro-inflammatory materials known to contribute to 
autoimmunity. If C1s cleaves some of these pro-inflammatory proteins, it 
renders C1s a role in host tolerance and explains its deficiency being causative 
of SLE. This will complement the protective effect of C1q which has already 
been known to be important in the apoptotic cells clearance. 
(391 words)  
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Chapter 1 Introduction  
 
1.1 GENERAL OVERVIEW OF THE IMMUNE SYSTEM  
The immune system consists of a host defensive network of lymphoid organs, 
immune cells, humoral factors and cytokines directed mainly against invading 
infectious agents whilst able to discriminate between the pathogens (nonself) 
from the body’s own cells and proteins (self) (Parkin and Cohen 2001). The 
importance of a functional and tightly regulated system is illustrated clinically 
by disease states of autoimmunity caused by over-activity/dysregulation and 
immunodeficiency with predisposition to severe or opportunistic infections 
caused by under-activity  (Parkin and Cohen 2001). The immune system can 
be divided into the adaptive and the innate responses which differ mainly by 
the mechanism of immune recognition of the receptors and the effector 
responses (Medzhitov and Janeway 2000; Parkin and Cohen 2001).  
 
The adaptive compartment consists of specialised T and B cells with a large 
repertoire of antigen receptors generated through somatic recombination and 
mutation (Tonegawa 1983; Tonegawa 1988; Medzhitov and Janeway 2000). 
This mechanism generates diversity with the number of potential B and T cell 




 respectively. In contrast, the whole 
human genome contains a relatively small number of protein encoding genes 
(approximately 22,000) (Pertea and Salzberg 2010). This diversity of B and T 
cell receptors allows the immune response to adapt to the heterogeneous group 
of microbes that can mutate and change over time (Medzhitov and Janeway 
2000). Specificity is conferred to the adaptive response by these receptors. 
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However, its response to control the invading microbes is delayed as time is 
required (three to five days) to generate sufficient number of effector cells 
from their initial small number through clonal expansion (Medzhitov and 
Janeway 2000). Concurrently, during clonal expansion, memory B and T cells 
are generated which allow for a rapid secondary immune response on repeated 
challenge with a similar pathogen (Vitetta, Berton et al. 1991). In summary, 
the adaptive immune response exhibits diversity, specificity and 
immunological memory.    
 
The innate compartment consists of elements such as neutrophils, monocytes, 
MΦ, complement, cytokines, and acute phase proteins (Parkin and Cohen 
2001). It differs distinctively by the recognition mechanism of their receptors 
focusing on few, highly conserved structures present in large groups of 
microorganisms collectively known as PAMPs (Janeway 1989). 3 common 
characteristics of PAMPs include: 1) poly-specificity, 2) self-nonself 
discrimination and 3) ability to elicit a rapid response (Janeway 1992). Poly-
specificity is conferred by PAMPs being common constituents of pathogenic 
microbes such as LPS, mannans, glycans, bacterial DNA and double-stranded 
RNA that cannot be easily altered without major changes to its core structure. 
Discrimination from self is the result of PAMPS being not found in the host. 
Finally, as PAMPs are recognized by PRRs found on many innate effector 
cells that are already present, for example MΦ and DCs, this results in the 
rapidity of the innate response as no prior clonal expansion is required 
(Janeway 1992; Medzhitov and Janeway 2000). Hence, a key function of 
PAMPs is to alert and poise the innate immune compartment to respond to 
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exogenous danger signals from invading pathogens that can result in injuries 
to the host.  
 
Danger signals from within the host, known as alarmins, can arise from sterile 
injuries (Bianchi 2007). This can occur with trauma, ischemia due to 
disruption of blood supply to vital organs (for example acute myocardial 
infarction), and autoimmunity. Like PAMPs, alarmins can also elicit an innate 
response. Collectively, alarmins (endogenous danger signals) and PAMPs 
(exogenous pathogen related danger signals) are known as DAMPs (Bianchi 
2007). Important examples of alarmins include HMGB1, S100 proteins and 
heat shock proteins among others (Lotze and Tracey 2005; Bianchi 2007). An 
appropriate immune response in health to an alarmin is important as it leads to 
the resolution of the injury and repair of the damaged tissue (Andersson and 
Tracey 2011). However, an exaggerated or inappropriate response can lead to 
disease states with further tissue damage or autoimmunity.   
 
Functionally, PRRs can be divided into three classes: 1) secreted, 2) endocytic, 
and 3) signaling with different resultant effector mechanisms (Medzhitov and 
Janeway 2000). Secreted PRRs include ficolins and MBL; which are important 
in the complement system (Lu, Thiel et al. 1990; Lu, Le et al. 1996; Lu, Wu et 
al. 2007). Their main roles include opsonisation of microbes for removal via 
phagocytosis through complement receptors and activation of the complement 
system to generate more opsonins, anaphylatoxins for immune cells 
recruitment and MAC formation with bacterial lysis (Lu, Thiel et al. 1990; 
Epstein, Eichbaum et al. 1996; Fraser, Koziel et al. 1998; Lu, Wu et al. 2007). 
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Endocytic PRRs are found on the surfaces of phagocytes such as MΦ and DCs 
allowing for the uptake of microbes for its delivery to the lysosomes for 
subsequent destruction (Medzhitov and Janeway 2000). The signaling PRRs 
are typified by the TLRs which when ligated will lead to downstream 
signaling with activation of immune response genes leading to the release of 
cytokines (TNF-α, IL-6), chemokines and increase expression of surface co-
stimulatory molecules (Janeway and Medzhitov 2002; Takeda, Kaisho et al. 
2003; Akira and Takeda 2004). The main role of PRRs thus is to eliminate the 
source of the danger signals (DAMPs) by various effector mechanisms so as to 
restore a homeostatic state.  
 
Although the immune system is divided into the innate and adaptive 
compartments, significant cross talk and synergy exists between the two with 
DCs at the interface. DCs are recognised as sentinels that act to survey the 
tissue environment through a wide array of PRRs (Akira, Uematsu et al. 2006; 
Takeuchi and Akira 2010). These PRRs enable DCs to mature in response to 
danger signals and function as professional APC interacting with naïve T-cells 
through a 3 signals process: 1) endocytic antigen uptake, processing, and 
presentation onto MHC class II, 2) co-stimulatory molecule expression and 3) 
cytokines (such as IL-12 a T-cell stimulating factor) (Janeway and Medzhitov 
2002).  
 
A clinically significant application of using these PAMPs is in the harnessing 
of their adjuvant innate effect to promote the adaptive immune response to 
develop vaccines against specific antigens on pathogenic microbes (Bendelac 
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and Medzhitov 2002). In addition, PRRs on DCs can also be used to direct 
antigen specifically to them so that an antigen specific adaptive response can 
be generated. DEC-205 on DCs has been used in this manner through 
engineered anti-DEC-205 monoclonal antibody with the antigen expressed in 
its heavy chain (Steinman 2012). This is an elegant example on how an innate 
compartment recognition receptor can be used to generate an adaptive 
response. In disease, the intimate relationship between the two immune 
responses is found in the rare monogenic deficiency of the early classical 
complement factors (innate compartment), which causes predisposition to 
certain infections but at the same time, greatly increases the risk of juvenile 
SLE, an autoimmune disease typified by the formation of autoantibodies from 
B cells (adaptive compartment) (Pickering, Botto et al. 2000; Cheng and 
Anderson 2012).    
 
1.2 INNATE IMMUNITY: THE DCS AS SENTINELS  
 
1.2.1 Role in microbial sensing 
DC is the elusive gatekeeper of adaptive immune response discovered by 
Nobel laureate Ralph Steinman in 1973 by its ability to initiate a vivid T cell 
response (Steinman and Cohn 1973; Steinman and Witmer 1978). In order to 
act as sentinels to survey the environment and bridge the innate and adaptive 
immune response, DCs are endowed with a wide array of PRRs. These PRRs 
of which the TLRs are the most important; are able detect the presence of 
invading microbes by their different signature molecular patterns in the form 
of PAMPs. A total of 10 TLRs have been identified in humans (Takeuchi and 
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Akira 2010). The TLRs recognise different ligands and can be classified based 
on their cellular localisation: extracellular on the cell surface or intracellular 
within endosomal compartments (Table 1.1).  
Table 1.1: Human TLRs. Adapted from Takeuchi and Akira 2010. 
 TLR Localisation Ligand Origin of Ligand 





TLR2 Plasma membrane 
 
Lipoprotein Bacteria, viruses, parasites 
 
TLR3 Endolysosome dsRNA Virus 
 
TLR4 Plasma membrane LPS Bacteria, viruses 
 
TLR5 Plasma membrane Flagellin Bacteria 
 
TLR6 Plasma membrane Diacyl lipoprotein 
 
Bacteria, viruses 
TLR7 Endolysosome ssRNA 
 
Virus, bacteria 





Endolysosome CpG-DNA Virus, bacteria, protozoa 
TLR10 
 
Endolysosome Unknown Unknown 
 
The selective activation of specific TLRs can yield distinct types of immune 
responses. For example, the endolysosomal set of TLRs (TLR3, TLR7, TLR8, 
and TLR9) recognises nucleic acids derived from viruses and bacteria, as well 
as endogenous nucleic acids in pathological states leads to the production of 
type I IFNs (Akira, Uematsu et al. 2006).  
 
Although the TLRs’ primary role is the sensing for exogenous danger signals, 
there is increasing evidence that DCs can also respond to endogenous signals 
(DAMPs) such as HMGB1, nucleosomes and DNA containing ICs release as a 
result of sterile host injuries and inflammation (Nace, Evankovich et al. 2012). 
Alarmins, such as HMGB1, have an adjuvant effect and is able to activate DCs 
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in a similar manner to PAMPs and mediate the adaptive immune response 
(Gallucci, Lolkema et al. 1999; Rovere-Querini, Capobianco et al. 2004). 
These alarmins are likely to mediate pathological adaptive responses in 
disease states such as autoimmunity where they activate DCs to initiate an 
abnormal response against self-antigens.  
 
The main role of DCs is to bridge the innate and adaptive responses to mediate 
and control the antigen specific response to a myriad of pathogens (Steinman 
2012). Immature DCs possess high endocytic and phagocytic capacity to 
capture antigen but expresses low levels of MHC class II molecules and co-
stimulatory molecules (Trombetta and Mellman 2005). Upon exposure to the 
presence of microbes in the forms of PAMPs that ligate the TLRs, DCs 
maturation occurs. This involves 1) cytoskeletal reorganisation and the 
acquisition of cellular mobility to home in to lymphoid tissues where naïve T-
cells are located, 2) downregulation of endocytic and phagocytic receptors,  3) 
expression of high levels MHC II and co-stimulatory molecules such as CD40, 
CD80 and CD86 and, 4) secretion of cytokines that polarise the adaptive 
immunity (Trombetta and Mellman 2005). 
 
Consequently, the matured DCs migrate to the secondary lymphoid organs 
such as lymph nodes via the afferent lymphatics towards the T cell region 
(Randolph, Angeli et al. 2005). The functional matured DCs scan through the 
numerous naïve T cells, and activate the specific cognate TCR which binds to 
the antigen loaded MHC on the DCs. This is done through a 3 signals process 
involving: 1) antigen presentation onto MHC class II, 2) co-stimulatory 
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molecule expression and 3) cytokines (such as IL-12 a T-cell stimulating 
factor (Janeway and Medzhitov 2002). The polarisation of T-cells into Th1, 
Th2, Th17 or Treg cells for different effector mechanism is dependent on the 
DCs’ cytokines pattern (Dong 2010).  
 
1.2.2 DCs subsets  
Research on the molecular markers and function of different DCs subsets is an 
ever increasing and expanding field (Steinman and Idoyaga 2010). Different 
DCs subsets in humans have been shown to elicit different immune responses 
through different T cells polarisation (Ueno, Schmitt et al. 2010). The 
importance of the necessity of the correct type of T cells polarisation by DCs 
in diseases is commonly illustrated with the use of leprosy. The tuberculoid 
form of the disease is characterised by a Th1 response which keeps the disease 
in check, while the lepromatous form as a result of Th2 response is fatal 
(Yamamura, Uyemura et al. 1991). However, as our project only involves the 
2 DCs subsets, pDCs and moDCs, they will be reviewed here.   
 
1.2.2.1 PDCs 
PDCs represent a subset that is distinct in morphology, phenotype and 













blood precursors (Grouard, Rissoan et al. 1997; Dzionek, 
Fuchs et al. 2000; Liu 2005). PDCs express TLR7 and TLR9 as their main 
PPRs and secrete large amount of IFN-α in response to viral PAMPs (Siegal, 
Kadowaki et al. 1999). IFN-α has been linked to SLE pathogenesis as the 
cytokine has been shown to be elevated in SLE patients since a few decades 
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ago and this is further supported with recent microarray studies demonstrating 
a IFN--related transcriptional signature (Hooks, Moutsopoulos et al. 1979; 
Crow, Kirou et al. 2003). Since pDCs are the most potent secretor of IFN-α, 
they have been strongly implicated in SLE pathogenesis (Chan, Nie et al. 
2012).  
 
SLE is an autoimmune disease characterised by formation of pathogenic IgG 
against numerous autoantigens mainly intracellular in location (more than 100 
has been described) (Sherer, Gorstein et al. 2004). PDCs may play a role as 
they have been shown to induce the expansion and differentiation of antigen-
specific memory B cells into IgG secreting plasma cells through the sequential 
action of type 1 IFN (IFN-α/β) generating non Ig-secreting plasma blasts and 
IL-6 inducing their differentiation into Ig-secreting plasma cells (Jego, 
Palucka et al. 2003). The presence of these autoantibodies will result in the 
formation of circulating ICs that are potent inducer of IFN-α production in in-
vitro studies involving both human PBMCs and pDCs (Bave, Alm et al. 2000; 
Lovgren, Eloranta et al. 2004; Lovgren, Eloranta et al. 2006).  
 
In our project, pDCs are studied indirectly through the use of human PBMCs 
with IFN-α as a read out in response to SLE ICs, formed from SLE patient’s 
serum and autoantigens from apoptotic U937 cells, as previously described 
(Santer, Hall et al. 2010). Santer and colleagues showed that IFN-α production 
was not detected when pDCs depleted PBMCs were stimulated by these SLE 
ICs demonstrating that pDCs were the main IFN-α producers. The use of 
PBMCs allows for greater ease of preparation without further purification 
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steps and also prevents the difficulty of obtaining sufficient pDCs for in-vitro 
studies as they constitute only a small percentage of the PBMCs population 
(0.1 to 0.7% of PBMCs) (Santer, Hall et al. 2010).   
 
1.2.2.2 Monocytes derived DCs 
The most commonly used human DCs for in-vitro studies are the moDCs as 
sufficient numbers of monocytes from human blood samples can be easily 
obtained and be differentiated to DCs through culturing with GM-CSF and IL-
4 (Sallusto and Lanzavecchia 1994).  
 
Numerous studies have utilised moDCs in the investigation of the effect of 
various molecule on the adaptive immune response. This is commonly done 
by looking at the following 4 aspects: 1) maturation markers expression which 
is a function of the ability of the moDCs to present antigens effectively to T 
cells, 2) cytokines profile of the moDCs determining whether it is in a pro- or 
anti-inflammatory state, 3) allogeneic T cells proliferation test/MLR to 
demonstrate whether points 1 and 2 provide the necessary signals require to 
cause T cells expansion, and 4) cytokines profile of the moDCs and allogeneic 
T cells reaction to determine the polarisation of the T cells.  
    
1.3 INNATE IMMUNITY: THE COMPLEMENT SYSTEM 
 
1.3.1 Pathways of the complement system    
The complement system consists of a large group of about 35 plasma and host 
cell surface proteins including recognition molecules (PRRs), serine protease 
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proenzymes, and regulatory proteins (Sim and Tsiftsoglou 2004). It was 
discovered by Nobel Prize winner, Jules Bordet during the 1900s, as heat 
liable serum components that enhanced the bacteriolytic effect of antibodies. 
Since these factors ‘complement’ the effects of antibody, the name of 
complement system was given. 
 
Their main function is the recognition of both exogenous and endogenous 
danger signals (DAMPs) and the clearance of their sources; namely invading 
microbes and damaged host cells respectively (Sim and Tsiftsoglou 2004). The 
system can be activated through 3 recognition pathways: 1) the classical, 2) 
alternative and 3) lectin pathways. This leads to a series of proteolytic, 
amplification steps culminating in the generation of three important effector 
interfaces: 1) opsonic fragments, 2) inflammatory anaphylatoxins and 3) MAC 
(Figure 1.1) (Reid 1986).  
 
1.3.1.1 The classical pathway  
C1q is the recognition molecule of the classical pathway and it binds to IgG or 
IgM on antibody-coated pathogens or in Ig aggregates (Figure 1.1) (Reid 
1986). However, other than antibody-mediated (IgG/IgM) complement 
response, non-antibody activators are present including some gram negative 
bacteria (Escherichia coli) (Tenner, Ziccardi et al. 1984), cellular and 
subcellular structures from damaged cells, proteins (CRP, myelin, β-amyloid 
peptide, and serum amyloid P component), carbohydrates, lipids and 





Figure 1.1: Complement system.The 3 different complement initiation pathways are 
shown. The classical pathway is initiated mainly by C1q binding to antibody coated 
pathogens. This results in the activation of C1r and C1s and eventual cleavage of C4 
to C4a and C4b. C4b binds to the surface of the pathogen and recruits C2 which is 
cleaved by C1s leading to the formation of C3 convertase (C4bC2a). C3 convertase 
will cleave C3 to C3a and C3b. C3b acts as a potent opsonin as well as participate in 
the formation of C5 convertase in association with C4bC2a. C5 convertase will 
mediate the last proteolytic step cleaving C5 to C5a and C5b. C5b acts as a nucleus 
for the recruitment of C6, C7, C8 and C9, to form the lytic complex (MAC) that will 
destroy its target. The lectin pathway does not require antibody and is initiated by 
direct binding of MBL to carbohydrate moieties on pathogens. MASPs are functional 
homologues of C1r and C1s, which will cleave C4 leading to the convergence of the 2 
different initiating event down the same path. The alternative pathway is initiated by 
continuous low level activation of C3 (tick-over levels). It is selectively amplified on 
pathogen surfaces due to its lack of inhibitory molecules. C3bBb and C3bBbC3b are 
its C3 and C5 convertase. C3b and C4b are two of the complement opsonic 
fragments. C3a and C5a are anaphylatoxins that will recruit inflammatory cells to the 
site of complement activation. All the complement proteases, proenzymes and active 
forms, (C1r, C1s, C2, MASPs, factor B (fB) and factor D (fD)), and their 
proteolytic steps are in red. Complement inhibitors are omitted for simplicity.       
 
C1q is a large 18-subunit protein formed from six each of the C1qA, C1qB 
and C1qC chains, each being coded by a separate C1q gene (Kishore and Reid 
2000; Lu, Teh et al. 2008). In blood circulation, C1q exists as a pentameric 
complex consisting of the recognition molecule C1q and the tetramer of two 
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serine proteases C1r and C1s (C1s-C1r-C1r-C1s). Binding of C1q to its 
ligands will lead to a conformation change that will result in mechanical 
stresses causing the autolytic cleavage and activation of C1r and C1r cleavage 
of C1s (Budayova-Spano, Lacroix et al. 2002). C1s will sequentially cleave 
C4 and C2 to initiate the complement cascade (Reid 1986; Kishore and Reid 
2000).  
 
The amplification process is achieved at 3 proteolytic steps mediated by C1s, 
C3 convertase (C4bC2a) and C5 convertase (C4bC2aC3b). Binding of an 
additional C3b to C4bC2a changes the specificity of the complex from C3 to 
C5 but the enzymatic active site remains at C2a (Reid 1986). Complement 
activation will lead to the deposition of opsonic C4 and C3 fragments (C4b 
and C3b), release of pro-inflammatory C3a and C5a fragments and MAC 
formation (Reid 1986). 
 
1.3.1.2 The alternative pathway  
Complement C3 is constantly activated at tick-over levels but it is selectively 
amplified on pathogen surfaces due to the lack of inhibitory molecules 
(Pangburn, Schreiber et al. 1981; Bexborn, Andersson et al. 2008). The 
alternative pathway equivalent C3 and C5 convertase homologues are C3bBb 
and C3bBbC3b respectively (Figure 1.1) (Reid 1986).    
 
1.3.1.3 The lectin pathway  
The lectin pathway is triggered after binding of MBL or ficolins to 
carbohydrate moieties on pathogen surface (Figure 1.1) (Matsushita and Fujita 
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1992; Fujita, Matsushita et al. 2004). Unlike C1q, MBL and ficolins acts as 
PRRs binding directly to pathogens without requiring antibody sensitisation 
(Duncan, Wijeyewickrema et al. 2008). MASP-2 is the main MASPs 
responsible for downstream cleavage of C4 and C2 leading to its convergence 
with the classical pathway (Duncan, Wijeyewickrema et al. 2008).        
 
1.3.2 Deficiencies of early classical complement factors and diseases    
Deficiency of any classical complement factors (C1 to C9) has been associated 
with increase susceptibility to infections (Rother 1986). This is intuitive as the 
complement system plays a critical role in the initial innate immune response 
against invading microbes (Parkin and Cohen 2001). However, of interest is 
the association of the deficiency of the early classical complement factors, 
C1q, C1r, C1s, C4 or C2, with both an immunodeficient state and 
autoimmunity, specifically SLE (Rother 1986; Pickering, Botto et al. 2000). 
This is an apparent paradox because of 2 reasons. 1) Susceptibility to 
infections signifies an under-activity of the immune response 
(immunodeficiency) while autoimmunity suggests a hyperactive or 
dysregulated state. 2) The complement system is part of the innate response 
while SLE is an autoimmune disease involving the B cells (adaptive immune 
response) (Rahman and Isenberg 2008).  These observations suggest that the 
early classical complement factors protect against the development of 
autoimmunity and that there is cross talk between the complement system and 




SLE is a systemic, autoimmune disease characterised by the presence of 
numerous autoantibodies directed against mainly nuclear autoantigens (Sherer, 
Gorstein et al. 2004). Subsequent organ injuries are believed to be caused by 
the deposition of ICs and complement activation (Rahman and Isenberg 2008). 
Logically, the formation of autoantibodies will require the following: 1) 
availability of autoantigens to be taken up, processed and delivered by 
professional APCs to autoreactive T cells, 2) presence of autoreactive T and B 
cells, and 3) loss of tolerance (Walport 2001). The involvement of the early 
classical complement factors in these areas will be covered.    
 
1.3.2.1 C1q and autoimmunity 
Since congenital C1q deficiency was first described in 1977, there are 
currently 64 cases reported worldwide (Cheng and Anderson 2012). It is the 
most common deficiency among the 3 factors that make up C1 complex 
(C1qr2s2) and has the highest disease penetrance in causing SLE (Pickering, 
Botto et al. 2000; Lewis and Botto 2006). 93% of congenital complete C1q 
deficiency patients will develop lupus as compared to 57%, 75% and 10% for 
C1r/s, C4 and C2 deficiencies respectively (Lewis and Botto 2006). Thus, the 
molecular basis for hereditary C1q deficiency is also the best defined 
(Pickering, Botto et al. 2000; Abe, Endo et al. 2009).  
 
ACs are believed to be the source of autoantigens (Casciola-Rosen, Anhalt et 
al. 1994). This is supported by in-vivo study where mice injected with 
syngeneic ACs formed autoantibodies (Mevorach, Zhou et al. 1998). Rapid 
clearance of ACs is expected to reduce autoimmune reactions by removing 
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them before the autoantigens are released and be available to the adaptive 
immune system (Walport 2001; Pittoni and Valesini 2002; Munoz, van Bavel 
et al. 2008).  
 
C1q binds to ACs from different cell types including keratinocytes (Korb and 
Ahearn 1997), HeLa cells (Paidassi, Tacnet-Delorme et al. 2008; Paidassi, 
Tacnet-Delorme et al. 2008), human PBMCs and vascular endothelial cells 
(Navratil, Watkins et al. 2001). Binding is targeted at the ACs surface blebs, 
where it is rich in SLE autoantigens, and is mediated by C1q globular heads 
(Casciola-Rosen, Anhalt et al. 1994; Navratil, Watkins et al. 2001). C1q 
ligands on ACs include: phosphatidylserine (Paidassi, Tacnet-Delorme et al. 
2008), DNA (Jiang, Cooper et al. 1992; Elward, Griffiths et al. 2005; Paidassi, 
Tacnet-Delorme et al. 2008), and calreticulin (Ogden, deCathelineau et al. 
2001). C1q binding to ACs can occur as a terminal event leading to its 
opsonisation without complement activation (Ogden, deCathelineau et al. 
2001) or cause complement activation with downstream deposition of C3b, a 
potent opsonin, on late ACs mediated by IgM (Zwart, Ciurana et al. 2004; 
Ogden, Kowalewski et al. 2005; Quartier, Potter et al. 2005). However, on 
ACs, complement activation appears to terminate at the level of C3 deposition 
(Elward, Griffiths et al. 2005). Rapid removal of ACs is expected to reduce 
stimulation of autoreactive B cells and minimise release of pro-inflammatory 
molecules associated with secondary necrosis (Urbonaviciute, Furnrohr et al. 
2008). However, C1q role in tissue debris clearance alone does not completely 
explain its protective role against SLE as other molecules such as MBL, a 
functional C1q homologue, also binds to ACs and aids in its removal through 
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phagocytosis (Ogden, deCathelineau et al. 2001) but has no convincing link 
with SLE (Monticielo, Mucenic et al. 2008; Tsai, Yao et al. 2009).   
 
C1q modulatory role on DCs may provide the additional mechanism to explain 
its protective role against SLE (Nayak, Ferluga et al. 2010; Ghebrehiwet, 
Hosszu et al. 2012). The effects of C1q on pDCs will be discussed here. PDCs 
express LAIR-1, an inhibitory C1q receptor with 2 cytoplasmic ITIM domains 
(Meyaard, Adema et al. 1997; Meyaard 2008; Bonaccorsi, Cantoni et al. 
2010). Cross-linking of LIAR-1 will cause phosphorylation of its ITIM 
tyrosine residues by a Src kinase, leading to downstream inhibitory activity 
(Xu, Zhao et al. 2000). C1q ligation and antibody cross-linking of LAIR-1 has 
been shown to decrease pDCs IFN-α secretion from CpG-ODN (Son, 
Santiago-Schwarz et al. 2012) and SLE ICs respectively (Bonaccorsi, Cantoni 
et al. 2010). Another mechanism that is potentially involved is the diversion of 
immuno-stimulatory SLE ICs from pDCs to monocytes resulting in reduced 
pDCs stimulation (Santer, Hall et al. 2010). The immuno-modulatory role of 
C1q is supported further by recent microarray expression study of PBMCs 
treated with SLE ICs in the presence of C1q and  downregulation of IFN-α 
response genes has been observed (Santer, Wiedeman et al. 2012).  
 
1.3.2.2 C1r/s and autoimmunity  
Hereditary deficiencies of C1r and C1s tend to occur concomitantly (Loos and 
Heinz 1986). In most cases, a predominant complete deficiency of either C1r 
or C1s was associated with a partial or almost complete deficiency of the 
other. The reason is unclear but not surprising as C1s and C1r are related 
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intimately in many ways: 1) C1r and C1s genes are in close proximity on the 
short arm of chromosome 12 within a distance of 9.5 kilobases (Kusumoto, 
Hirosawa et al. 1988), 2) C1r and C1s plasma concentration in healthy 
subjects are very similar suggesting that they are regulated similarly (Reid 
1986), and 3) C1r is critical in the formation of C1 complex and in its absence, 
there is inadequate association of the remaining components of C1 complex 
for its haemolytic function (Pickering, Naff et al. 1970).  
 
To date, since the last major review in 2000 by Pickering and Botto where a 
total of 14 C1r and/or C1s deficiency cases were identified (Pickering, Botto et 
al. 2000), another 8 new cases were added (Dragon-Durey, Quartier et al. 
2001; Amano, Ferriani et al. 2008; Abe, Endo et al. 2009; Bienaime, Quartier 
et al. 2010; Wu, Brookshire et al. 2011). C1r/s deficiency is rare as compared 
to C1q deficiency and the mechanism of its protective effect against SLE is the 
least studied among the early complement factors (C1q, C1r/s and C4). 
Published cases with complete C1r and/or C1s deficiency with their genetic 
mutations defined are summarised in table 1.2.  
 
In addition, C1r/s importance in the protection against SLE pathogenesis is 
illustrated in a case report of a lupus patient with normal serum C1q level but 
defective binding to C1r2C1s2 and impaired complement activation 
(Roumenina, Sene et al. 2011). The mutation in C1q B-chain (homozygous 
GlyB63Ser) had otherwise normal binding to other C1q ligands including 
IgG/IgM, CRP, pentraxins and ACs. Although binding to ACs was normal, C3 
deposition was absent consistent with the lack of complement activation.    
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Table 1.2: Features of clinical cases with complement C1r and/or C1s deficiency 
with gene mutations defined.
  Complement 
factor deficiency 
(mutation) 

















1/female/malar rash (sun 
exposure), polyarthritis, 
oral aphthous ulcers, digital 
pulp vasculitis, 
Hashimoto’s thyroiditis, 
nephritis and hepatitis. 
Increase susceptibility to 
infections./no family 
history(non-








2) CH50 0, and 
3) Increase in C3 




















Decrease C1r   
7/female/SLE 
manifestations including 


















   
 
1) ANA and anti-
Sm positive,  
2) CH50 0,  
3) C3 normal and 
C4 increase, 
4) IgG and C1q: 
renal biopsy IF.   
 
1) ANA and anti-
Sm positive,  
2)CH50 0, and 
3) C3 normal and 
C4 increase.   
 
1) CH50 0, and  
2) C3 normal and 
C4 increase.   
 
1) CH50 0, and  
2) C3 normal and 
C4 increase.   
 
(Amano, 









with 4 bp 
deletion leading 









but no SLE manifestations. 
At 6 year old had fever of 
unknown origin followed 
by convulsive fit and loss 
of consciousness.  Died at 
age 7 without regaining 
consciousness./no family 
history of SLE but cousins 
with complete C1s 
deficiency. 
1) CH50 0, and  
2) C3 and C4 
normal. 
(Endo, 
























(Deletion of 4 bp, 







manifestations: malar rash, 
chronic glomerulonephritis 




1) ANA 1/160 
and anti-dsDNA 
positive, 
2) Anti-Sm and 
anti-RNP 
negative,  
3) CH50 0,  
4) C3 normal and 
C4 increase, and  
5) Renal biopsy 
IF: positive for 
IgG and C3.   
 
(Suzuki, 
Ogura et al. 
1992; Inoue, 












C1r decrease  
 
13/female/recurrent fever 
of unknown origin, 
recurrent sacroiliac 
arthritis, hypersensitivity to 
multiple antibiotics./no 
family history of SLE but 
positive history for 
complete C1s deficiency. 
 
11/male/recurrent 
infections/ no family 
history of SLE but positive 
history for complete C1s 
deficiency.   
 
1) ANA (1/640) 
but anti-dsDNA 
negative, 
2) CH50 0, and  





1) ANA (1/40) 
but anti-dsDNA 
negative, 
2) CH50 0, and  













C1s decrease  
 
 
3 months/male/discoid rash, 
transverse myelitis, diffuse 
proliferative 
glomerulonephritis./family 
history of SLE (sister)  
1) ANA (1/80), 
anti-dsDNA and 
anti-Sm positive, 
2) CH50 0,  
3) C3 and C4 
increase, and  
4) Renal biopsy 
IF: positive for 
IgG, IgA, IgM, 









CH50, 50% haemolytic complement activity of serum; anti-Sm, anti-Smith antibody; 





C1r and C1s are 2 of the 3 proteases in the classical complement pathway 
which includes complement protein C2. Both C1r and C1s are specific 
proteases with C1r cleaving C1s and activating it. Activated C1s then cleaves 
the complement proteins C4 and C2. In terms of substrate specificity, C1s is 
the only known substrate of C1r but other C1s substrates have been described  
giving rise to its potential of having other physiological roles outside of the 
complement pathway (Eriksson and Nissen 1990; Nissen, Roepstorff et al. 
1990; Yamaguchi, Sakiyama et al. 1990; Busby, Nam et al. 2000; Naito, 
Sumida et al. 2012). Of interest is the association of C1r/s deficiency with 
autoimmunity which the classical function of C1r/s does not adequately 
explain.  
 
The substrate specificity of C1s, determined through the use of bioinformatics 
with a protease specificity model and search of the human proteome, is 
believed to involve many other intracellular proteins (Kerr, O'Brien et al. 
2005). This, when taken into context of the perfect interacting condition on 
ACs surfaces between C1s, recruited as C1 complex, and the exposed 
intracellular proteins make it plausible that novel cleavage substrates may be 
present of which some may have a role in SLE pathogenesis (alarmins and 
autoantigens). If the cleavage of these proteins leads to a loss of their 
pathogenic contribution to SLE, it will help to explain C1s protective effect.   
 
1.3.2.3 C4 and autoimmunity  
As C4 is not the main complement factor of interest in this project, its role in 
SLE pathogenesis will only be briefly covered. Other than its involvement in 
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the formation of the classical pathway C3 convertase (C4bC2a) which will  
cleave soluble C3 and deposit C3b onto the surfaces of the microbes or 
damaged cells for its clearance by phagocytosis, C4 and its receptor, CD35 
(CR1), play an important role in B cell tolerance (Carroll 2004). This is 
believed to be achieved through 2 mechanisms. Firstly, C4b-self-antigen 
complex that is formed after complement activation on ACs can bind to bone 
marrow and spleen stromal cells through CD35 (CR1). These stromal cells 
facilitate the presentation and concentration of these self-antigens to the 
developing autoreactive B cells so they will be negatively selected once a 
critical stimulatory threshold is reached. C4b and its receptor enhance this 
process by concentrating these autoantigens such that the threshold required 
for negative selection is reduced. This will lead to the removal of autoreactive 
B cells. Secondly, the C4b-self-antigen complex is believed to also bind to 
CR1-CD19-CD81 co-receptors and the autoreactive B cell receptor found on 
immature B cells. This will result in the stimulation of the immature auto-
reactive B cells leading to its negative selection (Carroll 2004).              
 
Experimental evidence to prove the role of C4 in B cell tolerance involved 
crossing C4 or C4 receptors deficient mice with mice carrying transgenes for 
both hen-egg lysozyme (HEL)-specific Ig and soluble HEL (Prodeus, Goerg et 
al. 1998). HEL-specific B cells failed to develop properly and were anergised 
in mice carrying both the transgenes for HEL-specific Ig and soluble HEL 
(Goodnow, Cyster et al. 1995). This was due to the exposure of the HEL-
specific B cells to its cognate antigen, soluble HEL, during the development 
phase of B cell leading to negative selection and development of tolerance. 
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However, when these double transgenes mice were crossed with C4 or C4 
receptors deficient mice, there was a loss of the HEL-specific Ig B cell anergy 
(Prodeus, Goerg et al. 1998). More importantly, when C4 or C4 receptors 
deficient mice were combined with a lupus-like murine model of CD95 (Fas) 
deficiency, the disease was more severe with higher ANA titres. These 
findings suggest an important role of C4 and its receptors in the development 
of B cell tolerance.  
 
Relatively, much more is known about C1q and C4 contribution to SLE 
pathogenesis as compared to C1s, the subsequent part of this chapter will 
highlight the importance of C1s as a classical pathway serine protease and 
developing the hypothesis of how it may provide protection against 
autoimmunity.  
 
1.3.3 Serine protease C1s   
 
1.3.3.1 Source of C1s    
Both C1r and C1s are glycoproteins of approximately 83kDa. They are 
produced as a single chain protein that is activated by cleavage into heavy (56 
kDa) and light (27kDa) chains (Reid 1986). C1r and C1s are produced 
predominantly in the liver but are also produced in the kidney, and cells of the 
nervous system (Kusumoto, Hirosawa et al. 1988), fibroblasts (Reid and 
Solomon 1977), MΦ (Muller, Hanauske-Abel et al. 1978), chondrocytes 
(Nakagawa, Sakiyama et al. 1997) and monocytes (Chevailler, Drouet et al. 
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1994). The location of production is important as it may provide clues to its 
physiological or pathological role.   
 
1.3.3.2 Structure of C1s   
C1s consists of 688 amino acids including a 15 amino acid leader sequence 
(Spycher, Nick et al. 1986; Mackinnon, Carter et al. 1987; Tosi, Duponchel et 
al. 1987). During C1 complex activation, it is cleaved by C1r at the peptide 
bond between Arg437 and Ile438 found within the serine protease domain, 
converting it into a 2 chains structure (the heavy chain from amino acid 
residues 16 to 437, and the light chain from amino acid residues 438 to 688). 
Under physiological condition, the 2 chains are held together by a disulfide 
bridge (Gal, Ambrus et al. 2002). 
 
Structurally, C1s like its other serine protease family members (C1r, MASP1, 
MASP2 and MASP3) have identical domain organisation and similar overall 
structure. All these enzymes are modular and consists of 6 domains (Figure 
1.2) (Gal, Barna et al. 2007). From the N-terminal, it comprises a CUB 
domain (CUB1) (Bork and Beckmann 1993) followed by an EGF-like domain 
(Campbell and Bork 1993), CUB2 domain, two CCP domains (Reid, Bentley 
et al. 1986) and a C-terminal serine protease domain (Gal, Barna et al. 2007). 
The C1r and C1s N-terminal CUB1-EGF-CUB2 domains are responsible for 
the Ca
2+
 dependent interaction between the two serine protease monomers and 
its interaction with C1q  (Thielens, Enrie et al. 1999; Gal, Barna et al. 2007; 
Bally, Rossi et al. 2009). The C1r and C1s C-terminal CCP1-CCP2-serine 




Figure 1.2: Domain organisation of C1s.The modular structure is similar in C1r, 
C1s, MASP1, MASP2 and MASP3. The N-terminal CUB1 (residues 16 to 128)-EGF 
(residues 129 to 174)-CUB2 (residues 175 to 289) domains are responsible for the 
Ca
2+
 dependent protein-protein interaction between the C1r homodimer and C1r-C1s 
heterodimer which are critical for the formation of the C1s-C1r-C1r-C1s tetramer 
(Thielens, Enrie et al. 1999). They also mediate the tetramer interaction with C1q 
forming C1 complex (Bally, Ancelet et al. 2013). The C1s catalytic fragment, 
consisting of the CCP1 (residues 290 to 355)-CCP2 (residues 358 to 422)-serine 
protease (residues 423 to 688) domains, has the active site and exosites for interaction 
with its substrate C4 (Rossi, Bally et al. 1998; Duncan, Mohlin et al. 2012). (Adapted 
from Gal, Ambrus et al. 2002.)   
 
  
1.3.3.3 C1s as a complexed complement protease (C1 Complex) 
C1s occurs and function physiologically as a complex with C1q and C1r (Reid 
1986). C1q is the recognition molecule that directs C1s to the location where 
complement activation is required. In addition, C1s is enzymatically more 
efficient when it exists as a complex. This was objectively measured by its 
catalytic efficiency (kcat/Km) alone and as C1 complex in the cleavage of a 
synthetic peptide containing C1s cleavage site on C4. C1 complex had a 7 fold 
higher efficiency in cleaving the peptide as compared to C1s alone (kcat/Km : 
0.371 mM/s versus 0.050 mM/s) (O'Brien, Quinsey et al. 2003).  
 
C1q is a complex molecule assembled from 18 polypeptides composing of 3 
different chains (A, B and C chains). Each chain comprises an N-terminal 
collagen-like region and a C-terminal globular region. A-B and C-C dimers 
are formed by disulfide bonds in their N-terminal ends. Each C-chain of the C-
C dimer will form a heterotrimeric collagen-like triple helix with an A-B 
dimer. C1q is formed from 3 of these resulting in a stalk (N-terminal end) that 
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branches out with 6 individual stalks (composing of an A-B dimer and one 
chain of the C-C dimer) ending in the C-terminal globular regions (Reid 1986; 
Kishore and Reid 2000; Lu, Teh et al. 2008). 
 
C1q interacts with the C1s-C1r-C1r-C1s tetramer through a total of 6 Ca
2+
-
binding sites found in C1r CUB1 and CUB2 modules and another lower 
affinity site in C1s CUB1 module (Bally, Rossi et al. 2009). Each of this site 
will interact with one of the 6 individual stalks of C1q (comprising of an A-B 
dimer and a C chain of a C-C dimer). The C1q interacting sites of C1r CUB1, 
C1r CUB2 and C1s CUB1 modules are at its A-chain Lys59, B-chain Lys61 
and C-chain Lys58 residues  (Bally, Ancelet et al. 2013). The in-vitro 
experimental finding is consistent and supported by a case report of a SLE 
patient with a rare C1q B-chain Gly63Ser mutation that leads to a functional 
defect of C1q binding to the C1s-C1r-C1r-C1s tetramer. This mutation is close 
to the C1q B-chain Lys61 residue and is likely to have disrupted C1q 
interaction with C1s-C1r-C1r-C1s tetramer and thus impeding the formation of 
C1 complex and preventing complement activation (Roumenina, Sene et al. 
2011). The proposed C1 complex model is still in the process of being refined 
as increasing data becomes available from X-ray crystallography structural 
studies of C1r and C1s along with binding studies between the C1s-C1r-C1r-
C1s tetramer and C1q with mutagenesis studies to elucidate the specific 
interacting sites (Gregory, Thielens et al. 2003; Gaboriaud, Thielens et al. 




1.3.3.4 C1s catalytic fragment  
Cleavage of C4 by C1s is the first of two critical proteolytic steps which will 
lead to the formation of C3 convertase (C4bC2a) (Reid 1986). This is 
mediated by C1s catalytic fragment consisting of the CCP1-CCP2-serine 
protease domains. The protein-protein interaction between C1s and C4 is 
specific and it provides insight on the mechanism behind the substrate 
specificity of C1s.   
 
Other than the C1s active site that mediates the proteolysis, exosites (substrate 
recognition sites) on C1s are also important in mediating the protein-protein 
interaction that will direct the substrate correctly to the enzymatic site. Both 
CCP modules of C1s provide additional exosites for the binding of C4. This 
was demonstrated through enzymatic kinetic studies using truncated C1s 
proteins (Rossi, Bally et al. 1998). The need for these exosites, however, is 
substrate specific as the cleavage of C2 was not greatly affected by the 
absence of the CCP domains in the truncated C1s (Rossi, Bally et al. 1998). 
Although, exosites on the C1s CCP modules are not important for C2 
cleavage, physiologically, it can be viewed that C4b which binds to C2 
bringing it close to C1s for cleavage plays a similar role to C1s CCP domains 
to C4.     
 
The 3-D structure of the CCP2-serine protease region of human C1s solved by 
X-ray crystallography also supports the important role of its CCP modules as 
part of C1s catalytic fragment (Gaboriaud, Rossi et al. 2000). The CCP2-
serine protease region has its ellipsoidal CCP2 module orientated 
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perpendicular to the surface of the serine protease domain. This orientation of 
serine protease and CCP2 domains is consistent with the fact that the latter 
provides additional exosites for C4 and to direct the cleavage site on C4 onto 
C1s active site.  
 
In addition to exosites within the two CCP domains, C1s exosite for 
complement C4 is also present on its serine protease domain involving a 
cluster of positively charged residues: Lys575, Arg576, Arg581, and Lys583 
(Duncan, Mohlin et al. 2012). These residues interact with a stretch of 
negatively charged sulfotyrosine residues found on C4 α-chain (Duncan, 
Mohlin et al. 2012). However, this interaction between the C1s serine protease 
domain exosite and C4 α-chain will only occur in the active C1s when the 
steric hindrance in its zymogen serine protease domain is removed after its 
proteolytic cleavage and activation by C1r (Perry, Wijeyewickrema et al. 
2013). The addition of these exosites, both on C1s CCP and serine protease 
modules, on the regulation of C4 proteolytic cleavage, in addition to the 
substrate specificity of C1s active site, can help to explain the highly specific 
nature of C1s cleavage.   
 
1.3.3.5 C1s active site and bioinformatics protease model   
C1s active site within its serine protease domain has been studied by different 
methodologies. This will allow the elucidation of its substrate specificity and 
provide the information required to create a computational protease model. 
Data can be obtained from the following sources: 1) cleavage sequences of all 
known substrates of the protease (in addition to knowledge of other useful 
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information such as the crystal structure of the enzymatic active site), 2) 
position specific synthetic combinatorial libraries, and 3) randomised phage 
display library (O'Brien, Quinsey et al. 2003; Boyd, Pike et al. 2005; Kerr, 
O'Brien et al. 2005). Essentially, creation of a protease model with data from 
source number 1 requires an expert in the protease and for source number 2, it 
is a potentially tedious and expensive process if all possible combinations are 
to be covered (Boyd, Pike et al. 2005). The inherent property of the phage 
display substrate system to be able to present a large number of potential 
substrates to the protease and means to identify those that present susceptible 
substrates is the main advantage of the system as compared to the others 
(Diamond 2007).          
 
PoPS is a publicly freely accessible bioinformatics tool 
(http://pops/csse.monash.edu.au/) that has been used by other investigators to 
create the computational C1s protease model (Boyd, Pike et al. 2005; Kerr, 
O'Brien et al. 2005). This model was recreated as the initial step to identify 
potential relevant novel substrates for the project. Features in PoPS that are 
useful included: 1) ability to predict and rank likely cleavages within a single 
substrate and within entire human proteome, and 2) ability to screen out 
unlikely targets when other factors such as secondary or tertiary structures 
were considered (Boyd, Pike et al. 2005).      
 
To date, for C1s serine protease, its substrate specificity had been studied at 
the prime subsites (enzyme subsites that interact with amino acid residues at 
the C-terminal end of the substrate cleavage site) using artificially synthesised 
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florescent quenched peptides in 2003 by O’Brien and workers. The inherent 
limit of this was evident as certain amino acid residues would need to be used 
to infer the likely effect of other amino acids with the similar side group 
property in that subsite (O'Brien, Quinsey et al. 2003). A more complete work 
was accomplished by Kerr and colleagues subsequently where a phage display 
library consisting of randomised octameric peptides interrupted by a fixed 
arginine residue at the P1 position was used (P4-P3-P2-R-P1’-P2’-P3’-P4’, where 
R-P1’ represented the cleavage site (scissile bond) at the C-terminal side of the 
arginine residue that was cut by C1s active site) (Figure 1.3) (Kerr, O'Brien et 
al. 2005). There is a requirement for arginine to be at P1 position for C1s to 
cleave it. The random octameric peptides were generated with the DNA 
sequence (NNK)3CGY(NNK)4 where N represented any nucleotide, K 
represented T or G and Y represented C or T.  
 
The approach used followed that of Cwirla and colleagues (Cwirla, Peters et 
al. 1990). The T7 phage coat protein displayed the octameric peptide with a 
6X histidine tag that was used to fix the amplified phage onto a solid phase 
consisting of nickel chelated Sepharose beads. After removal of the unbound 
phages by washing, the bead/phage suspension was divided into two aliquots, 
one which was mock treated and the other treated with C1s protease at 37°C 
overnight.  Phage cleaved from the solid phase was recovered and formed the 
sub-library for a repeat selection (panning). PCR and subsequent DNA Sanger 
sequencing was done on 96 randomly selected phage plaques to deduce the 
peptide sequences of the coat proteins that were cleaved by C1s. The results of 




Figure 1.3: Diagram of C1s protease and substrate interaction.The active site is 
the cleft in the protease structure which binds to and cleaves the substrate. This active 
site contains a number of contiguous pockets called subsites. Each subsite will bind to 
a single amino acid residue on the substrate. The property of each individual subsite 
as deduced from the X-ray crystallography of C1s catalytic fragment, the CCP2-
serine protease domains, are shown (Gaboriaud, Rossi et al. 2000). In addition, the 
amino acid sequences of the traditional C1s natural complement substrates (C1-INH, 
C3 and C4) are shown. Preferred amino acids at certain positions as determined by 
Kerr and coworkers’ phage display C1s cleavage study are indicated (Kerr, O'Brien et 
al. 2005). The notation of Schechter and Berger for the subsites (S4……S4’) and 
amino acid residues (P4……P4’) relative to the cleavage site (scissile bond) is used in 
this diagram (Schechter and Berger 1967). Standard single letter codes for amino 
acids are used.     
 
 
1.3.3.6 C1s substrate specificity  
The classical substrates of C1s are the complement proteins C4 and C2 (Reid 
1986). However, non-complement substrates have been described but their 
physiological relevance are not entirely clear (Gal, Ambrus et al. 2002). A 
summary of all the known substrates of C1s and its proposed physiological 
relevance is provided (Table 1.3).  
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Table 1.3: Serine protease C1s complement and non-complement substrates.
 C1s 
substrates 
Physiological functions (definite/propose) References 
Complement 
C4  
Classical complement pathway. C1s cleavage of C4 
to form C4b is the first proteolytic step leading to 





Classical complement pathway. C2 binds to C4b 
and is cleaved by C1s leading to the formation of 





C1s cleaves β2-microglobulin at the C-terminal end 
of lysine residue at position 58 and aid in the 
subsequent formation of des-Lys58-β2 
microglobulin through the deletion of the Lys58 by 
the separate action of a carboxypeptidase B. Des-
Lys58-β2 microglobulin is believed to play a role in 





MHC class I 
heavy chain  
C1s cleaves an area between the α2 and α3 domains 
of MHC class I generating non-membrane bound α1 
and α2 domains. Soluble MHC class I α1 and α2 
domains are proposed to have potential immune 
regulatory role through competitive inhibition for 




Type I and II 
collagen  
C1s can be detected in chondrocytes of hyaline 
cartilage by immunohistochemistry. Authors 
propose that C1s may be involved in the 
metabolism of cartilage matrix in health or 





IGFBP5  Fibroblasts secrete C1r and C1s. C1s cleaves 
IGFBP5 leading to the release of insulin-like 
growth factor I which is a potent trophic factor that 
will lead to cellular growth and regeneration. In 










C1complex activates canonical Wnt signaling by 
binding to Frizzled receptors followed by C1s-
dependent cleavage of the ectodomain of Wnt 
coreceptor low-density lipoprotein receptor-related 
protein 6. C1s is proposed to play a role in 
mammalian aging through its involvement in 
activating Wnt signaling. 
 
(Naito, 
Sumida et al. 
2012) 
 
In addition, Kerr and coworkers had used their phage display data to create a 
C1s bioinformatics model using PoPS to screen the human proteome and 
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found that many intracellular proteins were potential C1s substrates with 
higher cleavage scores (indicating a high likelihood of cleavage) than its 
natural substrates C4 and C2 (Kerr, O'Brien et al. 2005). This finding was 
disregarded by the authors as the extracellular complement protease C1s 
would not have the potential to interact and cleave these intracellular 
substrates in living cells. However, when the process of apoptosis with the 
extracellular exposure of many intracellular proteins and known C1 complex 
binding to ACs are considered, the possibility of C1s interacting with these 
potential substrates occurs. This gives rise to the possibility that they are yet 
undefined intracellular substrates and function of C1s. 
 
1.3.3.7 C1-INH 
C1-INH is the only regulator of the classical complement pathway at the level 
of both the serine proteases C1r and C1s (Duncan, Wijeyewickrema et al. 
2008). Other C1-INH targets include other proteases such as MASP-2, 
coagulation factors XIa and XIIa, and plasma kallikrein (Wagenaar-Bos and 
Hack 2006). It is a member of the superfamily of serpins (serine protease 
inhibitors) (Gettins 2002). It is a protein of 478 amino acids with a calculated 
molecular weight of 53 kDa. However, it is heavily glycosylated and native 
circulating C1-INH migrates with an apparent molecular weight of 104kDa on 
SDS-PAGE (Bock, Skriver et al. 1986).  
 
Mechanism of inhibition is through the irreversible equimolar covalent 
binding of C1-INH with C1s active site. This is a result of a conformation 
change in C1-INH that distorts C1s catalytic active site after C1s recognises 
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and cleaves C1-INH. As a consequence, there is incomplete proteolysis and 
binding of C1s active site to the P1-residue of the C1-INH scissile bond 
(Wagenaar-Bos and Hack 2006). 
   
The inhibitory activity of C1-INH is low compared with that of other serpins. 
This as measured by its association constant with C1s of 1.2   104 M-1s-1 is 
low as compared with another serpin, α1-antitrypsin, with its protease, 
neutrophil elastase, of 6.5   107 M-1s-1 (Gettins 2002). An interesting and 
physiologically relevant fact is that C1 complex bound to larger ICs is much 
less efficiently inactivated than when it is bound to smaller ICs (Doekes, van 
Es et al. 1983). In addition, C1 bound to the surface bound IgG (sensitised 
sheep red blood cells) requires 100-fold more C1-INH for inactivation than 
does the same amount of fluid-phase active C1(Tenner and Frank 1986).  
 
1.4 HMGB1   
 
1.4.1 Structure of HMGB1  
HMGB1 is a 215  amino acid proteins consisting of 3 domains: 2 positively 
charged DNA-binding domains (HMG boxes A and B) and an acidic tail 
containing aspartic and glutamic acids (Figure 1.4) (Lotze and Tracey 2005). It 
contains 43 lysine residues, of which there are 2 predominant lysine clusters 
within the 2 NLSs (NLS1 = amino acids 28 to 44; NLS2 = amino acids 179 to 
185). Post-translation modifications of the NLSs determine the direction of the 
nucleocytoplasmic shuttling. In addition, HMGB1 contains 3 highly conserved 
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cysteines that are readily oxidised (box A position 23 and 45, box B position 
106).  
 
Figure 1.4: Structure of HMGB1.A linear representation of HMGB1 is shown with 
residues constituting its A-box (yellow), B-box (green) and acidic tail (___). The 2 
NLSs contains lysine residues that when acetylated, will accumulate in the cytosol. 
The conserved cysteine residues at position 23, 45 and 106 are marked with an 
asterisk (*).  
 
 
1.4.2 Intracellular, Nuclear HMGB1     
Traditionally, HMGB1 is regarded as a non-histone chromosomal protein with 
biological function within the nuclear compartment (Bustin 1999; Bianchi and 
Beltrame 2000; Thomas 2001). HMGB1 binds to DNA with no sequence 
specificity (Bianchi, Beltrame et al. 1989). As a structural architectural 
chromosomal protein, it bends the double helix significantly after binding to 
its minor grove (Pil, Chow et al. 1993).  Known HMGB1 interactors that are 
important for its transcription and other function in the nuclear compartment 
includes the HOX proteins, p53, steroid hormone receptors and recombination 
activating gene 1 and 2 (RAG1/2) recombinase (Bianchi and Beltrame 2000). 
Although HMGB1 has multiple roles in the nuclear compartment, the defect in 
HMGB1-/- pups is mainly severe post natal hypoglycaemia and impaired gene 
expression by glucocorticoid receptors. Otherwise, cells lacking in HMGB1 
grows normally and has normal overall chromatin organisation; and HMGB1-




1.4.3 Extracellular HMGB1     
The unexpected extracellular immunological role of HMGB1 both in infective 
and sterile inflammation is only discovered at the turn of the century (Wang, 
Bloom et al. 1999; Scaffidi, Misteli et al. 2002). Ever since then, interest on 
the role of HMGB1 in different inflammatory diseases (both infective and 
sterile) as well as its potential as a therapeutic target has grown dramatically 
(Lotze and Tracey 2005; Yang and Tracey 2010; Andersson and Tracey 2011).   
 
Different post-translational modifications of HMGB1 have been described of 
which oxidation-reduction, acetylation and phosphorylation are the most 
important in its influence on HMGB1’s role as a mediator and alarmin in the 
innate immune response (Andersson, Wang et al. 2000; Gardella, Andrei et al. 
2002; Bonaldi, Talamo et al. 2003; Lotze, Zeh et al. 2007; Youn, Oh et al. 
2008).  
 
Extracellular HMGB1 is derived mainly from two pathways: 1) active 
secretion from activated MΦ (Wang, Bloom et al. 1999), neutrophils (Ito, 
Fukazawa et al. 2007) , mature myeloid DCs (Dumitriu, Baruah et al. 2005), 
pDCs (Dumitriu, Baruah et al. 2005), and activated natural killer cells 
(Semino, Angelini et al. 2005) or 2) passive release from primary or 
secondarily necrotic cells (late apoptotic cells) (Scaffidi, Misteli et al. 2002; 




HMGB1 does not have a secretion signal sequence. For active secretion, 3 
mechanisms have been described to allow its accumulation in the cytosol for 
eventual release: 1) hyperacetylation of HMGB1 lysine residues within its 2 
NLSs leads to its accumulation in secretory lysosomes (Bonaldi, Talamo et al. 
2003), 2) phosphorylation of its serine residues (Youn and Shin 2006), and 3) 
mono-methylation on lysine 42 in neutrophils (Ito, Fukazawa et al. 2007). The 
eventual release is via a vesicle-mediate secretory pathway triggered by 
lysophosphatidylcholine (Gardella, Andrei et al. 2002).   
 
1.4.4 Post-translational modifications 
Other than affecting its cellular localisation, there is accumulating evidences 
that post-translation modifications of HMGB1 can influence its ability to 
mediate various immunological processes (Dumitriu, Baruah et al. 2005; 
Venereau, Casalgrandi et al. 2012; Yang, Lundback et al. 2012).  
 
Oxidation occurs in HMGB1 that is released from primary and secondary 
necrotic cells (late ACs) (Urbonaviciute, Meister et al. 2009). This is 
consistent with the accumulation of reactive oxygen species and the loss of 
intracellular antioxidant (glutathione) during apoptosis (Curtin, Donovan et al. 
2002). This modification has been found to be of great importance in affecting 




Figure 1.5: HMGB1 redox status and activity.Mutually exclusive redox forms of 
HMGB1 promote different immunological activities: reduced cysteines make 
HMGB1 a chemoattractant, a disulfide bond between the cysteine residues at position 
23 and 45 with a thiol group at cysteine 106 makes it pro-inflammatory, and terminal 
oxidation of all its cysteines to sulfonates by reactive oxygen species abrogates both 
activities (Modified from Venereau, Casalgrandi et al. 2012). 
 
HMGB1 can exist in 3 different redox forms (Figure 1.5). The chemoattractant 
reduced HMGB1 (all-thiol-HMGB1) has its 3 cysteine residues containing a 
thiol group each (Venereau, Casalgrandi et al. 2012). The pro-inflammatory 
oxidised HMGB1 (disulfide HMGB1) contains a disulfide bond between the 
cysteine residues at position 23 and 45 with a thiol group at cysteine residue at 
position 106 and is able to induce TNF-α production in MΦ (Venereau, 
Casalgrandi et al. 2012; Yang, Lundback et al. 2012). Lastly, the cysteine 
residues of HMGB1 can also be terminally oxidised to sulfonates in the 
presence of high levels of reactive oxygen species and this abrogates both its 
cytokine-inducing and chemoattractant activities (Venereau, Casalgrandi et al. 
2012). The terminal oxidisation of  HMGB1 has also been shown to be able to 
redirect its ability from activation of the acquired immune responses toward 
tolerance (Kazama, Ricci et al. 2008). Notably, monocytic cells when 
stimulated with LPS has all-thiol-HMGB1 in the intracellular compartment 
(nucleus and cytosol) while the extracellular supernatant contains a mixture of 
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all-thiol-HMGB1 (chemoattractant) and disulfide-HMGB1 (pro-inflammatory) 
(Venereau, Casalgrandi et al. 2012).  
 
Less is known about the effect of other modification on HMGB1’s 
immunological property. Hyperacetylation is important as it directs HMGB1 
towards secretion by immune cells upon activation but whether this 
modification impacts its extracellular function is less clear. However, 
endogenous HMGB1 (hyperacetylated) released from moDCs after LPS 
stimulation had been found to have the ability to enhance the T cells 
proliferation (Dumitriu, Baruah et al. 2005).  
 
1.4.5 Interactions with DAMPs  
Other than post-translational modifications of HMGB1 affecting its biological 
activity, another important consideration is its ability to interact with other 
endogenous and exogenous danger signals (Hreggvidsdottir, Ostberg et al. 
2009). HMGB1 interacting partners include Pam3CSK4 (TLR1/2 ligand) 
(Hreggvidsdottir, Ostberg et al. 2009), LPS (TLR4 ligand) (Youn, Oh et al. 
2008; Hreggvidsdottir, Ostberg et al. 2009), nucleosome complexes 
(Urbonaviciute, Furnrohr et al. 2008), CpG-ODNs (TLR9 ligand) (Ivanov, 
Dragoi et al. 2007; Tian, Avalos et al. 2007; Hreggvidsdottir, Ostberg et al. 
2009), DNA-containing ICs (formed from SLE serum and necrotic cell 
supernatant as source of autoantigens) (Tian, Avalos et al. 2007; Cully 2013; 
Wen, Xu et al. 2013), and IL-1β (Hreggvidsdottir, Ostberg et al. 2009). 
Interacting partners with HMGB1 and the biological effects they mediate are 
summarised in table 1.4.    
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Table 1.4: HMGB1 interacting partners and their biological effects.
 Interacting 
partners 
Biological effects (source of HMGB1) References 
LPS  HMGB1 caused disaggregation of LPS from 
micelle and transferred it to CD14 to initiate 
TLR4 mediated response. HMGB1 had a 
synergistic effect with LPS in stimulating TNF-α 
production in human PBMCs and peripheral blood 
monocytes. (Prokaryotic expressed HMGB1) 
 






HMGB1-containing nucleosomes from ACs 
induced secretion of IL-1β, IL-6 and TNF-α from 
human MΦ and expression of co-stimulatory 
molecules from human moDCs. HMGB1-
containing nucleosomes induced anti-dsDNA and 
antihistone IgG in a TLR2 dependent manner. 










(type B), and 
IL-1β  
HMGB1 synergised with its partners to stimulate 
IL-6 production in cultured human PBMCs. 
(Purified native HMGB1 from bovine thymus, 








HMGB1 interacted with TLR9 in the endoplasmic 
reticulum Golgi intermediate compartment and 
hastened TLR9 redistribution to early endosomes 
in response to CpG-ODN leading to secretion of 
IL-6, IL-12 and TNF-α by mouse bone marrow 
derived DCs. (Endogenous HMGB1 released from 
mouse bone marrow derived DCs and MΦ after 















HMGB1 (in particular HMGB1 B-box) bound to 
CpG-ODN (type A) and stimulated IFN-α 
production in a TLR9 and RAGE dependent 
manner in mouse pDCs. (Purified native HMGB1 
from bovine thymus.)  
 
The induction of genes encoding type 1 IFN in 
PBMCs by SLE ICs was dependent on the 
presence of HMGB1 and RAGE.  
  






Requirement of HMGB1 in the induction of anti-
dsDNA antibody production by cultured SLE 
patient’s PBMCs through a TLR2 dependent 
pathway. (Endogenous HMGB1 found in ICs 
purified from SLE patient’s plasma.) 
 





HMGB1’s synergistic effect with LPS, Pam3CSK4, CpG-ODN and IL-1β in 
stimulating human PBMCs IL-6 production appears to be independent of 
HMGB1 post-translational modifications as similar result was obtained with 
different HMGB1 sources (native protein purified from bovine thymus and 
rHMGB1 from prokaryotic and baculovirus expression systems).  
 
1.4.6 Receptors   
Receptors that mediate HMGB1 inflammatory responses include RAGE, 
TLR2, TLR4, TLR9 and CD24-Siglec-10 (Siglec-G in mice) (Park, 
Svetkauskaite et al. 2004; Kokkola, Andersson et al. 2005; Park, Gamboni-
Robertson et al. 2006; Yu, Wang et al. 2006; Chen, Tang et al. 2009). CD24-
Siglec-10 is the only one mediating HMGB1 anti-inflammatory effects while 
the others mediate its pro-inflammatory responses (Chen, Tang et al. 2009).  
 
However, as many of the inflammatory responses are mediated by HMGB1 in 
a complex with DAMPs (LPS, CpG-ODN, and Pam3CSK4), nucleosomes or 
autoantibodies-autoantigens ICs, there may not be a direct HMGB1-receptor 
interaction and signaling. These HMGB1-partner molecule complexes are 
likely to signal through the partner molecule’s receptor (Hreggvidsdottir, 
Lundberg et al. 2012). Direct HMGB1-receptor binding has only been 
demonstrated with RAGE and TLR4 with the corresponding binding regions 
on HMGB1 elucidated (Huttunen, Fages et al. 2002; Yang, Hreggvidsdottir et 




RAGE is a multi-ligands receptor implicated in a wide variety of acute and 
chronic inflammatory diseases (Chuah, Basir et al. 2013). Like the TLR, it can 
be considered as a PRR and is able to bind to DAMPs such as HMGB1 and 
S100 proteins. RAGE had been shown to be important in mediating HMGB1 
pro-inflammatory effects in mouse MΦ (Kokkola, Andersson et al. 2005).   
 
1.4.7 Extracellular HMGB1, an alarmin that mediates inflammation   
 
1.4.7.1 Mediator of sepsis   
The inflammatory role of HMGB1 was first described in 1999 by Wang and 
colleagues as a late mediator of murine endotoxin lethality with the following 
three characteristics: 1) delayed release kinetics in endotoxin exposed mouse 
(peaking between 8 to 32 hours), 2) attenuation of lethality with neutralising 
HMGB1 antibodies and 3) the lethality of HMGB1 administration to mice 
even in the absence of LPS (Wang, Bloom et al. 1999). HMGB1 release by 
murine MΦ could be induced by LPS, TNF-α and IL-1. This finding was 
further strengthened with the observation that HMGB1 was elevated in 
patients with severe sepsis especially the non-survivors (survivor’s mean 
HMGB1: 25.2 ng/ml versus non-survivor’s mean HMGB1: 83.7 ng/ml) 
(Wang, Bloom et al. 1999). 
 
HMGB1 is able to exert its cytokine like activity either alone or in synergism 
with LPS (Figure 1.6) (Andersson, Wang et al. 2000; Youn, Oh et al. 2008). 
As discussed previously (Section 1.4.3.2), HMGB1 cytokine like activity is 
dependent on its redox status: the cysteines residues at position 23 and 45 must 
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form a disulfide bond and cysteine 106 must be in the thiol state (Venereau, 
Casalgrandi et al. 2012; Yang, Lundback et al. 2012). HMGB1 B-box is the 
proinflammatory region required for the stimulation of MΦ cytokines release 
and the critical region is from the position 89 to 108 (Li, Kokkola et al. 2003). 
Within this region, the cysteine 106 residue is critical for HMGB1 binding to 
TLR4 and mutation of this residue to alanine abrogated its binding to TLR4 
and prevented the MΦ cytokines release (Yang, Hreggvidsdottir et al. 2010).  
 
 
Figure 1.6: Interacting regions of HMGB1 with RAGE, TLR4 and LPS. HMGB1 
interaction with TLR4 occurs at position 89 to 108. This is the minimum region 
requires to recapitulate the pro-inflammatory activity of full length HMGB1. RAGE 
interacts with HMGB1 from position 150 to 183 of B-box and part of the linker 
region to the acidic tail. HMGB1 interaction with LPS is well defined. The A and B 
boxes must be in continuity for HMGB1 to be able to transfer LPS to CD14 that will 
result in TLR4 activation. The regions that interact with the LPS polysaccharide and 
lipid A moieties have been defined through truncation studies.        
 
With LPS, HMGB1 augments its pro-inflammatory activity in a synergistic 
manner. HMGB1 binds to LPS and facilitates its transfer to CD14 leading to 
TLR4 ligation and enhancement of TNF-α production by human monocytes 
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(Youn, Oh et al. 2008). This activity is dependent on the presence of both the 
A and B HMG boxes but not the acidic tail (Youn, Oh et al. 2008). The 
regions important for this activity have been further elucidated: HMGB1 
amino acid residues position 3 to 15 (within A box) and 80 to 96 (linker region 
and B box), are found to bind polysaccharide and lipid A moieties of LPS 
respectively (Youn, Kwak et al. 2011). As for the CD14 binding region, it 
involves region of the B-box (Figure 1.6). 
 
1.4.7.2 Mediator of sterile inflammation and autoimmunity   
HMGB1 has a broad repertoire of immunological activities ranging from 
induction of cytokine production, cell proliferation, chemotaxis, angiogenesis 
and cell differentiation (Andersson and Tracey 2011). Not surprisingly, it has 
been implicated in a variety of sterile inflammatory diseases: both 
autoimmune and non-autoimmune. HMGB1 as an alarmin has been shown to 
drive the pathogenesis of autoimmune diseases such as rheumatoid arthritis, 
SLE and autoimmune myositis (Harris, Andersson et al. 2012). For sterile 
non-autoimmune inflammation, blockage of HMGB1 by various therapies 
(neutralising anti-HMGB1 antibodies, antagonistic HMGB1 A-box, and 
blockage of RAGE-HMGB1 signaling) in animal models have demonstrated 
its involvement in acute pancreatitis, ventilator associated lung injury, 
haemorrhagic shock, hepatic and cardiac ischemic-reperfusion injuries, stroke, 
and cardiac allograft rejection (Yang and Tracey 2010).        
 
In SLE, HMGB1 was found both in local skin lesions and systemically in the 
serum of patients. The pathognomonic malar rash and photosensitivity are 
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common clinical features of SLE (D'Cruz, Khamashta et al. 2007). Increase 
HMGB1 expression has been observed in the epidermis and dermis infiltrates 
of lupus skin lesions. HMGB1 was found both in the cytoplasm of cells and 
extracellular space. Its presence was associated with increased TNF-α and IL-
1β in the dermal infiltrates (Popovic, Ek et al. 2005). Interestingly, ultraviolet 
irradiation, a known environmental trigger for SLE flare and photosensitivity, 
enhanced HMGB1 translocation to the cytoplasm and extracellular space in 
the SLE skin lesions (Barkauskaite, Ek et al. 2007).   
 
Systematically, serum HMGB1 had been shown to be elevated in both lupus 
mice and SLE patients (Jiang and Pisetsky 2008). Significant positive 
correlations between serum HMGB1 in ICs and clinical disease activity, 
presence of nephritis, anti-dsDNA antibodies titer and depressed complement 
C3 level had been found in SLE patients (n=165) (Wen, Xu et al. 2013). In a 
separate study of 69 lupus patients, urinary HMGB1/Creatinine ratio was 
found to correlate positively with disease activity, depressed C3 level and the 
presence of proteinuria (indicative of nephritis) (Abdulahad, Westra et al. 
2012). In addition to its association with global disease activity and nephritis, 
positive relationship between serum HMGB1 was also found with vasculitis 
and myositis; two other SLE manifestations (Li, Xie et al. 2010). The exact 
source of HMGB1 was uncertain but it was likely due to  increase cells death 
or decrease dead cells clearance (Ardoin and Pisetsky 2008).  
 
To understand HMGB1’s role in autoimmunity, its immunological effects on 
pDCs and moDCs in relation to IFN-α production and DCs maturation 
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respectively will be examined and this will provide the plausible causal 
relationship to the observed clinical association between HMGB1 and SLE. 
The presence of HMGB1 in DNA containing ICs was important in the 
inducing pDCs IFN-α production (Tian, Avalos et al. 2007). IFN-α is a key 
signature cytokine in SLE and can propagate the disease through various 
pathways: 1) increasing the autoantigens burden by different mechanisms, 2) 
causing differentiation of monocytes into DCs, and 3) causing differentiation 
of autoreactive B cells into Ig-secreting plasma cells (in cooperation with IFN-
β and IL-6). These points will be elaborated later in section 1.5.2. Lastly, 
pDCs can also release HMGB1 which acts in an autocrine loop with RAGE on 
pDCs to effect its maturation and continuous production of IFN-α after TLR9 
activation (Dumitriu, Baruah et al. 2005).  
 
HMGB1 can influence the adaptive response through its action on DCs (Table 
1.5). It affects DC chemotaxis and maturation to increase its ability to function 
effectively as professional APCs (Dumitriu, Bianchi et al. 2007; Yang, Chen 
et al. 2007). HMGB1 causes moDCs maturation and effect the necessary 
cytoskeletal organisation and the acquisition of cellular mobility to home in to 
lymphoid tissues, increases the expression of MHC class II and co-stimulatory 
molecules (CD80, 83 and 86), and secretion of cytokines necessary for Th 
cells polarisation (such as IL-12p70) (Dumitriu, Baruah et al. 2005; Dumitriu, 
Bianchi et al. 2007; Yang, Chen et al. 2007). This is translated to the positive 
effect of enhancing T cells proliferation and survival (Messmer, Yang et al. 




Table 1.5: Biological effects of HMGB1 on moDCs.












1) Chemoattractant to immature 
moDCs (with positive control of 
CCL5 and CCL21), 
2) moDCs maturation with 
upregulation of CD80, 83, 86, and 
HLA-A, B, C, 
3) Increased TNF-α, IL-6, CXCL8, 
IL-12p70, and  
4) T cells proliferation (MLR) with 




















1) Anti-HMGB1 and anti-RAGE 
antibodies abrogated CCR7 and 
CXCR4 expression on moDCs after 
LPS, TNF-α or CD40L stimulation,  
2) Anti-HMGB1 and anti-RAGE 
antibodies decreased migration to 
CCL19 and CXCL12, and  
3) Anti-HMGB1 antibodies 
prevented cytoskeletal remodeling 
after LPS stimulation. 
4) HMGB1 modulated and 
sustained moDCs maturation upon 
LPS stimulation (anti-RAGE 
antibody decreased CD80, 83, 86 
but not HLA-DR), 
5) HMGB1 increased IL-12p70 
with LPS stimulation (anti-RAGE 
decreased IL-12p70 but not TNF-α 
and IL-10), and 
6) HMGB1 increased CD4 cells 
expansion and survival 




































1) moDCs maturation with 
rHMGB1 or rHMGB1 B-box, 
2) Increased TNF-α, IL-1α, IL-6, 
IL-8, IL-12p70, RANTES secretion 
with rHMGB1 B-box,  
3) Increased T cells proliferation 
(MLR) with rHMGB1 B-box, and  
4) Th1 polarisation: increased IFN-







activation.   
(Messmer, 
























1) Wild type fibroblast caused 
moDCs maturation with 
upregulation of CD40, CD80, 
CD83, CD86 and HLA-DR, 
2) C57BL/6 mice rejected tumour 
after subsequent challenge with 
living RMA lymphoma cells if 
initial immunisation was done with 
wild type necrotic fibroblasts 
supernatant and apoptotic 
lymphoma cells or histidine tagged 
rHMGB1 and apoptotic lymphoma 
cells, and  
3) Coinjection of mice with 
HMGB1 with OVA elicited an 
increase in OVA-specific IgG 
antibody titer. 
Conclusion: HMGB1 had an 
adjuvant effect on both soluble 
(OVA) and cell associated antigens 






et al. 2004) 
 
HMGB1 importance in the mediation of an adaptive immune response has 
been demonstrated with in-vivo murine models. Immunisation of mice with 
HMGB1-containing nucleosomes induced the formation of anti-dsDNA and 
antihistone IgG in a TLR2 dependent manner (Urbonaviciute, Furnrohr et al. 
2008). Anti-dsDNA and anti-histone IgG are common autoantibodies in SLE 
patients (Sherer, Gorstein et al. 2004). Coinjection of HMGB1 with apoptotic 
tumour cells, a source of cell associated antigens, in mice led to tumour 
rejection. Concurrently, a similar response was seen with a soluble antigen 
OVA with an increase in OVA-specific IgG antibody titer with HMGB1 







1.5.1 Clinical presentation and epidemiology 
SLE is a systemic autoimmune disease typified by the presence of 
autoantibodies directed mainly against nuclear autoantigens such as DNA, 
RNA-associated proteins, core histones and nucleosomes (Mok and Lau 2003; 
Sherer, Gorstein et al. 2004). Its clinical presentation ranged from rash and 
arthritis to haematological manifestation of anaemia, leukopenia and 
thrombocytopenia, to others such as  serositis, nephritis, seizures, and 
psychosis  (Osio-Salido and Manapat-Reyes 2010). Regionally, it prevalence 
is between 30 to 50/100,000 population (Osio-Salido and Manapat-Reyes 
2010). Locally, SLE prevalence is estimated to be 40/100,000 population 
(Edwards 2001). It is a disease of significant mortality and morbidity and 
poses a significant economic burden on the sufferer and family (Mak 2010). 
 
Its exact etiology is unknown but it has a strong polygenic component 
involving more than 30 putative genes (Deng and Tsao 2010). However, rare 
monogenic inheritance pattern of SLE exists with early classical complement 
proteins C1q, C1r, C1s and C4 (Lewis and Botto 2006). The deficiencies of 
C1q, C1r, C1s, or C4 are strongly associated with SLE (odds ratio of 5 to 10) 
(Sestak, Furnrohr et al. 2011). Their strong dominant effect on disease 
pathogenesis is evident by the onset of disease in childhood and loss of the 





1.5.2 Pathogenesis  
Defects in normal immune homeostasis that lead to the autoantibody 
production in SLE is unclear but impaired clearance by MΦ of ACs leading to 
its accumulation and secondary necrosis remains one of the important 
mechanism in SLE pathogenesis (Denny, Chandaroy et al. 2006; Robak, Sysa-
Jedrzejowska et al. 2006). The classical complement factors, especially C1q, 
play an important role in clearance (Walport 2001; Cheng and Anderson 
2012).   Late ACs (secondarily necrotic) will release autoantigens and DAMPs 
(Urbonaviciute, Furnrohr et al. 2008). An important autoantigen targeted by 
autoantibodies and T cells in SLE patients is nucleosome (Bruns, Blass et al. 
2000; Suer, Dahnrich et al. 2004). Nucleosomes are the monomeric building 
blocks of chromatin consisting of a tetramer core of histone proteins (Histones 
H4, H3, H2A and H2B) surrounded by 2 superhelical turn of dsDNA.  
 
The release autoantigens have pathogenic roles by itself or in complex with 
autoantibodies (ICs). Nucleosomes produced during the process of apoptosis 
contained HMGB1 (a DAMP) (Urbonaviciute, Furnrohr et al. 2008). 
Apoptotic HMGB1-nucleosome (DAMP-autoantigen complex) elicited a pro-
inflammatory cytokine profile with human MΦ (TNF-α, IL-1β, and IL-6), 
caused DCs maturation and increased its ability to mediate T cells 
proliferation (Urbonaviciute, Furnrohr et al. 2008).  
 
As complexes with autoantibodies, 2 pathogenic mechanisms had been shown 
to be important. Firstly, the DNA-containing SLE ICs were able to cause 
pDCs TLR9 activation leading to IFN-α production. This was mediated by 
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HMGB1 and its receptor RAGE (Tian, Avalos et al. 2007). Secondly, 
induction of anti-dsDNA autoantibody production by SLE B cells required 
HMGB1 containing DNA ICs and involved TLR2 (Wen, Xu et al. 2013). In 
the same study, the intensity of HMGB1 content in circulating DNA 
containing ICs showed a positive correlation with SLE clinical parameters 
such as anti-dsDNA titer (r=0.839, p<0.001) and SLE disease activity index 
(SELDAI) (r=0.792, p<0.001)  (Wen, Xu et al. 2013). 
 
IFN-α is central in the pathogenesis of SLE and the presence of a type I 
interferon gene ‘signature’ in SLE patients’ peripheral blood provides clinical 
evidence of its importance (Bennett, Palucka et al. 2003; Crow, Kirou et al. 
2003; Crow 2005). Mechanistically, there are several ways that IFN-α can 
contribute to the disease process. Firstly, IFN-α can increase the autoantigens 
burden load to DCs. This can be achieved by 3 processes. 1) IFN-α 
enhancement of NETosis, where neutrophils extrude decondensed chromatin 
as potential nuclear antigens as elements of NETs (Garcia-Romo, Caielli et al. 
2011). NETs contain LL37 that increases pDC production of more IFN-α, 
hence creating a vicious feedback loop that fuels the disease process with 
more IFN-α (Gilliet and Lande 2008). 2) Enhancement of NK cells FasL 
expression leading to increase apoptosis (Kirou, Vakkalanka et al. 2000). 3) 
Augmentation of the cytotoxicity of activated CD8
+
 T cells which can also 
increase the number of ACs (Welsh, Bahl et al. 2012). Secondly, IFN-α also 
strongly promotes monocyte differentiation into DCs and these DCs are potent 
APCs that can activate autoreactive CD4
+
 T cells (Blanco, Palucka et al. 
2001). Thirdly, IFN-α is involved in the expansion and differentiation of 
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autoreactive B cells. Type 1 IFN, IFN-α and IFN-β, is required for the initial 
generation of non Ig-secreting plasma blasts with IL-6 inducing their 
subsequent final differentiation into Ig-secreting plasma cells (Jego, Palucka et 
al. 2003) 
 
In summary, complex of HMGB1 and autoantigens is important in SLE 
pathogenesis. As the main source of HMGB1 and autoantigens are the ACs 
and C1 complex is known to interact with them, it will be interesting to study 
the interaction of C1 complex with these intracellular proteins as they are 
gradually exposed to the extracellular milieu during apoptosis. 
.            
1.6 RATIONALE AND HYPOTHESES OF THE PRESENT STUDY  
 
1.6.1 Rationale of study  
Among the early classical complement proteins (C1q, C1r, C1s and C4) with 
significant association with SLE, C1r and C1s are the least studied. C1r’s role 
is restricted to the cleavage and activation of proenzyme C1s within C1 
complex. C1s, on the other hand, has a wider although still restricted substrate 
specificity consisting of 2 complement (C4 and C2) and 5 other non-
complement proteins (Reid 1986; Eriksson and Nissen 1990; Nissen, 
Roepstorff et al. 1990; Yamaguchi, Sakiyama et al. 1990; Busby, Nam et al. 
2000; Naito, Sumida et al. 2012). In addition, bioinformatics search of the 
human proteome with a C1s informatics model had shown intracellular 
proteins (identities not published) with higher predicted cleavage scores than 
its natural complement substrates (C4 and C2) (Kerr, O'Brien et al. 2005). 
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However, their significance was dismissed by the authors as interaction 
between extracellular C1s and these intracellular proteins would not have 
occurred with normal living cells. 
 
ACs are important sources of autoantigens and DAMPs in SLE (Casciola-
Rosen, Anhalt et al. 1994; Urbonaviciute, Furnrohr et al. 2008). As described 
previously, rapid clearance of ACs with involvement of C1q binding and 
activation of the complement system up to the deposition of C3b is important 
in preventing autoimmunity (Ogden, deCathelineau et al. 2001; Walport 2001; 
Zwart, Ciurana et al. 2004; Ogden, Kowalewski et al. 2005; Quartier, Potter et 
al. 2005). Nucleosomes and other autoantigens targeted by SLE autoantibodies 
are present in high concentrations on ACs surfaces (Casciola-Rosen, Anhalt et 
al. 1994; Radic, Marion et al. 2004). Hence, the ACs surfaces create the first 
level of potential interaction between C1s, recruited as C1 complex, and these 
intracellular proteins. The next question is whether HMGB1 and/or 
autoantigens are substrates of C1s. Preliminary cleavage site prediction using a 
C1s model done with PoPS demonstrated potential C1s cleavage sites on 
HMGB1. As the combination of autoantigens and HMGB1 is important in 
effecting various cellular mechanisms in SLE, cleavage of this important 
mediator with loss of its immunological activity may explain the protective 
role of C1s against SLE pathogenesis.  
 
The second potential level of interaction is on the SLE ICs where C1q is 
known to bind (Santer, Hall et al. 2010). HMGB1 containing SLE complexes 
are involved in both TLR9 activation in pDCs and anti-dsDNA antibody 
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production (Tian, Avalos et al. 2007; Wen, Xu et al. 2013). Hence, if C1s is 
found to cleave HMGB1, it will be interesting to look at its effect on these 
processes. The overall rationale of the project is illustrated in figure 1.7.  
 
 
Figure 1.7: The protective role of early complement factors and pathogenesis of 
SLE. Binding of C1q to ACs can cause phagocytosis. It can also activate the 
complement system which will lead to C3 cleavage and C3b deposition. C3b causes 
potent phagocytosis and clearance of ACs. C1q deficiency is thought to cause failure 
of ACs clearance leading to uptake of autoantigens by DCs and activation of DCs by 
DAMPs. These DCs can then activate autoreactive T-helper cells, which will help in 
the affinity maturation and class switching of autoreactive B cells. Pathogenic IgG 
autoantibodies will then be produced and they will form circulating ICs with 
autoantigens. HMGB1, a DAMP, when associated with ICs can cause potent IFN-α 
secretion from pDCs. IFN-α is a signature cytokine in SLE. Our hypothesis is that 
C1s may help to prevent autoimmunity by cleaving and inactivating DAMPs and 
autoantigens at two levels. The first is on the surfaces of ACs where it is present as 
C1 complex ( -1- ). The second level of interaction is on ICs where C1q binding is 







1.6.2 Hypotheses of study  
The hypotheses that are tested in this study are presented here but the specific 
executable aims required to test these hypotheses will be covered in each 
individual result chapters.  
 
The first hypothesis is C1s can cleave HMGB1 and result in a loss of its pro-
inflammatory activities. Preliminary cleavage site prediction using a C1s 
bioinformatics model revealed potential C1s cleavage sites on HMGB1. The 
cleavage will be confirmed with in-vitro studies using both C1s and C1 
complex with purified HMGB1 and ACs. Subsequently to test the hypothesis 
of whether cleavage of HMGB1 results in a loss of its pro-inflammatory 
activities, the following biological functions of HMGB1 will be examined:  
1) HMGB1 synergistic role with LPS in stimulating TLR4 activation, and  
2) HMGB1 role in SLE ICs in effecting TLR9 activation and IFN-α 
production.  
 
The second hypothesis is whether C1s can cleave other known SLE 
autoantigens from ACs. Other intracellular proteins that are found to be 
cleaved by C1s will be identified and a search of published literature will be 
done to determine if the cleaved targets are known SLE autoantigens.  
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Chapter 2 Materials and Methods   
 
2.1 BIOINFORMATICS TECHNIQUE: CREATION OF C1S PROTEASE 
MODEL   
PoPS, a free web based bioinformatics software, was used to create the C1s 
model. Data was extracted from the C1s substrate specificity study by Kerr 
and coworkers to create the model independently (Kerr, O'Brien et al. 2005). 
The following components were needed to be inputted into PoPS interface 
(Figure 2.1). 1) The number of subsites within the enzyme active site. 2) The 
specificity profile of each subsite amino acid residues (value of -5 to +5). A 
value of -5 reflected the most negative effect on binding of that residue for that 
subsite and +5 the most positive. A hash (#) symbol denoted a residue that 
prevented binding in PoPS (Boyd, Pike et al. 2005). 3) The relative weight 
(i.e. importance) of the subsite to the enzyme active site (value of 0 to 5).   
 
4 non-prime (S1 to 4) and 4 prime (S´1 to 4) subsites were entered for the C1s 
model. To obtain the specificity profile needed for PoPS of each subsite amino 
acid residues, the methodology used by Song was employed (Song, Matthews 
et al. 2011). First, the frequency of occurrence of amino acids at P4-P4´ 
positions from a fixed P1 arginine in the 93 positive phage sequences (out of 
96 screened) that were cleaved by C1s was obtained from the study by Kerr 
and colleagues (Kerr, O'Brien et al. 2005). Next the Δσ values were calculated 
with the following formula: 
   
    ( )    ( )




where n = 93 (total number of phage sequences analysed in the study), Obs(𝝌) 
was the observed frequency of amino acid x at the subsite in the 93 sequences 
analysed, and P(𝝌) = number of allowed synonymous codons encoding amino 
acid x   31 (the theoretical occurrence of amino acid x based on the coding of 
the octamer sequence) (Matthews, Goodman et al. 1994; Song, Matthews et al. 
2011). Kerr and coworkers used the random octameric peptides generated 
from the DNA sequence (NNK)3CGY(NNK)4 where N represented any 
nucleotide, K represented nucleotide T or G and Y represented nucleotide C or 
T. CGY encoded the required arginine at P1 position.  Using nucleotide K in 
the position 3 of the codon would prevent the formation of the stop codons 
TGA and TAA but not the remaining stop codon, TAG. Information from 
table 2.1 was used to obtain the number of allowed synonymous codons 
encoding each amino acid to calculate P(𝝌) for the codon sequence of NNK. 
Example, for the amino acid alanine (A), it would have the theoretical 
probability of occurrence P(𝝌) value of 2  31.  
 
Table 2.1: Number of allowed synonymous codons (total=31). Adapted from Song, 
Matthews et al. 2011. 
 Amino acid 
(Single letter 
code) 












1 1 2 1 3 3 2 2 1 1 
 
The Δσ value was a reflection of the difference between the observed 
frequency,     ( ), from the expected frequency,   ( ),  in terms of standard 
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deviation (Matthews, Goodman et al. 1994). As seen from above, the Δσ 
calculation took into account the number of synonymous codons for the amino 
acid residue in the expected probability, P(𝝌), calculation. 
 
A Δσ value of greater than 1 suggested that a particular amino acid was 
overrepresented at that subsite. To normalise the Δσ values of all the amino 
acid residues for that subsite, its Δσ was divided by the highest Δσ in the same 
subsite and corrected to a factor of 5. Although the specificity profiles of each 
subsite amino acid residues can be given a value of -5 to +5, all negative Δσ 
values were assigned a value of 0. The reason was because a lack of 
representation on the phage display was a reflection of a lack of cleavage but 
would not provide information whether it negatively influenced the cleavage. 
Only actual kinetics study would be able to provide this information necessary 
for the assignment of a negative value. Hence, for the specificity profile of 
each subsite amino acid residue in the C1s model, a scaled normalised value of 
0 to +5 was used. For the P1 position, arginine was given a weight of 5 and the 
rest of the amino acid residues given a valve of #. Lastly, the weight of each 
subsite was obtained by dividing its highest Δσ with the Δσ of arginine residue 
at position P1 (29.46) and multiplying it by a factor of 5.  
 
The 3 components required for PoPS were used to create the scoring matrix 
(PSSM). A sliding window technique was used by PoPS so that a score for 
each sequence of 8 consecutive amino acids (corresponding to 8 subsites in the 
C1s model) with the P1 amino acid fixed as arginine would be determined. The 
program essentially would shift the starting position of the window (of length 
59 
 
8) down the substrate and calculated the score when a sequence of 8 amino 
acid residues with arginine at P1 was found. The product of the weight for that 
position and the matrix entry was calculated for each residue in the window 
and the score obtained by summing all the products (Boyd, Pike et al. 2005). 
 
Figure 2.1: PoPS main and subsite amino acid residues specificity profile 
windows. A. The main PoPS program interface allowed user to determine the number 
of non-prime and prime subsites along with its vector weight. The values shown were 
that used for the C1s model. B. In this second window, the amino acid residues 
specificity profile of each subsite could be determined. In this diagram, the S4 amino 
acid residues specificity profile was shown.  
 
Primary sequence although important was not the only determinant of 
cleavage by C1s. Other important considerations were: 1) whether the 
cleavage site was structured (for example helices) or unstructured (extended), 




Proteins with unstructured (extended) conformation especially at the cleavage 
site were more susceptible to proteolysis. This work was done by Fairlie and 
coworkers where they did a bioinformatics analysis of the structure of small 
inhibitors of multiple proteases and concluded that the region that bound to the 
enzymatic active site were commonly in an extended (unstructured) β-strand 
conformation. This was consistent with the known observation why 
folded/structured regions of proteins were resistant to proteolysis while 
denatured proteins in an extended “stretched” conformation appeared to have a 
higher affinity and cleavage by proteases (Fairlie, Tyndall et al. 2000).  
 
In brief, to determine whether the cleavage site with the highest PoPS score 
was buried and structured (for example helices and bends) and hence less 
likely to be cleaved, the Protein Data Bank was accessed by PoPS to yield a 
single 3D model of the substrate (Berman, Westbrook et al. 2000). This was 
activated under the prediction results window under the tab named “structure”. 
Next, the Define Secondary Structure of Proteins algorithm was used by PoPS 
to calculate the accessibility of every residue in that substrate (Kabsch and 
Sander 1983). The minimum percentage of an amino acid that was solvent 
accessible to participate in a cleavage reaction was set at the default value of 
33%. If PoPS determined that at least one amino acid of P4-P4
´ 
positions was 
inaccessible (buried), the cleavage score would appear in grey font. In addition 
to predicting the cleavage site as buried (i.e. at least one amino acid residue 
was inaccessible), the secondary structure that each residue participate in was 
shown in the output window.     
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2.2 REAGENTS, CHEMICALS AND BUFFERS 
 
2.2.1 Reagents and chemicals  
Table 2.2: List of reagents and chemicals. (Catalogue numbers of critical reagents 
provided.)  
Categories Descriptions Sources 
Antibodies Alkaline phosphatase conjugated 











 Chicken anti-HMGB1 polyclonal 






 Goat polyclonal anti-human C1q (A301) 
 
Quidel (San Diego, 
CA, USA) 
 
 Goat polyclonal anti-human C1s (A302)   Quidel (San Diego, 
CA, USA) 
 
 Mouse anti- nucleophosmin monoclonal 
antibody, clone FC82291 (B0556) 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 
 Mouse anti-β-actin monoclonal antibody, 
clone AC-74 (A2228) 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 




Louis, MO, USA) 
 
 Mouse anti-polyhistidine monoclonal 
antibody, clone AD1.1.10 (MAB050) 
 












(Billerica, MA, USA) 
 
Chemicals Ampicillin Merck Millipore 
(Billerica, MA, USA) 
 
 Agarose (Seakem LE) 
 
Cambrex (East 












 1) Bio-Rad Protein Assay (Dye Reagent 
Concentrate) (#500-0006) 
 











 BSA (common protein usage) 
 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 


















 Marker: GeneRuler 100 bp DNA ladder 
 
Thermo Scientific  
(Waltham, MA, USA) 
 
 Marker: PageRuler plus prestained protein 
ladder 
 
Thermo Scientific  










Louis, MO, USA) 
 









Louis, MO, USA) 
 
Primers  Human HMGB1 cloning vector: 
  















Highlighted yellow: restriction site for 
Kpn I 
Highlighted green: restriction site for Age 
I 
^: restriction enzyme cutting site 
In red bold letters: start codon 
Underlined: TAA (stop codon) replaced 
with AAA (lysine) to be in-framed with 




 3.1 myc-His A sequencing 
primers:  
Forward Primer (5’ to 3’) T7:  
TAATACGACTCACTATAGGG  
 






Proteins Human C1 complex, purified from human 




(Billerica, MA, USA) 
 
 Human C1s (activated two-chains), 




(Billerica, MA, USA) 
 
 Human His-tagged recombinant C1s, 
carrier free (activated two-chains), mouse 
myeloma cell line, NS0-derived (2060-
SE-010)   
 




 Human complement C1q, serum purified 
(C1740) 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 




(Billerica, MA, USA) 
 
 Recombinant human HMGB1, carrier 
free, mouse myeloma cell line, NS0-
derived (1690-HM-025) 




 Recombinant His-tagged HMGB1, 









Louis, MO, USA) 
 




Cytokines  Recombinant human IL-4 
 




 Recombinant human GM-CSF 
 




 Recombinant human M-CSF 
 




 Recombinant human Interferon-αB2 
(11115-1) 
 
PBL Assay Science 









 ELISA Sets for TNF-α, IL-
6 and IL-10 
 
BD (Becton, Dickson 
and company) 
Biosciences (Franklin 
Lakes, New Jersey, 
USA) 
 





BD (Becton, Dickson 
and company) 
Biosciences (Franklin 
Lakes, New Jersey, 
USA) 
 
 VeriKine™ Human Interferon-α ELISA 
Kit (41100-2) 
 
PBL Assay Science 
(Piscataway, NJ, USA) 
Enzymes  
 





 Kpn 1  Promega (Madison, 
WI, USA) 
 
 Age 1 Promega (Madison, 
WI, USA) 
 
 T4 DNA Ligase and buffer 
 
New England Biolabs 
(Ipswich, MA, USA) 
 












































 L-glutamate  Caisson Laboratories 
(Logan, UT, USA)  
 






PAMPS  LPS (Escherichia coli: 05:55)  
 
Sigma-Aldrich (St. 




Annexin-V-FITC Apoptosis Detection Kit 
II 
BD (Becton, Dickson 
and company) 
Biosciences (Franklin 
Lakes, New Jersey, 
USA) 
 








 3.1 myc-His A  
A 5.5 kb cloning vector for CMV 






 Qiagen plasmid Maxi kit 
 
Qiagen GmbH (Hilden, 
Germany) 
 








2.2.2 Buffers  
Table 2.3: List of buffers and their compositions. 
Buffers Compositions 
Blue silver stain  1) G-250 Coomassie dye 0.12% (w/v), 
2) Ammonium sulfate 10% (w/v), 
3) Phosphoric acid 10% (v/v), and 
4) Methanol 20% (v/v).   
 
Cleavage buffer (for C1s and 
C1 complex) 
 
1) Tris 50 mM, 
2) NaCl 150 mM, and  
3) PEG8000 0.2% (w/v).  
 
Adjust pH to 7.4.  
 
Filter sterilised through a 0.22 μm syringe filter unit. 
 
DNA loading dye (6X) 1) 30% (v/v) glycerol,  
2) 0.25% (w/v) bromophenol blue, and   
3) Top up with distilled water. 
 
For denaturing DNA loading dye (6X), add in 0.6% 
(w/v) SDS. 
  
Laemmli Buffer (5X sample 
loading buffer for SDS-
PAGE)  
 
1) Tris-HCl pH 6.8 250 mM (50% (v/v) of Tris-HCl 
pH 6.8 500 mM), 
2) SDS 10% (w/v), and  
3) Bromophenol blue 0.05% (w/v). 
 
For reducing buffer, 0.5M DTT was added fresh 
prior to use. 
 
LB broth 25 g of LB powder to 1 litre of distilled water and 
autoclaved.  
 
Final concentration of constituents (pH 7.5):  
1) Bacto-tryptone 1% (w/v), 
2) Yeast extract 0.5% (w/v), and 
3) NaCl 0.5% (w/v).  
 
100 μg/ml of ampicillin was added for antibiotic 
selection after LB broth was cooled.  
 
LB agar 15 g/L of Bacto agar was added into the LB broth 
and autoclaved. 
  
100 μg/ml of ampicillin was used prior to pouring 




Diluted from 10X PBS (purchased from 1st Base, 
Singapore) with 0.22 μm filter sterile purified water, 
adjust pH to 7.4 with HCl, and filtered sterile in 
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 biohazard hood with 0.22 μm 1 liter filter unit using a 
vacuum pump. The 1X PBS was autoclaved prior to 
use.  
 
1X PBS final constituents:  
1) KH2PO4 1.76 mM,  
2) Na2HPO4 10.4 mM,  
3) NaCl 137 mM, and 
4) KCl 2.7 mM. 
  
0.05% PBST (ELISA wash 
buffer for BD OptEIA
TM 
TNF-α, IL-6 and IL-10) 
 
1X PBS with Tween 20 0.05% (v/v). 
SDS running buffer (5X)  
 
For 1 litre:  
1) 15.1 g Tris, 
2) 72 g Glycine, and 
3) 5 g SDS. 
 
Dissolve the above constituents with distilled water 
to 1 litre.   
 
1X TAE Diluted from 10X ultra-pure grade TAE (purchased 
from 1
st
 Base, Singapore) with distilled water to a 1X 
working solution. 
 
1X TAE final constituents (pH 8): 
1) Tris-acetate 40 mM, and  
2) EDTA 1 mM. 
 
0.1% (v/v) TBST (Western 
blot wash buffer) 
1) Tris 50 mM, and  
2) NaCl 150 mM. 
 
Adjust pH to 7.4. Tween 20 0.1% (v/v) added 
subsequently. 
 
Western blot stripping buffer 
(1X) 
1) Tris-HCl 62.5 mM, pH 6.8, 
2) SDS 2% (w/v), and 
3) 0.1 M β-mercaptoethanol. 
 
Western blot transfer buffer 
(10X) 
1) Tris 30.3 g, and 
2) Glycine 144 g. 
 
Dissolve the above constituents with distilled water 
to 1 liter. 
 
The 1X western blot transfer buffer consisted of the 
following constituents and was stored in 4°C: 
1) 10X western blot transfer buffer 100 ml, 
2) Methanol 200 ml, and   






2.3 SLE PATIENTS 
Juvenile SLE patients were recruited from KK Women’s and Children’s 
Hospital with the Institutional Review Board’s approval. All these patients 
fulfilled the diagnosis according to the revised 1982 American College of 
Rheumatology criteria for SLE (Tan, Cohen et al. 1982). After obtaining 
informed consent, 2 to 5 ml of blood was collected into BD Vacutainer Plus 
plastic serum tube (Catalogue number: 367986, BD (Becton, Dickson and 
company) Biosciences, Franklin Lakes, New Jersey, USA) and was allowed to 
clot for at least 30 minutes in room temperature. The samples were processed 
within 4 hours of collection by centrifuging the tubes at 1300 g for 10 minutes 
in room temperature. Serum found above the gel separator was aspirated in the 
BSL 2 hood and stored in sterile 1.6 ml tubes at -80°C.  
 
Anti-nucleosome titers of the patients were obtained using the ELISA kit from 
Euroimmun AG (Lübeck, Germany). Sera from four lupus patients with 
clinically active disease and the highest level of anti-nucleosome titers were 
chosen for the subsequent preparation of SLE ICs.    
 
2.4 CELL BIOLOGY TECHNIQUES  
 
2.4.1 Preparation of PBMCs  
Enriched peripheral blood leukocytes in the form of buffy coats, prepared 
from whole blood from healthy donors, were obtained from the National 
University Hospital Blood Bank with the Institutional Review Board’s 
approval. Each buffy coat (of approximately 25 ml) was extracted from the 
69 
 
blood pack with a sterile 18 gauge needle attached to a 50 ml sterile syringe 
and diluted with 1X PBS to a total volume of 60 ml. 30 ml of diluted sample 
was carefully layered onto 12.5 ml of Ficoll-Paque Plus in a 50 ml fulcrum 
tube (total 2 tubes) and centrifuged for 30 minutes at 400 g without breaks. 
The milky white interphase, containing the PBMCs, between the Ficoll and the 
serum was carefully aspirated with a 5 ml sterile Pasteur pipette. The 
interphase from the 2 tubes were pooled into a single 50 ml fulcrum tube and 
the volume top up to 50 ml with 1X PBS. The cells were washed a total of 4 
times (twice at 200 g for 15 minutes, and twice at 100 g for 10 minutes) with 
50 ml of 1X PBS each time. The PBMCs were subsequently diluted to the 
necessary cell density for downstream experiments or further processed to 
obtain blood monocytes.   
 
2.4.2 Isolation of blood monocytes 
To isolate blood monocytes, plastic adhesion to culture flask was used. The 
PBMCs were re-suspended in 40 ml of warm RPMI1640 containing 5% (v/v) 
BCS, 100 units/ml of Penicillin and 100μg/ml of Streptomycin, and split 
equally into two T-75 flasks and cultured for 1.5 hours at 37°C with 5% CO2. 
 
Non-adherent cells (mainly lymphocytes) were removed by four consecutive 
washes with 10 ml of pre-warmed RPMI1640 culture medium used as for 




2.4.3 Culturing of human moDCs and MΦ  
The isolated human monocytes were cultured in 6 well culture plates at a 
density of 1.5   106 cells/ml (2 ml of cell suspension in each well) in 
RPMI1640 culture medium containing 10% (v/v) BCS, 100 units/ml 
Penicillin, 100 μg/ml Streptomycin, 2 mM L-glutamine, 1 mM sodium 
pyruvate and 0.0012% (v/v) β-mercaptoethanol.  
 
To obtain moDCs, the cells were cultured in the presence of 20 ng/ml of GM-
CSF and 40 ng/ml of IL-4 for 6 days at 37°C with 5% CO2. For MΦ, the 
monocytes were cultured either in the presence of M-CSF 20 ng/ml to obtain 
M-CSF differentiated MΦ (MMF), or in the presence of GM-CSF 20 ng/ml to 
obtain GM-CSF differentiated MΦ (GMMF) for 6 days at 37°C in 5% of CO2. 
The differentiating cells were replenished with fresh medium every two days 
by aspirating half the volume of each well and replenishing the same volume 
with the respective cytokines. After differentiation for 6 days, DCs and MΦ 
were harvested by gentle scrapping for downstream experiment.  
 
2.4.4 Cell lines culture  
All cell lines were obtained via American Type Culture collection (Manassas, 
VA, USA) and kept in T-75 flasks with a total of 20 ml of medium in 
humidified incubator at 37°C in the presence of 5% CO2. The different media 







Table 2.4: Cell lines’ culture media compositions.
 Cell lines Media compositions 
HEK293T cells (Human 
embryonic kidney cells) 
DMEM with: 
1) BCS 10% (v/v), 
2) Penicillin 100 units/ml and Streptomycin 100 μg/ml, 
and  
3) L-glutamine 2mM.  
 
Jurkat T-cells RPMI1640 with: 
1) FCS 10% (v/v), 
2) Penicillin 100 units/ml and Streptomycin 100 μg/ml,   
3) L-glutamine 2 mM, 
4) Sodium pyruvate 1 mM, and 
5) β-mercaptoethanol 0.0012% (v/v). 
 
U937 cells  
 
RPMI1640 with: 
1) FCS 10% (v/v), 
2) Penicillin 100 units/ml and Streptomycin 100ug/ml, 
and   




2.4.5 Induction of apoptosis  
Jurkat T-cells were harvested and centrifuged at 400 g for 5 minutes and 
washed thrice with 1X PBS. Subsequently, the cells were re-suspended in 
serum free RPMI1640 with 100 units/ml Penicillin and 100 μg/ml 
Streptomycin to a density of 3   106 cells/ml and 2 mls were seeded into each 
well of the 6 well culture plate. Apoptosis was induced by UV irradiation 
(Spectroline Select XLE-1000 UV crosslinker outfitted with 254nm lamp 
manufactured by Spectronics Corporation (Westbury, NY, USA)) at a dose of 
500 mJ/cm
2
. The cover of the plate must be removed during the irradiation. 
The control viable cells were prepared in a similar manner but not irradiated. 
Apoptosis was assessed by the presence of DNA laddering and Annexin-V-




In certain experiments, Jurkat T-cells were re-suspended in 1X PBS with 
Penicillin (100 units/ml) and Streptomycin (100 μg/ml) at 5   107 cells/ml. 
Induction of apoptosis was done similar as above with UVC irradiation at 500 
mJ/cm
2
. As a comparator, necrotic Jurkat T- cells were obtained with repeated 
freeze-thaw cycles. Jurkat T cells at 5   107/ml in 1X PBS with Penicillin 
(100 units/ml) and Streptomycin (100 μg/ml) were initially freeze for 30 
minutes at -80°C and then thawed. The cycle was repeated thrice with freezing 
at -80°C for 10 minutes followed by thawing. The supernatant was collected 
after centrifugation at 500 g for 5 minutes to remove the cellular debris.  
 
U937 cells were commonly used as a source of autoantigens for the formation 
of SLE ICs with SLE patients’ sera (Bave, Alm et al. 2000). It was found to be 
better in the induction of PBMCs IFN-α production in complex with SLE 
autoantibodies as compared to the other cell lines (including Jurkat T-cells). 
Induction of apoptosis of U937 cells was done as previously described with 
minor variations (Lovgren, Eloranta et al. 2004). The cells were cultured, 
harvested, centrifuged at 500 g for 5 minutes and wash thrice in 1X PBS. 
Subsequently, the U937 cells were re-suspended to a density of 5   107/ml in 
1X PBS supplemented with Penicillin and Streptomycin in the same 
concentration used for the culture media. Induction of apoptosis was by UV 
irradiation at a dose of 500 mJ/cm
2
. The cells were cultured for another 24 
hours in the humidified incubator at 37°C in the presence of 5% CO2. The 
supernatant was collected after centrifugation at 500 g for 5 minutes to remove 




2.4.5.1 DNA laddering  
The presence of the characteristic DNA laddering of ACs was determined with 
the quick apoptotic DNA ladder detection kit manufactured by BioVision. In 
brief, after an appropriate period of time lapse after apoptosis induction, 1  
 105 cells were harvested and washed once with 1X PBS. The cells were 
pelleted by centrifugation at 500 g for 5 minutes. After removal of the 
supernatant, the cells were lysed with 35 μl of the kit’s lysis buffer and the 
mixture sequentially treated with 5 μl of the kit’s enzyme A for 10 minutes at 
37°C and followed by 5 μl of enzyme B for 30 minutes at 50°C. This was 
followed by the ammonium acetate-isopropanol DNA precipitation in –20°C 
for 10 minutes. The DNA was then pelleted by centrifuging at 18,000 g for 10 
minutes. The supernatant was removed and the DNA pellet washed with 0.5 
ml 70% ethanol. After ethanol removal, the sample was air dried at room 
temperature for 10 minutes and dissolved in 30 μl of the kit’s DNA suspension 
buffer and loaded onto a 1.2% (w/v) agarose gel containing 1:10,000 times 
dilution of GelGreen. 
 
2.4.5.2 Annexin-V-FITC/Propidium iodide staining   
The Annexin-V-FITC/Propidium Iodide Apoptosis Detection Kit II was used 
for this assay. A total of 1   105 cells were used per staining reaction and re-
suspended with 100 μl of Annexin-V binding buffer after being washed twice 
in cold 1X PBS. 5 μl of Annexin-V-FITC and 5μl of propidium iodide were 
added to each reaction and incubated for 15 minutes at room temperature in 
the dark. After incubation, 400 μl of Annexin-V binding buffer was added to 
each reaction. Cells were analysed by flow cytometry within an hour.  
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2.4.6 Cell culture treatment and stimulation  
 
2.4.6.1 In-vitro treatment of ACs with C1 complex and C1s 
The Jurkat T-cells were harvested, washed to remove all traces of serum from 
culturing medium and re-suspended in serum free RPMI 1640 with 100 
units/ml Penicillin and 100 μg/ml Streptomycin to a density of 3   106 
cells/ml and 2 ml were seeded into each of the 6 well culture plate. Induction 
of apoptosis was carried out as described with UVC irradiation. After UVC 
irradiation, the cells were incubated at 37°C in 5% CO2 for 2.5 hours before 
being harvested and transferred into 1.6 ml microcentrifuge tubes. 1X PBS, C1 
complex (Merck Millipore (Calbiochem), Billerica, MA, USA) or C1s (Merck 
Millipore (Calbiochem), Billerica, MA, USA), was added into the ACs and 
viable controls (Jurkat T-cells treated in the same manner except UV 
irradiation). The C1 complex concentration used was 5 μg/ml and C1s 
concentration of 5, 2.5 and 1 μg/ml. The cells were incubated at 37°C for 30 
minutes before the supernatant was collected by centrifugation at 1000 g for 5 
minutes at 4°C. SDS-PAGE and immuno blotting was done. To determine the 
specificity of cleavage by C1 complex, C1-INH (105 μg/ml) was used. 
 
2.4.6.2 In-vitro C1s digestion of HMGB1 and C1s treatment of HMGB1 LPS 
complex for cell stimulation   
To determine the in-vitro digestion of HMGB1, human serum purified C1s 
(Merck Millipore (Calbiochem), Billerica, MA, USA) and eukaryotic 
expressed rHMGB1 (R&D systems, Minneapolis, MN, USA) were used. BSA 
from Sigma-Aldrich (St. Louis, MO, USA) was used as a negative control and 
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complement C4 protein (Merck Millipore (Calbiochem), Billerica, MA, USA), 
a known C1s substrate, was used as a positive control of cleavage. All the 
reaction mixtures including the controls were prepared in 0.2 ml PCR tubes 
with the cleavage buffer as described in table 2.3 (50 mM Tris, 150 mM NaCl, 
0.2% (w/v) PEG8000). The enzyme, activated C1s, was used at a 
concentration of 11 μg/ml and the concentrations of HMGB1, C4 and BSA 
were at 10, 10 and 5 μg/ml respectively. The samples, including the controls, 
were incubated at 37°C for 20 to 24 hours in a Thermo Cycler (2720 Thermo 
Cycle, Life Technologies (Applied Biosystems) Carlsbad, California, USA).  
 
A different source of rHMGB1, the prokaryotic expressed His-tagged protein 
from GenScript (Piscataway, NJ, USA) was used to re-validate the cleavage 
observed with the rHMGB1 from mammalian expression system (R&D 
systems, Minneapolis, MN, USA). In addition, C1 complex (range of 
concentration: 1.72 to 13.75 μg/ml) comparison of C1s alone (range of 
concentration: 2.57 to 22 μg/ml) digestion of His-tagged rHMGB1 (20 μg/ml) 
in the cleavage buffer was done to determine the kinetics and cleavage pattern.  
 
Recombinant human C1s and recombinant human HMGB1 (both purchased 
from R&D systems, Minneapolis, MN, USA) and LPS (Sigma-Aldrich, St. 
Louis, MO, USA) were used in the preparation of cell stimuli. The in-vitro 
reaction mixtures were prepared in 0.2 ml PCR tubes in the cleavage buffer as 
above. For cell stimulation of monocytes, MΦ and DCs, recombinant human 
C1s (eukaryotic expression system), recombinant human HMGB1 (eukaryotic 
expression system) and LPS were prepared in a 10 μl reaction volume with the 
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cleavage buffer with HMGB1 at 5 μg/ml, recombinant human C1s at 2.75 
μg/ml and various LPS concentration. The reaction mixtures including the 
control buffer were incubated at 37°C for 24 hours in the Thermo cycler 
before being used for cell stimulation.  
 
For stimulation, 2 μl of each stimulus was added into 98 μl of monocytes, MΦ 
or DCs in triplicates in a 96-well flat bottom plate. The cells were bathed in 
OPTI-MEM 1 supplemented with Penicillin (100 units/ml) and Streptomycin 
(100 μg/ml) at a cell density of 6   105 cells/ml. After addition of stimuli, the 
cells were incubated in the humidified incubator at 37°C in 5% of CO2. After 
24 hours, the plate was centrifuged at 1000 g for 5 minutes and the supernatant 
carefully aspirated and transferred to a new plate. TNF-α, IL-6 and IL-10 
concentrations in the supernatant were determined by ELISA. 
 
For stimulation of cells with apoptotic supernatant as a source of endogenous 
HMGB1 in combination with LPS, Jurkat T-cells were washed thrice in 1X 
PBS and re-suspended in 1X PBS supplemented with Penicillin (100 units/ml) 
and Streptomycin (100 μg/ml) to a cell density of 3, 6, 9, 12 or 24 million per 
ml. UV irradiation was carried out as above with a dose of 500mJ/cm
2 
and 2 
mls of cell suspension in each well of a 6 well plate. The apoptotic supernatant 
was then harvested at different time-points by centrifugation at 1000 g for 5 
minutes.  
 
The DCs were harvested by gentle scrapping, washed with 1X PBS and re-
suspended in OPTI-MEM 1 supplemented with Penicillin (100 units/ml) and 
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Streptomycin (100 μg/ml) at a cell density of 6   105 cells/ml with different 
concentration of LPS of 0, 5 or 10 ng/ml. 90 μl of these different preparations 
were then seeded into each well of a 96 well plate format in triplicates for each 
test condition. 10 μl of each apoptotic supernatant sample was then added into 
the DCs. The cells were incubated in the humidified incubator at 37°C in 5% 
of CO2 for 24 hours before the supernatant was harvested as described above. 
TNF-α and IL-6 concentrations in the supernatant were determined by ELISA. 
 
2.4.6.3 Preparation of SLE ICs and PBMCs stimulation  
To generate SLE ICs, the sera from 4 juvenile SLE patients were added into 
the apoptotic U937 supernatant. These patients were selected because they had 
active disease and positive anti-nucleosome autoantibody. 100 μl of each 
stimulus was prepared with 40 μl of apoptotic U937 supernatant (40% v/v) 
with either 1 μl (100X dilution) or 10 μl (10X dilution) of serum from each 
patient in sterile 1.6 ml microcentrifuge tube. The volume was topped up to 
100 μl with 1X sterile PBS supplemented with 100 units/ml Penicillin and 100 
μg/ml Streptomycin. The mixtures were incubated at 37°C for 30 minutes to 
allow time for formation of ICs before addition into the IFN-αB2 primed 
PBMCs.  
 
After obtaining PBMCs from the buffy coat (Section 2.4.1), the cells were re-
suspended to a cell density of 5 million per ml of Macrophage-SFM with 100 
units/ml Penicillin and 100 μg/ml Streptomycin and primed with 500 units/ml 
of  IFN-αB2. 90 μl of cell suspension was seeded into each well in duplicates 
for each condition in a 96-well flat bottom plate. 10 μl of each stimulus was 
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added into each well. After further 24 hours incubation in the humidified 
incubator at 37°C in 5% of CO2, the plate was centrifuged at 1000 g for 5 
minutes and the supernatant carefully aspirated and transferred to a new plate. 
IFN-α concentration in the supernatant were determined by ELISA. The serum 
in combination with the apoptotic supernatant with the highest IFN-α response 
was subsequently used for all experiments. 
 
2.4.6.4 C1 complex, C1q and C1s treatment of apoptotic U937 cells 
supernatant  
Apoptotic U937 cells supernatant was prepared from 5   107 cells/ml of 1X 
PBS with antibiotics by UVC irradiation. Treatment of the apoptotic 
supernatant was done in 1.6 ml microcentrifuge tubes in a 40 μl reaction 
mixture at 40% (v/v) of apoptotic supernatant and C1 complex at a dose 1.5 to 
24 μg/ml. C1s was used at a dose from 25 to 100 μg/ml. For C1q treatment, an 
equimolar amount of C1q comparable to that present in C1 complex was used. 
C1-INH was also used (at 100 μg/ml) to determine the contribution of C1s in 
C1 complex in reducing the SLE ICs induction of IFN-α. The volume was 
topped up with 1X PBS with 100 units/ml Penicillin and 100 μg/ml 
Streptomycin. The mixture was then incubated at 37°C for 30 minutes before 
being put on ice and the sample denatured and reduced with the 5X Laemmli 
Buffer with DTT by heating to 100°C for 10 minutes before SDS-PAGE 
separation. 
 
Stimuli for PBMCs stimulation were prepared similarly except with the 
addition of SLE serum at 1% (v/v) into the 40 μl reaction volume. The 
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mixtures were similarly incubated at 37°C for 30 minutes before being added 
into the PBMCs.   
 
Slight variations in certain experiments included the followings. 
1) Use of different concentration of apoptotic supernatant from 20 to 40% 
(v/v). 
2) Use of different amount of SLE serum (50X dilution).  
3) Eventual use of greater cell density of PBMCs to increase the amount of 
IFN-α (8 million per ml).  
 
2.4.7 Mammalian cell protein expression   
HEK293T cells were transiently transfected with the calcium phosphate 
method as described previously (Sambrook and Russell 2006). 25 μg of  
pcDNA 3.1 myc-His A plasmid with a FLAG-HMGB1-polyhistidine DNA 
construct was used. In brief, HEK293T cells were cultured in DMEM 
supplemented with 10% (v/v) BCS, 100 units/ml Penicillin and 10 ug/ml 
Streptomycin, 2mM L-Glutamine and seeded the day prior to transfection in 
T-75 flask. The cells were allowed to divide for 21 to 24 hours  to achieve a 
confluency of approximately 50 to 75%. The supernatant was aspirated and 
replaced with fresh culture media and incubated for 1 hour at 37°C in the 
presence of 5% CO2 prior to the addition of the calcium phosphate plasmid 
complex.  
A total of 25 μg of plasmid  was added to 100 μl of 2.5 M CaCl2 and topped 
up with 0.1 TE buffer (1 mM Tris-HCl, 0.1 mM EDTA, pH 7.6) to 1 ml. 1 ml 
of 2X HEPES buffer (140 mM NaCl, 1.5 mM Na2HPO4, 50 mM HEPES, pH 
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7.05) was added rapidly to the mixture and allowed to stand at room 
temperature for 1 minute and then added immediately to HEK293T cells. The 
T-75 flask of cells was incubated for 4 hours at 37°C, washed twice with 10 
ml of warm 1X PBS (at 37°C) and replaced with 20 ml of SFMHEK293 and 
incubated for 48 hours. The supernatant was  aspirated,  centrifuged at 400 g 
for 5 minutes and filtered through 0.22μm to remove cell debris. 
 
2.5 MOLECULAR BIOLOGY TECHNIQUES  
 
2.5.1 PCR  
PCR reaction (50 μl) for cloning of HMGB1 was prepared with the following 
constituents: 
1) 5 μl of Pfu (Pyrococcus furiosus) DNA polymerase 10X buffer containing 
MgS04,  
2) 1 μl of dNTPs, 
3) 1 μl each of 10 μM of forward and reverse primers, 
4) 2 μl of cDNA sample, 
5) nuclease free water top up to final volume of 50 μl, and  
6) 0.3 μl of Pfu DNA polymerase (3 units/μl).  
 
The Thermo Cycler (2720 Thermo Cycle, Life Technologies (Applied 
Biosystems) Carlsbad, California, USA) was setup with the following 
protocol: 
1) Initial denaturation of 95°C for 5 minutes, 
2) 95°C for 1 minute,  
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3) Annealing temperature specific for HMGB1 primers (57°C) for 1 minute,  
4) Extension temperature 72°C for 2 minutes,  
5) Repeat for a total of 35 cycles for 2 to 4,  
6) Final extension at 72°C for 10 minutes, and  
7) Maintain at 4°C until removal from Thermo Cycler for storage. The 
annealing temperature used was 2°C below the Tm (melting temperature) 
of the pair of primers. The extension time for a particular PCR reaction 
was dependent on the length of the amplified target sequence. For Pfu 
polymerase, extension was carried out at 2 minutes/kb of expected DNA 
products. 
 
2.5.2 Agarose gel electrophoresis  
DNA was resolved with agarose gel containing GelGreen stain (1:20,000X 
dilution) in 1X TAE using a Hoefer HE 33 mini horizontal submarine unit 
(Hoefer, Inc. Holliston, MA, USA) at 80 Volts. The % (v/v) agarose gel used 
was dependent on the separation required. Typically, for resolution of linear 
DNA between the expected sizes of 500 bp to 7 kbp, a 1.2 % (v/v) agarose 
was used and for 100 bp to 3 kbp, a 1.5% to 1.8% (v/v) was used.    
 
Briefly, for a 1.2% (v/v) agarose, 0.6 g of agarose was added to 50 ml of 1X 
TAE buffer and heated to 100°C with a microwave. The mixture was 
intermittent checked and swirled to ensure that the agarose had completely 
melted with no particulates of agarose seen. The mixture was allowed to cool 
to approximately 60°C (by touch) and 2.5 μl of GelGreen stain was added and 
mixed by swirling. The agarose mixture was poured onto a cassette with the 
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appropriate plastic well comb. Upon solidifying, the agarose gel was placed 
into the electrophoresis unit with 1X TAE buffer. After adding in the 6X DNA 
loading dye (1 part to 5 parts sample), the samples were loaded into the wells. 
For analysis of sucrose gradient ultracentrifugation fractions, a 6X loading dye 
containing 0.6% (w/v) SDS was used. The SDS was used as a denaturant to 
free the nucleosome DNA fragments from its protein components (e.g. histone 
proteins). 
 
Electrophoretic separation was typically carried out at 80 Volts, and stopped 
when the bromophenol blue dye front was about 1 cm from the bottom edge of 
the horizontal agarose gel. The gels were visualised via UV illuminator with 
ChemiDoc MP Imager (Bio-Rad, Hercules, CA, USA) and the images 
captured digitally with a CCD (Charge-Coupled Device) camera unit. 
 
2.5.3 DNA Sanger Sequencing  
Sanger DNA sequencing reaction was carried out with BigDye Terminator 
Cycle Sequencing kit version 3.1 purchased from Life Technologies (Applied 
Biosystems, Carlsbad, California, USA) in accordance with manufacturer’s 
protocol with some minor variation. Briefly, the 20 μl reaction was prepared as 
followed: 
1) 1 μl of sequencing primer (5 μM),  
2) 3 μl of kit’s sequencing buffer, 
3) 300 ng of DNA sample,  
4) Top up with nuclease free water to 18 μl, and  
5) Add 2 μl of BigDye reaction premix.  
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The sequencing cycling was done with the following setup: 
1) Denaturation at 96°C for 30 seconds,  
2) Annealing of primer at 50°C for 15 seconds, 
3) Extension at 60°C for 4 minutes, and  
4) Repeat cycle from 1 to 3 for 30 cycles and  
5) 4°C until removal from Thermal Cycler.  
 
Clean-up of DNA sequencing reaction to remove the unincorporated ddNTPs, 
enzyme and salt was carried out. The reaction mixture was transferred to a 1.6 
ml microcentrifuge tube for ethanol DNA precipitation and clean-up. 3 μl of 3 
M sodium acetate pH 4.6, 14 μl of nuclease free water, and 63 μl of 100% 
ethanol were added to the 20 μl sequencing reaction mixture and the 
precipitation was carried out at -20°C for 30 minutes. Centrifugation was 
subsequently done at 18,000 g for 30 minutes with the Eppendorf 
microcentrifuge 5424 (Eppendorf, Hamburg, Germany). The supernatant was 
aspirated and the DNA pellet washed with 500 μl of 70% ethanol and 
centrifuged at 18,000 g for 10 minutes. The ethanol was aspirated completely 
and the pellet was allowed to air-dry in room temperature for 10 to 15 minutes. 
The sample was stored at -20°C until it was delivered to the sequencing 
laboratory. 
 
2.5.4 Purification of DNA from agarose gel/solution 
The DNA band or product from solution was purified using the Illustra GFX 
PCR DNA and Gel band Purification kit as per manufacturer’s protocol. Gel 
band purification was carried out after restriction endonucleases digestion of 
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the insert and plasmid for cloning. After electrophoretic separation, the 
agarose gel was viewed under UV trans-illumination and excised, into a 1.6 ml 
microcentrifuge tube and weighed. 100 μl of the kit’s capture buffer 
(minimum 300 μl) was added for every 0.1 g of excised gel and heated to 
60°C. The melted gel sample mixture was transferred to the kit’s column and 
incubated for 1 minute, and centrifuged at 16,000 g for 30 seconds.  The 
column was washed with 500 μl wash buffer and centrifuged at 16,000 g for 
30 seconds and the waste in the collection tube was discarded. The column 
was incubated with 40 μl of nuclease free water for 5 minutes and the purified 
DNA eluted by centrifugation at 16,000g for 1 minute into a fresh 1.6 ml 
microcentrifuge tube. 
 
For purification of PCR DNA product in solution, 500 μl of capture buffer was 
added to the PCR reaction mixture of up to 100 μl. The subsequent steps were 
as stated above for the DNA purification from agarose gel. 
 
2.5.5 Restriction endonuclease digestion 
The double restriction digestion was performed for the PCR product and 
pcDNA3.1 expression plasmid at 37°C for 4 hours in the water bath with a 
reaction volume of 40 μl. The constituents of the reaction mixture were as 
followed: 
1) 30 μl of DNA sample (typically 0.4 to 3 μg of DNA),  
2) 4 μl of 10X restriction buffer (Multi-Core (Promega. Madison, WI, USA)),  
3) 0.4 μl of acetylated BSA (10 μg/ml), 
4) 1 μl restriction enzyme, Kpn I and Age I, (10 units/ml), and  
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5) Top up to 50 μl with nuclease free water. 
 
2.5.6 Ligation of DNA insert into vector 
DNA ligation of restriction enzymes digested DNA insert and vector was 
carried out in 10 μl ligation reaction volume with T4 DNA ligase and T4 DNA 
ligase buffer overnight at room temperature. Briefly the amount of DNA insert 
to vector was calculated with the following equation for a molar vector to 
insert ratio of 1:3: 
                 (  )  
                                   (  ) 
            (  )
 
 
The 10 μl reaction mix constituted the following: 
1) X μl of vector to be used,  
2) Y μl of vector as calculated,  
3) 0.1 μl of T4 DNA ligase enzyme,  
4) 1 μl of T4 DNA ligase buffer, and  
5) Top up to 10 μl with nuclease free water. 
 
2.5.7 Bacterial transformation with plasmid DNA  
The Escherichia coli strain DH5α (Invitrogen, Carlsbad, California, USA) was 
used for transformation and propagation of plasmid DNA. The transformation 
competent DH5α in a 1.6 ml microcentrifuge tube was thawed on ice.  
 
5 μl of the ligation reaction was added into 50 μl of competent bacteria cells 
and incubated immediately on ice for 30 minutes. The competent bacteria cells 
with the ligated product mixture was heat shocked at 42°C (in a water bath) 
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for 90 seconds and then put back on ice for another 5 minutes. 200 μl of SOC 
medium (Sigma-Aldrich, St. Louis, MO, USA) was added into it and the 
mixture shake on a shaking platform at 200 rpm for 30 minutes at 37°C after 
which  100 μl of the mixture was spread onto an LA plate and incubated 
overnight at 37°C. The SOC medium was warmed to 37°C 5 minutes before 
usage.  
 
2.5.8 Cloning of HMGB1 gene into target vector 
Cloning primer pairs specific to HMGB1 were synthesized (Section 2.2.1). 
The HMGB1 gene would be inserted into a pcDNA3.1 myc-His A with a pre-
existing 5’ DNA sequence encoding an anionic trypsin-2 precursor signal 
peptide (Mus muscularis) followed by FLAG (DYKDDDDK) tag between the 
Hind III and Kpn I restriction sites (Figure 2.2).    
 
 
Figure 2.2: Multiple cloning site for pcDNA3.1 myc-His A. A secretory signal 
peptide and FLAG tag DNA sequences were previously cloned into the expression 
plasmid between the Hind III and Kpn I was used.   
 
For the 5’ forward primer, the design was as followed: 3 nucleotides to allow 
restriction enzyme to sit on, Kpn I restriction site sequence (not found within 
the gene of interest), 5’ end of gene of interest starting with ATG start codon 
with extension to a suitable length into gene. For the 3’ reverse primer, the 
design was as such: 3 nucleotides to allow restriction enzyme to sit on, Age I 
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restriction site (not found in HMGB1 gene), TAA (stop codon) replaced with 
AAA, reverse complement of 3’ end of HMGB1 gene of a suitable length. The 
removal of the stop codon would allow the incorporation of the Histidine tag 
into the C-terminal end of the protein.  
 
The primers were checked for specificity, primer dimer interactions, secondary 
structures and for suitable melting temperature. The HMGB1 gene was 
amplified from the cDNA in a PCR reaction and resolved by agarose gel 
electrophoresis to check that it was of the correct expected length. The PCR 
product was purified with the Illustra GFX PCR DNA and Gel band 
Purification kit. Restriction digestion was performed as described for the 
plasmid and DNA insert separately and separated by agarose gel 
electrophoresis and the desired restricted products excised, purified and ligated 
as described above. After ligation, transformation of competent bacterial cells 
was carried out.  
 
2.5.9 Purification of plasmids from transformed bacteria 
Wizard Plus SV Minipreps DNA purification system was used in the small 
scale purification of plasmid for DNA sequencing of bacterial DNA clones 
from the LA agar that had been transformed with the pcDNA3.1 myc-His A 
plasmid that conferred the ampicillin resistance trait. This was done prior to 
the use of the expression plasmid for large scale purification for transient 




In brief, each unique bacterial colony was picked with a sterile 100 μl pipette 
tip and inoculated into 5 mls of LA broth and allowed to grow overnight. The 
bacteria were pelleted with centrifugation at 10,000 g for 5 minutes and the 
culture medium removed by pouring. The pellet was resuspended in 250 μl of 
cell resuspension solution and 10 μl of alkaline protease solution was added 
with mixing by inversion 4 times. Mixture was incubated at room temperature 
for 5 minutes and 350 μl of the neutralisation solution was added with mixing 
by inversion. Centrifugation was done at 16,000 g for 10 minutes at room 
temperature. The supernatant was then decanted into the spin column with the 
collection tube and centrifuged at 16,000 g for 1 minute at room temperature. 
The flowthrough was discarded from the collection tube and reused. The 
column was washed twice, first with 750 μl of wash buffer followed by 
centrifugation at 16,000 g for 1 minute and then with 250 μl of wash buffer 
and centrifugation for 2 minutes at 16,000 g. Each time, the flowthrough was 
discarded. After the last wash, the spin column was transferred onto a sterile 
1.6 ml microcentrifuge tube and the plasmid eluted from the column with 50 
μl of nuclease free water and centrifugation at 16,000 g for 1 minute. DNA 
sequencing to check the integrity of the insert was done as described in section 
2.5.3.       
 
QIAGEN plasmid Maxi kit was used for the purification of plasmids from 
transformed bacteria. Briefly, a single bacteria colony transformed with the 
correct plasmid checked by DNA sequencing was picked from a LA plate and 
inoculated into a starter culture of 2 ml of LA broth. The culture was grown 
for 8 hours at 37°C with shaking at 200 rpm. 400 μl of this starter culture was 
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added into 200 ml of LA broth and cultured for 12-16 hours at 37°C with 
shaking at 200 rpm. The bacterial cells were harvested by centrifugation at 
3,000 g for 15 minutes at 4°C and re-suspended in 10 ml of resuspension 
buffer P1 containing 100 μg/ml RNase A. 10 ml of lysis buffer P2 was added, 
mixed thoroughly and incubated for 5 minutes at room temperature. 10 ml of 
ice-chilled neutralisation buffer P3 was then added, immediately mixed and 
incubated on ice for 20 minutes. The cell lysate was centrifuged at 20,000 g 
for 30 minutes at 4°C. The supernatant was collected into a fresh centrifuge 
tube and loaded onto a QIAGEN-tip 500 column which was pre-equilibrated 
with 10 ml of equilibration buffer QB. The sample was allowed to drip 
through the column via gravity flow. The column was then washed twice with 
30 ml wash buffer QC before the resin-bound DNA was eluted with 15 ml of 
elution buffer QF. To precipitate the eluted DNA, 10.5 ml isopropanol was 
added and centrifuged at 20,000 g for 30 minutes at 4°C. The DNA pellet was 
dissolved with 5 ml of 70% (v/v) ethanol at room temperature and centrifuged 
at 15,000 g for 10 minutes. The DNA pellet was air-dried, dissolved in 400 μl 
of nuclease free water, quantified via Nanodrop and stored at -20°C.  
 
2.6 PROTEIN CHEMISTRY TECHNIQUES  
 
2.6.1 Protein quantification  
Protein quantification was determined with the Bradford assay using the Bio-
Rad protein assay kit. In brief, seven serial dilutions of a standard BSA 
solution were prepared, starting with concentration of 400 μg/ml to 6.25 μg/ml 
and a final blank. 10 μl of each standard and the protein samples were added, 
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in duplicates, into the wells of a 96-well (flat bottom) microtiter plate. The 5X 
dye reagent was diluted (1 part dye to 4 parts distilled water) and syringe 
filtered through a Millex-HV (33 mm) Syringe Filter Unit with a 0.45 µm 
PVDF membrane. 
 
200 μl of the dye was added to each well and incubation done at room 
temperature for 5 minute. Absorbance was measured at 595 nm with the 
Model 680 Microplate reader (Bio-Rad. Hercules, CA, USA.). A standard 
curve was constructed by plotting the known BSA concentrations versus 
absorbance at 595 nm and sample concentrations determined from the curve. 
 
2.6.2 SDS-PAGE electrophoretic separation of proteins and western blot  
For samples derived from apoptotic supernatant (from apoptotic Jurkat or 
U937 cells) with different treatment conditions, equal and comparable sample 
volumes were used. DTT was weighed and added into the 5X Laemmli buffer 
to obtain a DTT concentration of 0.5 M. This was prepared fresh on the day of 
usage if reduction of disulphide bonds was required. 1 part of the 5X Laemmli 
buffer was added to 4 parts of sample.  The samples were heated at 100°C for 
10 minutes and centrifuged to collect all the condensation on the cap of the 1.6 
ml microcentrifuge tube before loading into the wells of the SDS-PAGE gel. 
For non-reducing gel where the disulphide bonds were to be left intact, the 5X 











12.5% 15%  
Distilled water  
 
3.05 ml  3.17 ml  2.35 ml  
1.5 M Tris pH 8.8  
 
- 2.5 ml 2.5 ml 
0.5 M Tris pH 6.8  
 
1.25 ml  - - 
10% (w/v) SDS 
 
50 μl 100 μl 100 μl 
30% (w/v) acrylamide Bis-acrylamide 
solution (Acrylamide: Bis-Acrylamide Ratio: 
37.5: 1) 
 
0.65 ml  4.16 ml  5 ml 
10% (w/v) Ammonium persulfate 
 
25 μl 50 μl 50 μl 
Tetramethylethylenediamine (TEMED)   
 
5 μl 5 μl 5 μl 
 
Fixed percentage resolving gel with a stacking gel layer, of the dimension of 
83 by 73 mm (width   height), was casted using the mini-PROTEAN casting 
module with a 1.5 mm spacer plate. 2 percentages were used: 12.5% for 
separation of proteins with a molecular weight of approximately 20 to 100 
kDa and 15% for separation of proteins with a molecular weight of 
approximately 5 to 70 kDa (Table 2.5 for gel compositions). Electrophoresis 
was carried out at 100 Volts until the required resolution was achieved as 
assessed by the migration of the Bromophenol blue dye front.  
 
The resolved proteins on SDS-PAGE were electroblotted onto a PVDF 
membrane with the Bio-Rad Mini Trans-Blot Cell bathed in chilled 1X 
western blot transfer buffer (Table 2.3) on a magnetic stirrer. The transfer was 
typically done at a constant voltage of 100 Volts for 1.5 hours. After transfer, 
the membrane was blocked with 5% (w/v) non-fat milk in 0.1% (v/v) TBST 
for 1 hour with gentle shaking (80 rpm) on an orbital shaking platform. The 
blocked membrane was then incubated overnight with the primary antibody in 
92 
 
5% (w/v) non-fat milk in 0.1% (v/v) TBST overnight at 4°C. The membrane 
was washed thrice for 10 minutes each with 0.1% TBST and incubated with 
secondary antibody conjugated with alkaline phosphatase enzyme (at 1:4000 
dilution) in 5% (w/v) non-fat milk in 0.1% (v/v) TBST for 1 hour at room 
temperature with shaking at 80 rpm. The membrane was washed thrice for 10 
minutes each with 0.1% (v/v) TBST and incubated with 600 μl (per 
membrane) of the Immun-Star AP Chemiluminescent substrate for 2 minutes 
with subsequent detection by chemiluminscence exposure of X-ray film. 
 
For re-probing of membrane with another primary antibody, the membrane 
was washed thrice for 5 minutes with 0.1% (v/v) TBST on an orbital shaker 
and then bathed in 10 ml or more of western blot stripping buffer to 
completely soak the membrane in a sealed plastic bag. Stripping was done at 
50°C (water bath) for 20 to 30 minutes dependent on the intensity of the prior 
signal with occasional agitation. The membrane was then retrieved carefully 
and washed thrice with 5 minutes washes with 0.1% (v/v) TBST and then 
blocked in 5% (w/v) non-fat milk in 0.1% (v/v) TBST for 30 minutes. The 
stripping efficacy could be tested with the addition of chemiluminescent 
substrate in the absence of antibodies. After the stripping, the membrane could 
be used for re-probing with a new primary antibody. 
 
Densitometry analysis was done with ImageJ 1.43u (National Institutes of 




2.6.3 Polyacrylamide gel staining  
 
2.6.3.1 Coomassie blue sliver stain 
Blue silver stain is a colloidal Coomassie stain and was prepared as previously 
described (Candiano, Bruschi et al. 2004). It has a detection limit of 
approximately 1 ng of protein, in-between that of the conventional silver 
staining and Coomassie stain. After resolving the proteins with SDS-PAGE, 
the gel was soaked and washed thrice with distilled water for 10 minutes each 
with shaking to remove the SDS from the proteins. Subsequently, the gel was 
soaked in the Blue silver stain overnight for no less than 12 hours, and 
subsequently de-stained with repeat changes of distilled water.  
 
2.6.3.2 Silver staining  
Silver staining was done as previously described (Chevallet, Luche et al. 
2006). As the sensitivity of silver staining is high, all reagents utilised must be 
ultra-pure and gels manipulations if necessary, must be handled with non-
powdered latex gloves or nitrile gloves. The proteins were resolved with SDS-
PAGE, and the gel was soaked in fixation solution containing 30% (v/v) 
ethanol, 10% (v/v) acetic acid twice. The first fixation was for 30 minutes and 
the second, after a change of fixation solution was done overnight with 
continuous shaking at 80 rpm. 
  
After overnight fixation, the gel was washed twice with 20% ethanol for 10 
minutes each and subsequently in distilled water twice for 10 minutes. The gel 
was then sensitised in 0.02% (w/v) sodium thiosulfate (pentahydrate salt) for 1 
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minute. The gel was then washed twice in distilled water for 1 minute each 
and then soaked in 12 mM of silver nitrate for 20 minutes to 2 hours. After 
impregnation with silver nitrate, the gel was washed for 10 seconds with 
distilled water.  
 
Development of gel was with the developer solution containing 3% (w/v) 
potassium carbonate, 0.00025 % (v/v) formalin (or 250 μl formalin per liter), 
0.0000125 % (w/v) sodium thiosulfate (or 125 μl of a 10%(w/v) sodium 
thiosulfate per liter) with gentle swirling until the required intensity was 
obtained. The gels were then drained and placed into the stop solution 
containing 4% (w/v) Tris and 2% (v/v) acetic acid for 30 minutes and washed 
twice with distilled water. 
 
2.6.4 Mass spectrometry  
 
2.6.4.1 Samples reduction and alkylation  
Samples for mass spectrometry identification were prepared with extreme care 
to prevent keratin and other exogenous contamination. A 5X SDS running 
buffer (Table 2.3) was prepared fresh with ultrapure (Type 1) water with 50 
mM of DTT. 4 parts of sample was added to 1 part of this buffer and heated 
for 100°C for 10 minutes. The sample was cooled to room temperature and 
Iodoacetamide was added to a concentration of 20 mM (prepared as 200 mM 





Samples were then loaded onto commercially purchased 8-16%, 10 well, pre-
cast gel (Thermo Scientific (Pierce). Waltham, MA, USA) with one empty 
lane in between the samples. The samples were resolved with electrophoresis 
at 100 Volts with fresh 1X SDS running buffer and subsequently washed with 
ultrapure water and stained with blue silver stain (fresh) in a new plastic 
container.   
 
2.6.4.2 Identification of proteins   
The mass spectrometry service was provided externally by the mass 
spectrometry laboratory under the Experimental Therapeutics Centre (Biopolis 
Shared Facilities) which included gel cutting, trypsin digestion, extraction, LC 
MS/MS, database search and Scaffold reporting. 
The database searching was done after extraction of the tandem mass spectra. 
All MS/MS samples were analysed using Mascot (Matrix Science, London, 
UK; version 2.4.0) and X! Tandem (The GPM, thegpm.org; version 
CYCLONE (2010.12.01.1)). Mascot was set up to search the 
IPI_human_20130201 database (91,464 entries) assuming the digestion 
enzyme trypsin. X! Tandem was set up to search a subset of the 
ipi.HUMAN.v3.87 database also assuming trypsin. Mascot and X! Tandem 
were searched with a fragment ion mass tolerance of 0.60 Da and a parent ion 
tolerance of 300 PPM. Iodoacetamide derivative of cysteine was specified in 
Mascot and X! Tandem as a fixed modification. Pyroglutamate from glutamate 
of the n-terminus, s-carbamoylmethylcysteine cyclisation (N-terminus) of the 
n-terminus, deamidation of asparagine and glutamine and oxidation of 
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methionine were specified in Mascot and X! Tandem as variable 
modifications.  
 
Scaffold (version Scaffold_4.0.5, Proteome Software Inc., Portland, OR) was 
used to validate MS/MS based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 
95.0% probability by the Peptide Prophet algorithm with Scaffold delta-mass 
correction (Keller, Nesvizhskii et al. 2002). Protein identifications were 
accepted if they could be established at greater than 99.0% probability and 
contained at least 2 identified peptides. Protein probabilities were assigned by 
the Protein Prophet algorithm (Nesvizhskii, Keller et al. 2003).  
 
2.6.5 Enzyme Linked Immunosorbent Assay  
 
2.6.5.1 Human cytokines detection from cell stimulation  
For the detection of human cytokines secreted from human primary cells 
(PBMCs, monocytes, MΦ and DCs), the experimental setup was typically in a 
96-well format either in duplicates or triplicates. The cell numbers per well 
was dependent on the cell type used and the cytokines to be detected. After 24 
hours of incubation with the stimuli, the supernatant was typically centrifuged 
at 1,000 g for 5 minutes to remove the cells and transferred to a new plate and 
stored in -20°C until further examination.  
 
For human TNF-α, IL-6 and IL-10, detection was done with commercially 
available ELISA kits (BD OptEIA
TM
 ELISA sets from BD Biosciences. 
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Franklin Lakes, New Jersey, USA). The ELISA was done in triplicates for 
each test condition for these cytokines and performed according to the 
manufacturer’s instructions. In brief, the capture antibody was diluted (1:250) 
into the coating buffer (0.1 M sodium carbonate, pH 9.5) and were coated onto 
a 96 well Maxisorp Nunc plate (100 μl per well) overnight at 4°C. The plate 
was washed thrice with 300 μl of 0.05% (v/v) PBST per well and blocked with 
200 μl of BD assay diluent (10% (v/v) heat inactivated FCS in 1X PBS) per 
well in room temperature for 1 hour. After blocking, the wells were washed 
thrice with 0.05% PBST. Subsequently, 100 μl of the cytokine standards and 
samples (appropriately diluted in the assay diluent) were added. The samples 
were incubated in the plate overnight at 4°C and subsequently washed 5X with 
0.05% (v/v) PBST. The biotinylated detection antibody and streptavidin 
conjugated HRP was diluted into the assay diluent together at a dilution factor 
of 1:250 for each and 100 μl was added to each well and incubated for 1 hour 
at room temperature. The wells were finally washed 7X with 0.05% (v/v) 
PBST and 100 μl of TMB substrate was added into each well and allowed to 
develop in the dark for 15-30 minutes. The reaction was stopped with 50 μl of 
stop solution (1 M Sulphuric acid) per well, and the absorbance at 450nm was 
read immediately with the Model 680 Microplate reader (Bio-Rad. Hercules, 
CA, USA). The linearised standard curve was constructed by plotting the 
known cytokine concentrations versus that of the absorbance readings (Log 
scale). The absolute concentration of each sample was derived by comparing 
against the standard curve and back-multiplying with the dilution factor used 




IFN-α was detected from human PBMCs with the VeriKine™ Human 
Interferon-α ELISA Kit (PBL Assay Science. Piscataway, NJ, USA). The 
experiment was done in duplicates and the PBMCs used at a density of 5 or 8 
  106/ml. 
 
The high sensitivity range of standards (12.5 to 500 pg/ml) was prepared. Test 
samples of unknown IFN-α concentration was diluted 10X using the kit’s 
dilution buffer (10 μl of sample into 90 μl of buffer). 100 μl of IFN-α known 
standards, blank and test samples were added in duplicates into each well of 
the pre-coated microtiter plate, sealed and incubated in room temperature for 1 
hour. Wells were washed with 250 μl of the kit’s diluted wash buffer once by 
inverting and blotting the plate on absorbent paper, followed by tapping the 
plate dry.  100 μl of diluted detection antibody solution was then added to all 
wells, covered and incubated for 1 hour in room temperature. After 1 hour, the 
contents of the plate were emptied and the wells washed thrice with the diluted 
wash buffer. After washing, 100 μl of diluted HRP conjugate solution was 
added to all wells, covered and incubated for 1 hour in room temperature. 
During this incubation period, the TMB substrate solution must be warmed to 
room temperature. After 1 hour, the contents of the plate were emptied and the 
wells washed 4X with diluted wash buffer. 100 μl of TMB substrate was 
added into each well and incubation was done in the dark, for 15 minutes 
without a plate sealer. After the 15 minutes incubation, 100 μl of the kit’s stop 
solution was added to each well. And the plate absorbance at 450 nm 




2.6.5.2 Determination of SLE patients’ anti-nucleosome titers  
The anti-nucleosome titers were determined using commercial kit that used 
native mononucleosomes purified from calf thymus that was free from histone 
H1 and non-histone proteins. This antigen was found to be specific for SLE 
and did not cross react with sera from scleroderma patients (Suer, Dahnrich et 
al. 2004). 3 calibrator standards were provided: 200 RU/ml (Calibrator 1), 20 
RU/ml (Calibrator 2) and 2 RU/ml (Calibrator 3), along with a positive and 
negative control. A cut-off value of 20 RU/ml was used as at this level, 204 
healthy blood donors that were tested by this kit were anti-nucleosomes 
negative according to the product insert. The patients’ sera stored in -80°C 
were thawed prior to usage and diluted 200X with the sample buffer. 
 
100 μl of the 3 calibrators, positive and negative controls along with the test 
samples were transferred into the individual pre-coated microplate wells and 
incubated for 30 minutes at room temperature. After incubation, the wells 
were emptied and wash thrice using 300 μl of the 1X wash buffer for each 
wash (diluted from 10X concentrate; 1 part concentrate into 9 parts distilled 
water). The wash buffer were left in the well for 30 to 60 seconds per washing 
cycle and the liquid disposed completely by tapping it on an absorbent paper 
with the wells facing downwards to remove all residual buffer.  
 
After washing off the samples, 100 μl of the enzyme conjugate (HRP-labelled 
anti-human IgG) was added into each well and incubated at room temperature 
for 30 minutes. The enzyme conjugate was then emptied and washed thrice as 
described above. Subsequently, 100 μl of the kit’s substrate solution was 
100 
 
added into each well and incubated for 15 minutes at room temperature away 
from direct sunlight. 100 μl of stop solution was then added into each micro-
well and absorbance at 450 nm measured within 30 minutes. The standard 
curve from which the anti-nucleosome titer was obtained was from point-to-
point plotting of the absorbance value at 450 nm of the 3 calibrators against 
their corresponding antibodies unit.     
  
2.6.6 Nickel-Nitrilotriacetic acid resin purification of polyhistidine tagged 
protein  
Purification of the His-tagged rHMGB1 protein from the expression medium 
obtained from the transient transfection of HEK293T cells was done with the 
Ni-NTA resin (Qiagen GmbH. Hilden, Germany).  
The following reagents were prepared (syringe filtered sterilise with a 0.22 μm 
filter unit). 
1) 10X binding buffer: Tris 200 mM, NaCl 3.5 M, and Imidazole 100 mM 
(pH 8.0).   
2) 1X Ni-NTA wash buffer: Tris 20 mM, NaCl 500 mM and Imidazole 10 
mM (pH 8.0). 
3) 1X Ni-NTA elution buffer: Tris 20 mM, NaCl 500 mM and Imidazole 250 
mM (pH 8.0). 
 
In brief, 500 μl of the Ni-NTA resin slurry was aliquoted out from the storage 
bottle into a 50 ml conical base tube and allowed to stand for 10 to 15 minutes. 
After the resin had settled, the storage medium (approximately 50% of the 
volume of slurry) was removed leaving behind the Ni-NTA resin. 40 ml of the 
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expression medium (after centrifugation to remove the cell debris and syringe 
filter sterilised) was added to 250 μl of the Ni-NTA resin with 1/10 volume of 
the 10X binding buffer (4.5 ml). Gentle rotatory mixing was done overnight at 
2 to 3 rpm at 4°C to allow for protein binding to the nickel base resin. 
 
After the overnight incubation, the mixture was decanted into the gravity flow 
Poly-Prep chromatography columns (Bio-rad. Hercules, CA, USA) which 
would trapped the Ni-NTA resin. The flowthrough was collected for analysis 
to determine the adequacy of binding.     
 
Washing was done with 10 CVs of the 1X Ni-NTA wash buffer (according to 
the amount of resin which was used in proportionate to the amount of 
expression medium). After washing, the protein was eluted with 1X Ni-NTA 
elution buffer with each elution fraction of 1 CV. The flowthrough, fractions 
from the washing and elution were analysed by SDS-PAGE and subsequently 
silver staining to determine purity.    
 
2.7 STATISTICAL ANALYSIS 
Continuous data were expressed as mean values of experimental triplicates or 
duplicates with standard deviation. Tests for statistical significance were 
performed with Pearson correlation and the Student’s 2-tails unpaired T-test, 
where p < 0.05 was considered significant. Statistical analysis was done with 
STATA version 11.2 (StataCorp. College Station, Texas, USA.).  
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Chapter 3 Identification of Novel Substrates of C1s     
 
3.1 C1S AND AUTOIMMUNITY  
Complete C1s deficiency in humans although rare, is a strong risk factor for 
SLE. Up to 50% of C1s deficient patients will develop lupus (Lewis and Botto 
2006). C1s protective role against autoimmunity is not well studied and is not 
easily explainable solely by its traditional role as a classical complement 
serine protease involves in cleaving C4 and C2 to form C3 convertase 
(C4bC2a). Although C1s is viewed as a specific protease, other non-
complement substrates although few in numbers, have been described over the 
years (reviewed in 1.3.3.6 and summarised in table 1.3). However, none of 
these had a clear pathologic role to play in SLE. This coupled with the 
observation by Kerr and colleagues that other intracellular substrates were 
predicted to have highly probable cleavage sites by C1s (Kerr, O'Brien et al. 
2005) led us to hypothesise whether proteins with specific roles in SLE such 
as DAMPs (e.g. HMGB1) and autoantigens could be cleaved by C1s and their 
pathological roles in the disease disrupted as a result.  
 
To test this hypothesis, the specific aims for this chapter were: 
1) To develop a bioinformatics model of C1s capable of evaluating and 
screening for putative C1s substrates,  
2) To evaluate for in-vitro cleavage of these putative substrates by incubation 
of purified C1s/C1 complex with purified protein targets,  
3) To delineate the potential cleavage sites on the identified target such that 
the resultant biological effect of the cleavage could be predicted, and  
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4) To evaluate for cleavage of these putative substrates by using ACs as a 
more physiological source of native proteins and treating them with 
purified C1s/C1 complex.  
 
3.2 C1S BIOINFORMATICS MODEL   
The first priority was to create a C1s model to primarily use it to evaluate 
potential target proteins and secondarily to screen the human proteome for 
novel substrates.  
 
The freely available online software, PoPS, was used to create the C1s model 
(http://pops.csse.monash.edu.au/)(Boyd, Pike et al. 2005). This was used by 
Kerr and colleagues in their study of C1s substrate specificity for the purpose 
of developing specific C1s inhibitors to combat complement activation in 
pathological states (Kerr, O'Brien et al. 2005). However, the PSSM necessary 
to assign the relative weight to each subsite and amino acid residue in PoPS 
was not available in their publication. Data had to be extracted from their 
published figure on the frequency of occurrence of each amino acid residue on 
the substrate preferred at different subsite position to create the protease model 






Subsites  S4 S3 S2 S1 S1' S2' S3' S4' 
Wt. 1.49 1.67 1.86 5 0.70 0.77 0.43 0.56 
Amino acids  n Δσ Wt. n Δσ Wt. n Δσ Wt. Wt. n Δσ Wt. n Δσ Wt. n Δσ Wt. n Δσ Wt. 
Gly, G 8 0.84 0.48 14 3.38 1.72 32 10.97 5.00 # 
  
0.00 11 2.11 2.31 10 1.69 3.33 
  
0.00 
Ala, A 14 3.38 1.92 7 0.42 0.21 12 2.53 1.15 # 12 2.53 3.08 10 1.69 1.85 
  
0.00 10 1.69 2.86 
Val, V 8 0.84 0.48 12 2.53 1.29 
  
0.00 # 12 2.53 3.08 
  
0.00 12 2.53 5.00 13 2.95 5.00 








































Tyr, Y 18 8.80 5.00 
  





















0.00 6 1.76 2.98 



























































































































































Table 3.1: Δσ and normalised weight for each C1s subsite.  The frequency (n) of each amino acid for each subsite was counted from the bar chart in the 
work by Kerr and co-workers (Kerr, O'Brien et al. 2005). Amino acid residues with a frequency of 5 or less were given a value of 0. Residue with the highest 
Δσ in each subsite was highlighted red and residues with negative Δσ were given a weight of 0 (highlighted in green). The normalised weight (Wt.) of each 
amino acid at each subsite and relative weight of each subsite was calculated as described. The amino acids were represented by their standard 3 and 1 letter 




To do so, the Δσ values for all amino acid residue positions, P4 to P´4, were 
calculated for each amino acid that had a frequency of more than 5 in each 
subsite position (see section 2.1 for detailed description of the methodology) 
(Table 3.1). A frequency of 5 was what would be expected if each amino acid 
had an equal chance of being represented in that subsite in the 96 phage 
plaques that were screened. Δσ reflected the difference of the observed 
frequency from the expected frequency in terms of standard deviation 
distribution of the amino acids (Matthews, Goodman et al. 1994). For each 
subsite, the relative weight of each amino acid residue was normalised by 
dividing its Δσ with the highest Δσ in the same subsite and multiplying it by a 
factor of 5. Residues with a frequency of 5 or less were given the lowest 
weight of 0. Subsequently, the weight of each subsite was obtained by 
dividing its highest Δσ with the Δσ of arginine residue at subsite S1 (29.46) 
and multiplying it by a factor of 5. 
 
3.2.1 Cleavage scores of known C1s substrates  
The results from table 3.1 were inputted into PoPS to create the C1s model. 
This model was used to determine the cleavage scores of known C1s 
substrates with well-defined cleavage sites (Table 3.2). The model accurately 
predicted the correct cleavage sites with the highest scores, out of all the 
possible cutting sites with arginine at position P1, within the protein for all the 
substrates. The lowest score of 38.3 returned among the four substrates was 







Table 3.2: PoPS scores for known C1s substrates with well-defined cleavage 
sites.








Complement C2 AAB97607 R243-K244 
(SLGR-KIQI) 
 
46.9 (Kerr, O'Brien et 
al. 2005) 
Complement C4  AAB67980 R756-A757 
(GLQR-ALEI) 
 
40.1 (Kerr, O'Brien et 
al. 2005) 
C1-INH CAA30314 R466-T467 
(SVAR-TLLV) 
 







EAW96253.1 R792-A793  
(NVGR-ANGL) 
40.4 (Naito, Sumida 
et al. 2012) 
Cleavage sites were denoted with standard single letter amino acid codes and their 
corresponding positions in the proteins. The dash symbol “-” between two single 
letter amino acid codes represented the cleavage site.  
 
Next, the accessibility of the cleavage sites were examined using the PoPS 
accessible surface area database which was created by automatically mining 
and pruning the Protein Data Bank to determine a single 3D model for the 
substrate. If at least one of the amino acid position recognised by the active 
site subsites was buried within the protein, the cleavage score for that subsite 
would appeared in gray alerting to the possibility of potential inaccessibility. 
The secondary structure of the whole protein would also be annotated by PoPS 














Table 3.3: Accessibility and secondary structures analysis of cleavage 
sites. 










Buried (in at 
least one amino 
acid residue at 
the cleavage 
site) 
Complement C2 Amino acid 







- - - -   - - - - 
 
No  
Complement C4  Amino acid 





 - - TT  . . . . 
 
Yes  
C1-INH Amino acid 





















S . S .   EEEE 
Yes 
- : assumed to be accessible   
T: hydrogen bond turn  
E: extended strand 
S: bend  
. : no regular secondary structure  
 
None of the substrates had its cleavage site amino acid residues predicted to 
participate in the formation of helices which is known to impede enzyme 
active site-substrate interaction. However, only the complement protein C2 
was predicted to be cleavable at its known C1s scissile bond based on the 
criteria that 1) no definite secondary structure was found that would hinder the 
interaction and, 2) the whole cleavage site P4 to P´4 was accessible (not 
buried). As the other substrates has been shown to be cleavable by C1s at its 
native condition, the prediction of buried and inaccessibility by PoPS must be 
wrong. This, however, did not mean that PoPS accessibility prediction was not 
useful. The purpose of it was only to alert the investigator that there was a 
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possibility of inaccessibility. Other factors such as the number of buried amino 
acid residues within the cleavage site and the importance of the different 
positions in its interaction with its enzyme subsites would need to be 
considered independently.   
 
3.2.2 Identification of novel C1s substrates  
The bioinformatics C1s model was used to search the whole human proteome 
using PoPS with the purpose of identifying potential novel C1s substrates. 
This yielded too large a number of hits to be reasonably processed. The 
number of hits were 37,428, 33,488 and 17,379 out of 38,647 proteins 
processed when threshold scores of 30, 35 and 40 were used respectively (last 
accessed on 14
th
 November 2013) (Boyd, Pike et al. 2005). No accessibility 
threshold was set in the search as it was shown above (section 3.2.1) that this 
would have excluded 3 of its known substrates (C4, C1-INH and low-density 
lipoprotein receptor-related protein 6). 
 
Because of the large number of potential hits even with the highest threshold 
score of 40, a targeted approach was used to screen for potential novel C1s 
substrate based on its pathophysiological significance in SLE and the 
likelihood of protein-substrate interaction based on current knowledge.  
 
The likelihood of protein-substrate interaction was a common feature of 
previously identified non-complement C1s substrates in terms of C1q binding 
(which would recruit C1r and C1s to form C1 complex) either directly 
(Nissen, Roepstorff et al. 1990)  or indirectly through another interacting 
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partner (Eriksson and Nissen 1990; Naito, Sumida et al. 2012). For others, the 
only support for C1s potential physiological or pathological role was the 
production of C1s within the microenvironment of its putative substrate 
(Yamaguchi, Sakiyama et al. 1990; Busby, Nam et al. 2000).  
 
The strategy involved 1) identifying molecules of known importance in SLE 
pathogenesis and had interactions with known C1q ligands (so that enzyme 
(C1s)-substrate interaction had the opportunity to occur), 2) screening the 
substrate for potential cleavage with PoPS C1s model, and 3) determining the 
cleavage in-vitro with purified putative substrate and activated C1s.       
 
3.3 HMGB1, A NOVEL SUBSTRATE OF C1S  
 
3.3.1 Potential C1s cleavage sites identified on HMGB1  
Based on the above strategy, HMGB1 was screened with PoPS for potential 
C1s cleavage site due to its importance in SLE pathogenesis, its known 
interaction with DNA (a known C1q ligand) in the form of nucleosome which 
HMGB1 was known to form a complex with (Urbonaviciute, Furnrohr et al. 
2008), and its exposure and eventual release into the extracellular environment 
(Bell, Jiang et al. 2006) where it could interact with C1s. The highest PoPS 
score obtained for HMGB1 was 33.3 for the putative cleavage site at arginine 




Figure 3.1: Predicted C1s cleavage sites on HMGB1. The 3 cleavage sites with the 
highest PoPS scores were marked with inverted triangles (▼ or ▼). The secondary 
structure as determined by PoPS accessible surface area database was shown below 
HMGB1 primary sequence. The putative cutting sites at arginine 70 and 97 were 
predicted to be buried (▼) as at least one of its amino acid residues was inaccessible. 
Arginine 163 was the most likely cleavage site as it had the highest score and there 
was an absence of any significant secondary structure. The second possible cleavage 
site was arginine 97. Even though, it was predicted as inaccessible, only the P4’ 
position of arginine 97 (alanine 101) was involved in alpha helix formation and hence 
it was possible that the site could still be accessed by C1s active site.           
 
3.3.2 Eukaryotic expressed rHMGB1 was cleaved in-vitro by C1s 
To determine whether HMGB1 could be cleavable by C1s as predicted, 5 
μg/ml of eukaryotic expressed rHMGB1 (R&D Systems, Minneapolis, MN, 
USA) was incubated with 2.75 μg/ml of activated two chains C1s in the 
cleavage buffer (Tris 50 mM, NaCl 150 mM, and PEG8000 0.2% (w/v), pH 
7.4) overnight (for 20 hours) at 37°C. HMGB1 had a predicted molecular 
weight of 24.9 kDa but this rHMGB1 had an apparent molecular weight of 
close to 37 kDa. This was likely a result of post-translation modification (e.g. 
glycosylation) as this protein was produced with a mammalian expression 
system. The rHMGB1 was cleaved into 2 distinct fragments (with molecular 
weights of approximately 30 and 22 kDa) that could be detected by western 
blotting with rabbit polyclonal anti-HMGB1 (Figure 3.2 A). However, 




Figure 3.2: HMGB1 was cleaved specifically by activated C1s. A. The rHMGB1 
was cleaved into two distinct bands (F1 and F2) after an overnight incubation at 37°C 
with activated C1s. Western blot detection with rabbit polyclonal anti-HMGB1 was 
done after 12.5% SDS-PAGE separation under reduction condition and transfer onto 
a PVDF membrane. B. Cleavage of HMGB1 was specific. C4, rHMGB1 and BSA 
were incubated with C1s overnight at 37°C. C1s cleaved C4 α-chain to a C4a peptide 
(not detected on this gel) and α´ polypeptide (marked with ←) as expected. However, 
C1s did not cut BSA (silver staining after 12.5% SDS-PAGE separation under 
reducing condition). 
 
The cleavage of HMGB1 by activated C1s was specific (Figure 3.2 B). 
Activated C1s cleaved C4, a known substrate, at its known cleavage site on the 
α-chain. This gave rise to a small C4a peptide of molecular weight of 9 kDa 
and a larger α´ polypeptide which would form C4b with the β- and γ-chains 
through inter-chains disulphide bonds. When BSA (a negative control) was 
incubated with C1s under similar conditions, no cleavage could be observed. 
The C1s preparation used was pure as assessed by silver staining with only the 
heavy and light chains of C1s seen on the gel after reducing SDS-PAGE 
separation.               
 
3.3.3 Prokaryotic expressed rHMGB1 was similarly cleaved by C1s 
To determine whether post-translational modification of HMGB1 could affect 
the cleavage by C1s, His-tagged rHMGB1 expressed by Escherichia coli was 
incubated with activated C1s. His-tagged rHMGB1 had an apparent molecular 
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weight of 25 kDa, close to the predicted 24.9 kDa.  This was expected for a 
prokaryotic expressed protein as it would not be post-translationally modified. 
It was cleaved into 2 fragments, similar to eukaryotic expressed rHMGB1 
(Figure 3.3).  
 
Figure 3.3: Prokaryotic expressed rHMGB1 cleavage by activated C1s was 
similar to eukaryotic expressed rHMGB1. Activated C1s at different 
concentrations were incubated overnight (for 20 hours) at 37°C with 20 μg/ml of His-
tagged HMGB1 (expressed in Escherichia coli) in the cleavage buffer. The reaction 
mixtures were subsequently separated by 15% SDS-PAGE under reducing condition 
(DTT) and the protein bands visualised after silver staining. The overall pattern of 
cleavage by C1s was similar for both rHMGB1.  
 
3.3.4 HMGB1 was more efficiently cleaved by C1s in C1 Complex  
The cleavage pattern of His-tagged HMGB1 (expressed in Escherichia coli) 
by C1 complex was similar to activated C1s alone (Figure 3.4). Both 
generated two fragments F1 and F2 with molecular weights of approximately 
20 kDa and 12 kDa respectively. However, the cleavage appeared more 
efficient and complete for C1 complex. This was expected as C1 complex had 
been shown previously to be catalytically more efficient as compared to 




Figure 3.4: Cleavage pattern of HMGB1 by C1 complex was similar to C1s. 20 
μg/ml of prokaryotic expressed rHMGB1 was incubated overnight (20 hours) with C1 
complex (C1qr2s2) and activated C1s. The reaction mixtures were subsequently 
separated by 15% SDS-PAGE under reducing condition (DTT) and western blot 
detection (with polyclonal anti-HMGB1 (rabbit), monoclonal anti-polyhistidine 
(mouse) and polyclonal anti-C1s (goat)) was done after transfer onto PVDF 
membrane.  
 
Both fragments were detectable with rabbit polyclonal anti-HMGB1 but not 
with the mouse monoclonal anti-polyhistidine. This suggested that either 1) 
the fragment containing the 6X histidine was very small or 2) the fragment 




3.3.5 Delineation of cleavage sites with N-terminal FLAG and C-terminal 
polyhistidine tagged rHMGB1  
An expression plasmid with an N-terminal secretory peptide followed by a 
FLAG (DYKDDDDK) tag, HMGB1 cDNA and a C-terminal polyhistidine tag 
was constructed and inserted into a pcDNA 3.1 A (Invitrogen, Life 
Technologies, Carlsbad, California, USA) vector with a constitutively active 
CMV promoter region (Figure 3.5 A). This construct was created so that the 
source of the fragments could be identified.    
 
Figure 3.5: FLAG-rHMGB1-His construct with secretory signal sequence. A. 
The rHMGB1 construct consisted of a secretory signal peptide sequence followed by 
an N-terminal FLAG tag sequence and the HMGB1 cDNA sequence. Lines 1, 2, and 
3 denoted the DNA sequence on the construct that was inserted into the pcDNA 3.1 A 
vector. The (__) denoted the Kozak sequence. The letters in blue represented the 
single letter amino acid codes. The stop codon TAA was changed to AAA encoding 
lysine (K) in frame with the C-terminal poly-histidine tag. B. Schematic 
representation of secreted FLAG-rHMGB1-His protein consisting of 224 amino acid 
residues.  
 
Transient transfection of HEK293T cells was achieved with calcium 
phosphate transfection and the protein expressed in a serum free medium 
optimised for these cells. The secreted FLAG-rHMGB1-His protein, collected 
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48 hours after transfection, was further purified using Ni-NTA Sepharose 
beads in a column format (Qiagen GmbH, Hilden, Germany). The purified 
protein was assessed to be pure by silver staining (Figure 3.6 A). 
 
Figure 3.6: Purification of FLAG-rHMGB1-His with Ni-NTA beads and C1 
complex digestion of FLAG-rHMGB1-His protein. A. Elution profile of FLAG-
rHMGB1-His protein from Ni-NTA column. The resin was washed with 10 CVs of 
wash buffer containing Tris 20 mM, NaCl 500 mM and imidazole 10 mM at pH 8.0. 
Subsequent elution was carried out with elution buffer containing Tris 20 mM, NaCl 
500 mM and imidazole 250 mM at pH 8.0. The mixtures were separated with 12.5% 
SDS-PAGE under denaturing condition (DTT) and the protein bands visualised with 
silver staining of the gel. B. C1 complex digestion of FLAG-rHMGB1-His yielded 
two distant bands that contained the N-terminal FLAG tag. No fragment was found 
containing the polyhistidine tag. Reaction mixtures were separated with 15% SDS-
PAGE under denaturing condition (DTT) and western blot detections were done with 




The FLAG-rHMGB1-His protein was treated with C1 complex and 2 
fragments were generated, similar to the cleavage of other sources of 
rHMGB1 (section 3.3.2 and 3.3.3). Both the fragments (F1 and F2) contained 
the N-terminal FLAG tag suggesting that there were more than one cleavage 
site. No fragment with the poly-histidine tag was detected.  
 
Figure 3.7: Cleavage of HMGB1 by C1s was consistent with PoPS predicted 
cleavage sites. A. Cleavage of HMGB1 generated 2 fragments from its N-terminal 
end. The predicted cleavage site at arginine 163 would give a polypeptide (F1´) of 
163 amino acid residues with a predicted molecular weight of 18.9 kDa based on its 
sequence. Cleavage at arginine 97 would give a polypeptide (F2´) of 97 amino acid 
residues with a predicted molecular weight of 11.4 kDa. The other fragments F3´, F4´ 
and F5´ were not observed. However, as presented in section 3.2.1, the cleavage at 
arginine 163 was more likely to occur than arginine 97 meaning that F5´ was unlikely 
to occur in large amounts even if present. B. C1s cleavage of His-rHMGB1 
(expressed in Escherichia coli) generated fragments F1 and F2 that were detected by 
western blot with a rabbit polyclonal anti-HMGB1 after separation with 15% SDS-
PAGE under reducing condition (DTT). The observed fragments F1 and F2 molecular 
weights were very close to what were predicted for F1´ and F2´.     
 
The prokaryotic expressed His-tagged rHMGB1 had an apparent molecular 
weight of 25 kDa (Figure 3.3) as compared to the apparent weight of 35 kDa 
(Figure 3.2) of the eukaryotic expressed rHMGB1 which was likely the result 
of post-translational modifications. The cleavage of the His-tagged HMGB1 
by C1s generated two fragments F1 (approximately 20 kDa) and F2 
(approximately 12 kDa) from the intact 25 kDa protein (Figure 3.7 A). These 
results were consistent with the predicted cleavage sites at arginine 97 and 163 
positions of HMGB1 (section 3.3.1) as the calculated (theoretical) molecular 
weights of F1´ generated from cleavage at arginine 163 and F2´ generated 
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from cleavage at arginine 97 were 18.9 and 11.4 kDa respectively which was 
similar to what was observed (Figure 3.7).   
 
In summary, from the in-vitro experiments, it was determined that C1s cleaved 
HMGB1 at two positions and they were likely located at arginine 97 and 163. 
Secondly, post-translational modifications of HMGB1 did not seem to affect 
the cleavage of HMGB1 as both prokaryotic and eukaryotic expressed 
rHMGB1 had similar cleavage patterns. Lastly, C1s alone appeared to be 
enzymatically less efficient as compared to C1s in C1 complex. The next 
section of this chapter would focus on experiments that determined if C1s 
would cleave HMGB1 that was released from ACs.  
 
3.4 INTERACTION OF C1S AND HMGB1 RELEASED FROM 
APOPTOTIC JURKAT T CELLS  
 
3.4.1 Jurkat T cells underwent apoptosis after ultra-violet irradiation  
The first step was to optimise the induction of apoptosis in a cell-line so that 
its interaction with C1s and C1 complex could be determined. Ultra-violet 
irradiation was chosen as a modality of inducing apoptosis for 2 reasons. 1) It 
would not affect the subsequent downstream experiments that required 
stimulation of immune cells as there would be no carry over toxicity effects 
unlike that of drugs/chemicals induced apoptosis. 2) Ultra-violet irradiation 
was a known environmental trigger for SLE flare and hence its use as an 
inducer for apoptosis would be the most physiologically relevant (Rahman and 




Figure 3.8: Induction of apoptosis in Jurkat T cells and HMGB1 release kinetics. 
A. DNA laddering, a feature of apoptosis, was seen in Jurkat T cells 4 hours post 
UVC irradiation. B. HMGB1 was released in a time-dependent manner after 
apoptosis. The supernatant of UVC irradiated Jurkat T cells was collected over a 48 
hours period and resolved on SDS-PAGE (under denaturing condition) and detected 
with a rabbit polyclonal anti-HMGB1 after transfer onto a PVDF membrane. C to G. 
Flow cytometry of Annexin-V-FITC propidium iodide stained control and UVC 
irradiated Jurkat T cells. After UVC irradiation, the percentage of Annexin V and 
propidium iodide double positive cells increased from baseline of 15.75% (C), to 
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20.73% at 2 hrs (D), 55.61% at 4 hrs (E), 88.27% at 6 hrs (F) and 98.69% at 24 hrs 
(G). There was a characteristic pattern of apoptosis progressing from Annexin-V-
FITC single positive (representing early apoptosis) to Annexin-V-FITC propidium 
iodide double positive (representing late apoptosis or secondary necrosis).  
 
On UVC irradiation (dose of 500mJ/cm
2, λ=254 nm), Jurkat T cells underwent 
apoptosis with the initial loss of the polarity of phospholipid bilayer with 
positive staining with Annexin-V, representing early apoptosis, followed by 
eventual loss of its membrane integrity when the propidium iodide stain was 
able to enter the cells and stain its DNA (Figure 3.8 C to G). The cells that 
were positively stained for Annexin-V and propidium iodide represented a 
phase of late apoptosis or secondary necrosis. HMGB1 was released in a time-
dependent manner by the apoptotic Jurkat T cells and it corresponded to the 
loss of membrane integrity. Next, the interaction between C1 complex and C1s 
with this HMGB1 released by ACs was investigated.  
 
3.4.2 HMGB1 released by apoptotic Jurkat T cells was cleaved by C1s and C1 
complex   
Jurkat T cells were UVC irradiated (dose of 500mJ/cm
2, λ=254 nm) and 
incubated at 37°C in 5% CO2 for 2.5 hours before being harvested and 
transferred into 1.6 ml microcentrifuge tubes. The viable control cells were 
treated in the same manner except the UVC irradiation. The cells were treated 
with C1 complex (5 μg/ml), serum purified C1s (5, 2.5 and 1 μg/ml) and 
buffer control. After treatment, the cells were then incubated at 37°C for a 
further 30 minutes before the supernatant was collected by centrifugation at 




HMGB1 was present in the apoptotic Jurkat T cells supernatant 3 hours after 
UV irradiation (500mJ/cm
2, λ=254 nm) (Figure 3.9 A). Treatment of the ACs 
with C1 complex resulted in the absence of detectable HMGB1 in its 
supernatant. The cleavage of HMGB1 was an efficient process as the period of 
incubation was only 30 minutes at 37°C before the reaction was stopped by 
heating it in 5X loading buffer containing DTT and SDS. The C1s found in the 
C1 complex used was present both in the proenzyme form (single chain, 83 
kDa) and enzymatically active form (two chains, 56 kDa and 27 kDa) in both 
the apoptotic and control cells supernatant (Figure 3.9 A and B). The auto-
activation of proenzyme C1s seen in the serum free condition was caused by a 
known phenomenon of intramolecular autocatalysis (Ziccardi 1982). 
 
C1s in the complex with C1q and C1r cleaved HMGB1 more efficiently than 
C1s alone (Figure 3.9 C). Even with higher concentration of C1s (as evident 
by the greater intensity of the two chains of C1s at 56 kDa and 27 kDa) as 
compared to that present in C1 complex (Figure 3.9 C), HMGB1 was cleaved 
to a lesser extent (densitometry analysis of the intensity of the remaining 
HMGB1 band). This was consistent with the previous experiment in section 
3.3.4 where C1 complex was able to cleave His-tagged rHMGB1 more 





Figure 3.9: C1 complex cleaved HMGB1 that was released by apoptotic Jurkat T 
cells. A. C1 complex treatment of ACs resulted in the loss of HMGB1 in its 
supernatant. Small amount of HMGB1 was also seen in the control cells (CCs) 
supernatant and this could be the result of cell death at baseline (see figure 3.8 C). 
C1s was present both in its proenzyme form (83 kDa) and activated two chains form 
(56 kDa and 27 kDa). B. Activated two-chains C1s cleaved HMGB1 in a dose 
dependent manner but was less efficient as compared to C1s in C1 complex. C. 
Densitometry analysis of the relative amount of activated C1s in C1 complex and C1s 
alone showed that even when C1s in C1 complex was 0.6 that of 5 μg/ml of C1s, it 
was able to cleave HMGB1 completely while C1s at 5 μg/ml was not able to do so. D. 
HMGB1 existed in a different redox form in ACs as compared to necrotic cells 
(NCs). The HMGB1 in ACs migrated faster than HMGB1 from NCs when separated 
by non-reducing SDS-PAGE. The more rapid migration was due to a more compact 
conformation of disulphide HMGB1 (intra-molecular disulphide bond between 
cysteine residues 23 and 45) found in ACs (Venereau, Casalgrandi et al. 2012). The 
NCs supernatant was obtained by repeated freeze-thaw cycles followed by 
centrifugation at 1000 g for 5 minutes to remove the cellular debris.          
 
HMGB1 found in the supernatant of apoptotic Jurkat T cells was in the 
oxdised form (disulphide HMGB1) (Figure 3.9 D) and C1 complex was able 
to cleave it. The finding of oxidised form of HMGB1 in ACs was consistent 
with previous published study (Urbonaviciute, Meister et al. 2009).  
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As the cleavage by C1s alone of HMGB1 released from ACs were inefficient, 
it was likely that its cleavage of other potential intracellular protein targets 
would be as inefficient. Hence, C1s found in C1 complex was used for 
subsequent ACs experiments. 
 
3.4.3 Cleavage of HMGB1 by C1 complex was specific  
To determine the specificity of cleavage by C1 complex, C1-INH was used. 
The cleavage of HMGB1 by C1 complex could be completely inhibited with 
the addition of C1-INH. Hence, C1s found in C1 complex was responsible for 
the cleavage of HMGB1 in the apoptotic supernatant (Figure 3.10). The 
possibility of other potential contaminating proteases that led to the loss of 
HMGB1, that could be present in the purified C1 complex, was excluded.  
 
Figure 3.10: C1 complex cleavage of HMGB1 was inhibited with C1-INH. When 
C1-INH at a concentration of 105 μg/ml was added to C1 complex, the loss of 
HMGB1 band in the apoptotic supernatant was inhibited. This reduced the possibility 
that the cleavage of HMGB1 was due to possibly other contaminating proteases that 
could be found in the C1 complex preparation. His-tagged rHMGB1 was used as a 
positive control in the western blot with rabbit polyclonal anti-HMGB1. (CCs: control 




3.5 LOSS OF OTHER PROTEINS IN C1 COMPLEX TREATED 
APOPTOTIC JURKAT T CELLS SUPERNATANT      
To investigate whether other proteins could be cleaved by C1 complex, the 
total supernatant of C1 treated and non-treated apoptotic Jurkat T cells were 
analysed by SDS-PAGE under reducing condition followed by Coomassie 
staining. Loss of band intensity in the lane resolving the apoptotic supernatant 
proteins mixture of C1 complex treated ACs as compared to non-treated was 
used as a surrogate marker of possible cleavage of a target protein by C1 
complex. The putative identities of these proteins were determined by band 
excision of the corresponding bands in the non-treated sample and subsequent 
mass spectrometry identification (Figure 3.11).  
 
There was no perceivable band that reduced in intensity at the 25 kDa region 
of the C1 complex treated ACs that could suggest the presence and cleavage of 
HMGB1. Possible explanations included: 1) HMGB1 was not present in 
sufficient quantity at this time point (3 hours post-apoptosis with 3 million 
ACs per ml) for detection by Coomassie blue staining and/or 2) its presence 
and cleavage was masked by some other more abundant protein of similar 


















Figure 3.11: Reduction in specific bands intensity in C1 complex treated 
apoptotic Jurkat T cells supernatant. A. 15% SDS-PAGE under reducing condition 
(DTT) showed 4 bands: A´ (≈ 100 kDa), B´ (≈60 kDa), C´ (≈50 kDa) and D´ (≈40 
kDa), that reduced in intensity with C1 complex treated. The bands were visualised 
after Coomassie blue staining. C1s treatment did not result in any changes in the 
bands intensity as compared to ACs supernatant alone. The experimental setup was as 
described in section 2.4.6.1 where UVC induced apoptotic Jurkat T cells were 
harvested at 2.5 hours after irradiation and treated with C1 complex, C1s or buffer 
and incubated at 37°C for another 30 minutes before the supernatant was collected by 
centrifugation at 1000 g for 5 minutes at 4°C. B. 8-16% SDS-PAGE with reduction of 
samples (DTT) followed by alkylation with Iodoacetamide (stained with Coomassie 
blue). This repeat was done for band excision and mass spectrometry analysis. 
Similar result was obtained as (A). Four bands showing a reduction in intensity were 
observed (A, B, C and D). These bands were of comparable molecular weights with 
those found in the non-gradient 15% SDS-PAGE (Figure 3.11 A). These were excised 
and processed for mass spectrometry identification by the mass spectrometry 
laboratory in Experimental Therapeutics Center, Biopolis shared facilities.       
 
 
3.5.1 Additional putative novel C1s substrates identified by mass spectrometry  
Each band contained 5 to 7 proteins (those with identification probabilities of 
100%) as determined by mass spectrometry (Table 3.4). This result was 
expected considering the limited resolving capability of 1D SDS-PAGE by 
molecular weight alone. It was reasonable to assume that not all proteins 
identified within a band would be cleaved by C1 complex.   
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Bands Identified Proteins Accession no. M.W.  (kDa) Coverage 
(%) 
Exclusive Unique Peptide 
Count 
A Elongation factor 2  IPI00186290 95 29 18 
Importin subunit beta-1 IPI00001639 97 8.1 5 
Isoform 2 of Heat shock protein HSP 90-alpha IPI00382470 98 7.0 4 
26S proteasome non-ATPase regulatory subunit 2  IPI00012268 100 7.0 4 
Transitional endoplasmic reticulum ATPase  IPI00022774 89 7.8 4 
B Isoform M2 of Pyruvate kinase isozymes M1/M2 IPI00479186 58 46 20 
T-complex protein 1 subunit eta IPI00018465 59 32 12 
T-complex protein 1 subunit zeta IPI00027626 58 20 6 
T-complex protein 1 subunit alpha IPI00290566 60 17 6 
T-complex protein 1 gamma isoform C IPI00552715 56 17 5 
59kDa protein IPI00302925 59 11 5 
T-complex protein 1 subunit delta IPI00302927 58 8.9 3 
C Isoform alpha-enolase of Alpha-enolase  IPI00465248 47 48 15 
Elongation factor 1-alpha 1  IPI00396485 50 49 13 
cDNA FLJ56389, highly similar to Elongation factor 1-gamma IPI00000875 56 16 7 
Tubulin alpha-1C chain IPI00218343 50 12 4 
Proteasome 26S non-ATPase subunit 11 variant (Fragment) IPI00105598 48 9.7 3 
60S ribosomal protein L4 IPI00003918 48 9.4 3 
Hsc70-interacting protein  IPI00032826 41 8.4 3 
D Isoform 2 of Nucleophosmin  IPI00220740 29 18 3 
Glyceraldehyde-3-phosphate dehydrogenase  IPI00219018 36 52 9 
60S acidic ribosomal protein P0 IPI00008530 34 26 5 
Transaldolase  IPI00744692 38 10 3 
Actin, cytoplasmic 1  IPI00021439 42 17 3 
Table 3.4: Potential novel C1s substrates identified by mass spectrometry. The proteins in bands A, B, C and D were identified by mass spectrometry and 




2 proteins found in band D in the list (Table 3.4), nucleophosmin and actin, of 
which existing antibodies were currently being used in our laboratory were 
used for western blot to test the validity of the mass spectometry results. Both 
proteins were present on western blot of the ACs supernatant and were found 
between the 35 and 55 kDa molecular marker confirming the mass 
spectometry result from band D. Of interest was that loss of the 
nucleophosmin band but not the actin band, in the C1 complex treated 
supernatant. This was in agreement with our assumption that not all proteins 
identified within a band would be cleaved by C1 complex.     
Figure 3.12: Validation of mass 
spectrometry result for band D 
(Figure 3.11) with western 
blotting. In this repeat 
experiment, HMGB1 released 
from apoptotic Jurkat T cells was 
cleaved by C1 complex as shown 
previously. In addition, two 
proteins, nucleophosmin and 
actin, that were identified by 
mass spectrometry in band D 
(Figure 3.11) of non-treated 
apoptotic supernatant were 
detected by western blotting with 
existing antibodies used in the 
laboratory. Of interest is the 
identification of another novel 
C1s substrate, nucleophosmin. 
This confirmed our assumption 
that not all proteins identified 
within a band would be cleaved 
by C1 complex explaining why a 
band would reduce in intensity 












In summary, C1 complex cleaved HMGB1 that was released from ACs. This 
is physiologically relevant as C1 complex is known to be recruited onto the 
surfaces of ACs where it plays a role in its clearance. This cleavage was 
efficient with 5 μg/ml of C1 complex and a 30 minutes incubation period at 
37°C with the ACs. In addition, other putative protein targets were also 
identified with mass spectrometry of the bands that were present in the non-
treated ACs supernatant that decreased in intensity with C1 complex 
treatment. This result was verified by western blotting for 2 of the proteins 
found in band D (Figure 3.11) and it led to the identification of an additional 
protein, nucleophosmin, which was cleaved by C1 complex. Nucleophosmin 
maybe a protein of significance in SLE as autoantibodies against it had been 




Chapter 4 HMGB1 and ACs interaction with LPS  
 
4.1 EFFECT OF C1S ON HMGB1 SYNERGISM WITH LPS    
 
4.1.1 Synergistic effect of HMGB1 on LPS induced cytokines release  
To study the biological effect of HMGB1 cleavage by C1s, an in-vitro system 
involving its synergistic activity with LPS in stimulating cytokines release was 
used. The mechanism in which HMGB1 achieved this was through its ability 
to bind to LPS micelle causing its disaggregation to monomeric form which 
would then bind to CD14 leading to downstream signaling through TLR4 
activation (Youn, Oh et al. 2008). This phenomenon was demonstrated 
previously in human monocytes TNF-α production (Youn, Oh et al. 2008) and 
human PBMCs IL-6 production (Hreggvidsdottir, Ostberg et al. 2009). The 
reason for choosing this biological activity of HMGB1 to study was because 
the regions required for its synergism with LPS was well characterised and 
hence would be useful in the clarification of its C1s cleavage sites if loss of 
this activity was found (Youn, Oh et al. 2008; Youn, Kwak et al. 2011).   
 
A eukaryotic expressed rHMGB1 (R&D Systems, Minneapolis, MN, USA) 
was used for these experiments instead of a prokaryotic source from 
Escherichia coli due to concerns about LPS contamination being a 
confounding factor in the experiments. This rHMGB1 was originally stored in 
1X PBS with 1 mM EDTA and 1 mM DTT meaning that it was in the reduced 
form (all thiol) and would not have any intrinsic cytokine stimulating activity 
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by itself (see section 1.4.4). Hence, any cytokine potentiating effect would be 
due to HMGB1 effect with LPS.  
 
To create the in-vitro system, optimisation experiments were first carried out 
to evaluate the range of doses of HMGB1 and LPS to be used. The effect of a 
fixed dose of HMGB1 (400 ng/ml) on a range of LPS concentrations (0.125 to 
50 ng/ml) on human MΦ and DCs was examined. Human MΦ were used as a 
representation of the phagocytic component of the innate immune response 
responsible for clearing the source of a PAMP (such as LPS). DCs, on the 
other hand, were used as it represented the professional APCs that would 
mature when they encountered PAMPs which would then enable them to 
present antigens efficiently to T cells.    
  
4.1.2 HMGB1 synergised with LPS causing MΦ and DCs cytokines release  
HMGB1 and LPS were pre-incubated for 24 hours at 37°C in the cleavage 
buffer (Tris 50 mM, NaCl 150 mM, and PEG8000 0.2% (w/v), pH 7.4) to 
allow for complex formation before being added into the cells. The stimuli 
were prepared at 50X the eventual cell culture concentration to minimise any 
effect that Tris and PEG8000 could have on the cells. A 24 hours period was 
chosen to examine rHMGB1 stability with LPS as it would eventually be 
necessary to incubate them with C1s for this duration to examine the effect of 
HMGB1 cleavage by C1s. Different pre-incubation conditions had been used 
in the past by different investigators ranging from 60 minutes at 37°C (Youn, 




Figure 4.1: HMGB1 effect on LPS induced TNF-α, IL-6 and IL-10 secretion 
from human MΦ. A. At LPS doses of less than 25 ng/ml, HMGB1 (400ng/ml) had a 
synergistic activity on TNF-α production. However, at higher LPS doses, the effect 
was inhibitory. B. IL-6 trend was similar to TNF-α. At very low doses of LPS (< 1 
ng/ml), HMGB1 had a synergistic effect with LPS but at higher doses, the effect 
became inhibitory. C. For the anti-inflammatory cytokine IL-10, the synergistic 
activity of HMGB1 was seen at the whole range of LPS doses. HMGB1 alone did not 
result in the release of the 3 cytokines tested. HMGB1 and LPS were incubated for 24 
hours in sterile 0.2 ml PCR tubes at 37°C before addition into human MΦ in OPTI-
MEM I medium supplemented with 100 units/ml of Penicillin and 100 μg/ml of 
Streptomycin. The stimuli were prepared at 50X the eventual concentration in the cell 
culture and 2 μl of each stimuli was added into 98 μl of cell suspension at a density of 
0.6 million per ml. The LPS and HMGB1 concentrations labelled above represented 
the eventual concentrations in the cell culture. All experiments were performed in 
triplicates and presented as means ± SD. This result was a representation of 3 
independent repeats.        
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HMGB1 synergism with LPS was seen in MΦ and DCs in terms of TNF-α, 
IL-6 and IL-10 secretion (Figure 4.1 and 4.3). For MΦ, the synergistic effect 
was evident for all the 3 cytokines examined and was most prominent at lower 
LPS concentrations (0.25 to 1 ng/ml). However, for the pro-inflammatory 
cytokines (TNF-α and IL-6), the effect of HMGB1 at higher concentrations of 
LPS was inhibitory (Figure 4.1). This was consistently seen in different 
batches of MΦ differentiated from monocytes from different healthy blood 
donors. Hence, for our in-vitro system to be used to study the synergistic pro-
inflammatory activity of HMGB1 with LPS and the consequence of its 
cleavage by C1s, low doses of LPS must be used when MMF were used. 
Interestingly, this inhibitory activity of HMGB1 was observed only in MMF 
but not GMMF (Figure 4.2). This suggests that the inhibitory function of 
HMGB1 is through a mechanism that is not present in GMMF.   
 
Figure 4.2: HMGB1 inhibitory effect at high LPS doses was restricted to MΦ 
differentiated with GM-CSF. This figure showed the results from MΦ differentiated 
(M-CSF or GM-CSF) from purified monocytes from a single blood donor. The 
HMGB1 and LPS were incubated for 24 hours in sterile 0.2 ml PCR tubes at 37°C 
before addition into the cells. A. At a LPS dose of more than 1 ng/ml, HMGB1 had an 
inhibitory effect. The IL-6 secreted was also lower at different LPS concentration for 
MMF as compared to GMMF at similar cell densities (0.6   106/ml). B. Synergistic 
effect of HMGB1 was observed at a LPS dose of less than 1 ng/ml for the GMMF and 
the IL-6 secretion saturated at a LPS dose of 10 ng/ml. All experiments were 
performed in triplicates and presented as means ± SD. Results were analysed using 
Student’s t-test (2-tails): **p < 0.01, and ***p < 0.001. 
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For DCs, the synergistic effect of HMGB1 with LPS in TNF-α, IL-6 and IL-10 
secretion was observed with LPS from 0.125 to 50 ng/ml. However, DCs were 
generally less responsive to LPS requiring a much higher dose than MΦ before 
TNF-α, IL-6 and IL-10 release could be observed. No inhibitory effect of 
HMGB1 on LPS was observed in DCs (Figure 4.3).         
 
Figure 4.3: HMGB1 effect on LPS induced TNF-α, IL-6 and IL-10 secretion 
from human DCs. A, B &C. HMGB1 exhibited a synergistic effect with LPS at all 
the doses tested for TNF-α, IL-6 and IL-10 secretion. HMGB1 alone (400 ng/ml) did 
not result in release of the cytokines tested. All experiments were performed in 
triplicates and presented as means ± SD. This result was a representation of 3 
independent repeats.       
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Next, a dose titration of HMGB1 with a fixed low dose of LPS (1 ng/ml) was 
examined further in MΦ. For HMGB1, a dose of between 12.5 to 100 ng/ml 
was chosen as this range of concentrations was found in patients with severe 
sepsis from bacterial infection and hence pathologically relevant (Wang, 
Bloom et al. 1999).  
Figure 4.4: Increasing dose of HMGB1 increased the TNF-α, IL-6 and IL-10 
production in MΦ by LPS. A, B & C. There was a statistical significant increase in 
TNF-α, IL-6 and IL-10 secretion induced by 1 ng/ml of LPS when the HMGB1 
increased from 50 to 100 ng/ml. Results were analysed using Student’s t-test (2-tails): 
*p < 0.05.  
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The dose effect of HMGB1 on LPS induced cytokines release on monocytes 
were also similarly demonstrated for TNF-α and IL-6 secretion (Figure 4.5). 
The critical threshold for HMGB1 synergistic effect appeared to be in the 
range of 50 to 100 ng/ml where statistical significant increases in the pro-
inflammatory cytokines were observed in MΦ and monocytes. This range of 
HMGB1 doses was pathologically relevant as it was found in severely septic 
patients (Wang, Bloom et al. 1999). Although HMGB1 doses of higher than 
100 ng/ml might increase its synergism with LPS, it would not be clinically 
relevant. In addition, as HMGB1 cleavage by activated C1s alone was not an 
efficient process, even if the loss of synergism were to occur after its cleavage; 
the use of high doses of HMGB1 in the in-vitro studies might lead to a false 
negative result due to the presence of a large amount of uncleaved HMGB1.         
 
Figure 4.5: Effect of HMGB1 on LPS induced monocytes TNF-α and IL-6 
secretion. A statistical significant increase in LPS induced TNF-α and IL-6 secretions 
were observed when HMGB1 dose was increased from 50 to 100 ng/ml. The 
experiments were performed in triplicates and presented as means ± SD. This result 
was a representation of 2 independent repeats. Statistical analysis was done with 
Student’s t-test (2-tails): *p < 0.05, ** p < 0.01.   
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In summary, the following facts were established that would help to determine 
the conditions used to test the hypothesis that C1s cleavage of HMGB1 would 
result in the loss of its synergistic activity with LPS. 
1) The rHMGB1 and LPS retained its ability to stimulate cytokines release 
even after a period of 24 hours incubation at 37°C.        
2) For monocytes and MΦ, an increase in HMGB1 from 50 to 100 ng/ml led 
to the greatest increase in cytokines release in combination with LPS.  
3) For MMF, HMGB1 had an inhibitory effect on TNF-α and IL-6 release 
when increasing doses of LPS were used. 
 
4.1.3 HMGB1 synergistic effect with LPS was lost after C1s cleavage   
The effect of C1s cleavage of HMGB1 was studied with eukaryotic expressed 
recombinant C1s and HMGB1 (both from R&D Systems, Minneapolis, MN, 
USA). C1s alone was used instead of C1 complex so that the effect could be 
attributed to C1s alone and not a result from C1q or C1r. The reaction 
mixtures were prepared at 50X the eventual cell culture concentrations in 0.2 
ml sterile PCR tubes. 2.75 μg/ml of activated C1s was incubated with 5 μg/ml 
rHMGB1 with different LPS concentrations of 0, 12.5, 25, 50 and 5000 ng/ml 
in the cleavage buffer (Tris 50 mM, NaCl 150 mM, and PEG8000 0.2% (w/v), 
pH 7.4). All the stimuli, including negative controls, were prepared similarly 
in the 0.2 ml PCR tubes and incubated for 24 hours at 37°C before addition 
into the cells. The conditions and concentrations of C1s and rHMGB1 used 
were similar to that of the in-vitro cleavage study (Figure 4.6).       
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Figure 4.6: In-vitro cleavage of HMGB1 by 
activated C1s. The rHMGB1 (5 μg/ml) was 
cleaved into two distinct bands (F1 and F2) after 
an overnight incubation at 37°C with activated 
C1s (2.75 μg/ml). Western blot detection with 
rabbit polyclonal anti-HMGB1 was done after 
12.5% SDS-PAGE separation under reducing 
condition and transfer onto a PVDF membrane. 
 
 
Figure 4.7: C1s treatment of HMGB1 reduced its synergistic effect with LPS in 
MΦ.  A, B & C. For all the 3 cytokines tested, HMGB1 synergistic activity with LPS 
was lost. A & B. No synergistic activity was observed for TNF-α and IL-6 at an LPS 
dose of 10 ng/ml. The LPS alone at 10 and 100 ng/ml elicited similar TNF-α and IL-6 
indicative of a saturated response at an LPS dose beyond 10 ng/ml. The labelled 
concentrations in the figure represented the actual cell culture concentrations. All 
experiments were performed in triplicates and presented as means ± SD. Results were 
analysed using Student’s t-test (2-tails): n.s.- not significant, *p < 0.05, **p < 0.01, 
and ***p < 0.001. 
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Incubation of HMGB1 and LPS with activated C1s led to a loss of its 
synergistic activity with LPS with a reduction of TNF-α, IL-6 and IL-10 levels 
in MΦ (Figure 4.7). For most of the LPS concentrations used, C1s reduced the 
cytokines induced by the HMGB1-LPS complex to a level similar to that of 
LPS alone. For TNF-α and IL-10, only the difference between C1s treated 
HMGB1-LPS complex and LPS alone at 0.5 ng/ml remained statistically 
significant. For IL-6, the statistical significant difference was between C1s 
treated HMGB1-LPS and LPS alone at 1 ng/ml. This was not unexpected 
considering that the cleavage of HMGB1 by C1s was not complete even after 
24 hours of incubation at 37°C and the residual amount of intact HMGB1 left 
might have provided the synergism to LPS (Figure 4.6).   
 
The synergism of HMGB1 with LPS in inducing IL-6 release was similarly 
disrupted with C1s treatment in other cell types (DCs, GMMF and monocytes) 
(Figure 4.8). However, C1s treatment did not completely abrogated HMGB1 
effect on LPS at some of the LPS concentrations used. This was likely the 
effect of residual amount of intact HMGB1 left due to incomplete cleavage by 
C1s. DCs consistently exhibited a similar pattern of synergism with LPS at a 
wide range of the LPS concentrations (0.5 to 50 ng/ml).   
Figure 4.8: C1s treatment of HMGB1 reduced its synergistic effect with LPS 
induced IL-6 secretion in DCs, MΦ (GM-CSF differentiated) and 
monocytes.(next page) A.  For DCs, HMGB1 synergistic activity was observed with 
0.5 to 50 ng/ml of LPS. C1s treatment reduced IL-6 to a level close to LPS alone. B. 
For GMMF, a similar trend was observed but only at low doses of LPS (0.25 to 0.5 
ng/ml). The IL-6 secretion was saturated at an LPS dose of more than 1 ng/ml. C. For 
monocytes, LPS induced IL-6 secretion was enhanced in the presence of HMGB1 and 
this activity was abrogated with C1s treatment. A, B and C represented 3 independent 
experiments done at different time. The cell density used was 0.6   106 /ml for all 3 
cell types. Experiments were performed in triplicates and presented as means ± SD. 







4.1.4 C1s cleavage sites on HMGB1 predicted a loss of synergism with LPS    
The loss of HMGB1 synergism with LPS was consistent with its predicted 
cleavage sites by C1s. This provided additional evidence and supported the 
conclusion from chapter 3 results that the bioinformatics prediction of the C1s 
cleavage sites was correct where the apparent molecular weight of the 
fragments observed after rHMGB1 (prokaryotic expressed rHMGB1) were 
consistent with the theoretical molecular weights of the predicted fragments.  
 
The regions of HMGB1 that interacted with LPS and CD14 of the CD14-
MD2-TLR4 receptor complex were well characterised (Figure 4.9) (Youn, Oh 
et al. 2008; Youn, Kwak et al. 2011). HMGB1 A and B boxes must be in 
continuity for it to retain its biological activity with LPS (Youn, Oh et al. 
2008). As illustrated in figure 4.9, cleavage at R97 at the B-box would 
separate the HMGB1 regions responsible for binding to the lipid A and 
polysaccharide moieties of LPS with the rest of the B-box. This will cut 
HMGB1 at the region known to interact with CD14. CD14 has been shown to 
bind to HMGB1 B-box through in-vitro pull down assay (Youn, Kwak et al. 
2011). Although in the pull down assay, no truncated B-box regions were used 
to delineate the region in greater detail. It was likely that the mechanism of the 
loss of HMGB1 synergism with LPS was due to the separation of the region 
on HMGB1 that interacted with CD14 from the region that would bind to the 
LPS (i.e. fragment F2´ that contained the regions known to interact with LPS). 
This conclusion was based on the assumption that the B-box region from 
amino acid residues 88 to 97 (10 amino acids in length) would be insufficient 
for CD14 interaction. This assumption was likely to be true as the peptide 
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from amino acid residues 80 to 96 demonstrated binding to LPS but did not 
transfer LPS to CD14 indicative that the region that interacted with CD14 was 
from amino acid positions 98 to 162 of the B-box.     
 
Figure 4.9: Predicted C1s cleavage site at R97 would lead to loss of HMGB1 
ability to transfer LPS to CD14. A. Schematic representation of HMGB1 and 
predicted C1s cleavage sites at R163 and R97. F1´ to F5´ represented all the potential 
fragments that could be formed from the 2 cleavage sites. R163 was likely to be the 
most efficiently cleaved based on its higher PoPS score indicative of higher 
likelihood of cleavage based on primary structure. In addition, R163 was predicted to 
be completely accessible while R97 was predicted to be buried in at least one amino 
acid residue position. Hence, F5´ would likely be a transient intermediary even if it 
was formed. It was likely that the actual fragments that were formed would be F1´, 
F2´, F3´ and F4´. B. Cleavage at R97 but not R163 would lead to a loss of HMGB1 
ability to synergise with LPS. The result from the C1s treatment of HMGB1-LPS 
complex leading to a loss of its synergism with LPS was consistent with cleavage at 
R97. This would lead to a disruption of the binding regions of HMGB1 with LPS and 
its CD14 binding region.       
 
4.2 APOPTOTIC JURKAT T CELLS SUPERNATANT-LPS 
INTERACTION   
HMGB1 has been known to be released during late cell apoptosis (Bell, Jiang 
et al. 2006). Some of this HMGB1 would be found complexed with 
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nucleosomes that were released from ACs (Urbonaviciute, Furnrohr et al. 
2008). These HMGB1-nucleosomes when purified from ACs exhibited pro-
inflammatory effect inducing cytokines release in MΦ and had the ability to 
induce DCs maturation. However, it was also possible that some free HMGB1 
would be present in the ACs supernatant.  
 
In chapter 3, the release of HMGB1 from ACs was reproduced using UVC 
irradiated Jurkat T cells. It was further determined that C1 complex treatment 
of the apoptotic Jurkat T cells would lead to the loss of HMGB1 from its 
supernatant. Therefore, to further investigate the physiological relevance of 
C1s cleavage of HMGB1 in the context of autoimmunity and inflammation, 
the effect of total apoptotic supernatant from late ACs on DCs as well as its 
interaction with LPS would be studied. DCs were chosen for this in-vitro study 
in view of its central sentinel role in sensing the microenvironment and 
bridging the innate with the adaptive immune response. It was hypothesised 
that with the failure of clearance of ACs by phagocytosis; the apoptotic 
supernatant separated from the cellular debris might have pro-inflammatory 
activity by itself or could potentiate the effects of other PAMPs such as LPS.  
If any significant pro-inflammatory activity was found, the treatment effect 
with C1s or C1 complex would be investigated.   
 
4.2.1 ACs supernatant was not pro-inflammatory  
The apoptotic supernatant from Jurkat T cells, even those obtained from late 
secondarily necrotic ACs (72 hours), did not elicit any IL-6 secretion from 
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DCs (Figure 4.10). This was despite concentration of the apoptotic supernatant 
from 3 million per ml of ACs by 8X with a low molecular weight cut-off 
ultrafiltration tube (3 kDa) before addition into the DCs cell culture at 10% 
(v/v). HMGB1 was used as a surrogate marker showing the leakage of 
intracellular proteins during late apoptosis when the cell membrane integrity 
was compromised (Figure 4.10 A). The leakage of intracellular protein 
corresponded with the increasing number of late ACs as determined by flow 
cytometry with Annexin-V-FITC and propidium iodide staining (Section 
3.4.1).  
 
Figure 4.10: Supernatant from apoptotic Jurkat T cells did not elicit IL-6 release 
from DCs. A. HMGB1, an intracellular protein, was released when increasing 
number of ACs became secondarily necrotic. Western blot detection was done with a 
polyclonal rabbit anti-HMGB1 after SDS-PAGE separation under reducing condition 
and transfer onto a PVDF membrane. B. Apoptotic supernatant at different time-
points were collected from UVC irradiated Jurkat T cells (3   106 cells/ml of serum 
free RPMI1640 supplemented with Penicillin and Streptomycin), centrifuged at 500 g 
for 5 minutes to remove the cell debris and stored at 4°C until the last sample was 
collected before usage. All the supernatant were concentrated 8X with a 3 kDa 
molecular weight cut-off and added into DCs at 10% (v/v). The positive control with 
LPS (5 ng/ml) gave an IL-6 level of 12970   1833 pg/ml (mean   SD) in this 
experiment (not shown). Experiments were performed in triplicates and presented as 
means ± SD. 
 
4.2.2 ACs supernatant was anti-inflammatory 
Next, the effect of the apoptotic supernatant on LPS induced TNF-α and IL-6 
secretion was examined. The effect of increasing duration of cell apoptosis 
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and number of ACs of which the supernatant was obtained from was 
examined. The apoptotic supernatant was obtained at 3, 6, 24, 48 and 96 hours 
after UVC irradiation with increasing number of ACs per ml (3, 6, 9, 12 and 
24 million per ml) of 1X PBS with 100 units/ml of Penicillin and 100 μg/ml of 
Streptomycin. The Jurkat T cells were re-suspended in 1X PBS instead of 
serum free RMPI 1640 (both with antibiotics) to eliminate the effect of the 
control conditions being more healthy as it would be  receiving 10% (v/v) of 
fresh RPMI1640 instead of the nutrients depleted RPMI1640 by the cells 
undergoing apoptosis at various time-points. Hence, the control medium used 
was UVC irradiated 1X PBS with antibiotics (same medium as the ACs) that 
was incubated for 96 hours at 37°C in 5% CO2. The supernatant was collected 
and the cell debris removed by centrifugation at 1000 g for 5 minutes twice. 
The samples were stored at 4°C prior to usage for DCs stimulation once the 
last time-point was collected. For this experimental set-up, DCs were 
stimulated with LPS for 30 minutes prior to the addition of apoptotic 
supernatant at 10% (v/v). 
 
The apoptotic supernatant had an anti-inflammatory effect on LPS induced 
pro-inflammatory cytokines release (TNF- α and IL-6) and its effect was most 
marked with LPS induced TNF-α production (Figure 4.11). For the ACs 
concentration of 3 to 12 million per ml, the apoptotic supernatant was anti-
inflammatory for the supernatant collected at all the time-points. Only at 24 
million of ACs per ml, the supernatant collected at 96 hours exhibited a 
synergistic activity with 10 ng/ml of LPS. Positive correlation was observed 
with increasing duration of apoptosis and decreasing anti-inflammatory effect 
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on LPS induced TNF-α secretion for supernatant obtained from 6 to 24 million 
per ml of ACs (Figure 4.12).  
 
The amount of HMGB1 increased with increasing duration of apoptosis 
(Figure 4.11 F). The kinetics of HMGB1 release was examined for 24 million 
per ml of ACs. From 3 to 24 hours of apoptosis, there was less than 5 μg/ml of 
HMGB1 in the apoptotic supernatant and this increased to between 5 to 10 
μg/ml at 48 hours and 96 hours. At 48 and 96 hours, the amounts of HMGB1 
were similar with a relative density of 1.6 and 1.5 respectively on western 
blotting. The estimated HMGB1 concentrations were determined by 
densitometry analysis with His-tagged HMGB1 standards of 5, 10 and 15 
μg/ml which had a relative density of 1, 1.7 and 2.7 respectively. Hence, the 
HMGB1 concentration in the DCs culture (for figures 4.11 E and 4.13 E) 
would be in the range of 500 to 1000 ng/ml for 48 and 96 hours supernatant as 
they would be 10X diluted when added at 10% (v/v) for cell stimulation.  10 μl 
of the ACs supernatant was added into 90 μl of DCs in OPTI-MEM I medium 
with antibiotics. This HMGB1 concentration should be more than sufficient to 
synergise with 10 ng/ml LPS for both TNF-α and IL-6 secretion (Figure 4.3). 
However, of interest, although the amount of HMGB1 at 48 and 96 hours were 
similar for the 24 million per ml of ACs, only the TNF-α at 96 hours but not at 
48 hours was significantly above the buffer control (Figure 4.11 E). This 
suggested that factors, immunosuppressive in nature, in the apoptotic 





Figure 4.11: Interaction of total apoptotic supernatant with LPS on DCs TNF-α 
secretion. For this experiment, increasing number of ACs per ml of 1X PBS (with 
antibiotics) from which the supernatant was obtained from were used: A: 3   106 
ACs/ml, B: 6   106 ACs/ml, C: 9   106 ACs/ml, D: 12   106 ACs/ml, and E: 24   
10
6
 ACs/ml. The effects of the supernatant alone and with LPS were examined. A. 
The apoptotic supernatant from all the time-points was immunosuppressive. Even at 
96 hours, there was a statistical significant reduction of TNF-α as compared to buffer 
alone with 10 ng/ml of LPS. B, C & D. With increasing duration of apoptosis, there 
was an increasing trend of TNF-α secretion with LPS 10 ng/ml. However there was 
still a statistical significant reduction of TNF-α as compared to buffer alone at 96 
hours.  E. For stimulation with supernatant from 24   106 ACs/ml at 96 hours, 
synergism with LPS 10 ng/ml was observed and the TNF-α secretion was increased 
significantly above the medium control. F. Release kinetics of HMGB1 for 24   106 
ACs/ml over time. Densitometry analysis was done on the western blot obtained after 
SDS-PAGE under reducing condition and transfer onto a PVDF membrane with a 
rabbit polyclonal anti-HMGB1. For these experiments, LPS was added into the DCs 
culture for 30 minutes prior to the addition of the ACs supernatant. These 
experiments were conducted independent of each other and were performed in 
triplicates and presented as means ± SD. Results were analysed using Student’s t-test 
(2-tails): n.s.-statistically not significant, *p < 0.05, and ***p < 0.001. 
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Figure 4.12: Supernatant from increasing length of apoptosis was associated 
with decreasing immunosuppression of TNF-α induced by LPS. A to D. 
Relationship between supernatant from increasing duration of apoptosis with DCs 
TNF-α secretion induced by 10 ng/ml of LPS. Beyond 6   106 ACs/ml, there was a 
strong positive correlation between increasing length of apoptosis from which the 
supernatant was derived from and TNF-α secretion (r > 0.9). F. There was also a 
positive correlation between relative amounts of HMGB1 and TNF-α secretion albeit 
weaker than the relationship between duration and TNF-α. Each point represented a 
single ELISA result. r = Pearson product-moment correlation coefficient.   
 
For DCs IL-6 secretion induced by LPS, the general trend was also towards 
immunosuppression especially with apoptotic supernatant from the earlier 
time points, 3 and 6 hours (Figure 4.13). It was likely the various components 
of the apoptotic supernatant (both pro- and anti-inflammatory) would interact 
in a complex manner with LPS. The apoptotic supernatant was a complex 
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mixture containing different proteins (Figure 4.13 E), and likely other 
macromolecules such as lipids and DNA which were not assayed.     
Figure 4.13: Interaction of total apoptotic supernatant with LPS on DCs IL-6 
secretion. A. For apoptotic supernatant from 3   106 ACs/ml, no perceivable 
immuno-suppressive or immuno-stimulatory effect was observed for all the time 
points. B to E. With increasing duration of apoptosis, there was an increasing trend of 
IL-6 secretion with LPS 5 and 10 ng/ml. This trend was seen for 24   106 ACs/ml but 
less distinct. F. 15% SDS-PAGE (reducing condition) showed a complex mixture of 
proteins from supernatant obtained from the 96 hours (Commassie blue stained gel).  
Experiments  were performed in triplicates and presented as means ± SD. Results 
were analysed using Student’s t-test (2-tails): n.s.-statistically not significant, *p < 
0.05, and **p < 0.01. 
 
The apoptotic supernatant from Jurkat T cells by itself had no pro-
inflammatory effect in terms of IL-6 that was measured (Figure 4.10 B). It was 
generally immunosuppressive in nature although at the longest duration of 
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apoptosis of 96 hours, the apoptotic supernatant exhibited some pro-
inflammatory effect, albeit low, with LPS with DCs prepared from purified 
monocytes of some donors. As the pro-inflammatory effect in general was not 
marked and no obvious synergism was seen between the HMGB1 present in 
the apoptotic supernatant and LPS, it would be difficult to test the effect of 
C1s cleavage in this in-vitro system.  
 
In addition, although HMGB1 containing nucleosomes had been shown to be 
pro-inflammatory in nature when purified from ACs (Urbonaviciute, Furnrohr 
et al. 2008), the apoptotic supernatant in the whole did not exhibit any pro-
inflammatory effect on the DCs in terms of TNF-α and IL-6. This could be the 
result of anti-inflammatory components that were present in the apoptotic 
supernatant.     
  
4.2.3 Mono-nucleosomes containing fraction was pro-inflammatory  
Urbonaviciute and colleagues (2008) demonstrated that HMGB1-containing 
nucleosomes prepared from purified nuclei of chemically (staurosporine) 
induced apoptotic Jurkat T cells by micrococcal nuclease treatment, lysis and 
then sucrose gradient ultracentrifugation separation induced IL-1β, TNF-α, IL-
6 and IL-10 release (Urbonaviciute, Furnrohr et al. 2008). A similar 
methodology described previously by Suer et al. (Suer, Dahnrich et al. 2004) 
was used but with modifications including 1) the use of UVC irradiation (with 
reasons discussed previously in section 3.4.1) and 2) the use of late apoptotic 
supernatant to evaluate the activity of the mono-nucleosomes that were 
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released from secondarily necrotic cells rather than obtaining them from lysed 
micrococcal nuclease treated nuclei.       
 
In brief, supernatant from 250    6 apoptotic Jurkat T cells was obtained at 
72 hours of culturing in a humidified incubator at 37°C with 5% CO2 after 
UVC irradiation. Cell debris was removed with ultracentrifugation at 100,000 
g for 1 hour at 4°C (HITACHI preparative ultracentrifuge CP90WX with the 
P40ST rotor, Hitachi Koki Co., Ltd. Tokyo, Japan.). The apoptotic supernatant 
was concentrated and buffer exchanged into the 10 mM Tris/HCl pH 7.4 with 
150 mM NaCl using the ultrafiltration column with a molecular cut-off of 100 
kDa to 1 ml. It was then layered onto an 11 ml discontinuous sucrose gradient 
(2 ml each of 50%, 40%, 30%, 20% (v/v) sucrose and 3 ml of 10% (v/v) 
sucrose in 10 mM Tris/HCl pH 7.4 with 150 mM NaCl). The sample was 
centrifuged at 142,000 g for 22 hours at 4°C.  Twelve 1 ml fractions were 
collected, dialysed into 1X PBS and concentrated to 50 μl with a 100 kDa 
molecular weight cut-off ultrafiltration column before cell stimulation. 
 
Fractions 5, 6, and 7 induced IL-6 secretion from human MΦ (Figure 4.14). 
These fractions contained the mono-nucleosomes as evident by the presence of 
DNA fragments of 150 bp in length. Fraction 2 which contained the largest 
amount of HMGB1 among all the fractions did not induce a comparable IL-6 
secretion as compared to fraction 5 which has approximately 7 fold lesser 
HMGB1 (213   63 pg/ml versus 1960   237 pg/ml: means ± SD). There was 
no obvious relationship between the intensity of HMGB1 in the fraction and 
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IL-6 secretion. It appeared that most of the HMGB1 was not complexed with 
the mono-nucleosomes. However, as HMGB1 was retained by the 100 kDa 
molecular weight cut-off ultrafiltration tube during buffer exchange and 
concentration, it was likely to exist as a complex with a molecular weight 
above that. The histones proteins were found in the same fractions as the DNA 
that was larger than 150 bp in length which was consistent with the formation 
of nucleosome particles that made up the chromatin.      
 
 
Figure 4.14: Apoptotic supernatant that was fractionated with sucrose gradient 
ultracentrifugation exhibited pro-inflammatory activity with MΦ. A. Stimulation 
with 4% (v/v) of various fractions that were concentrated and buffered exchanged 
into 1X PBS with a 100 kDa molecular weight cut-off ultrafiltration tube exhibited 
pro-inflammatory effect on MΦ in terms of IL-6 secretion. The peak IL-6 activity was 
observed with fraction 5 which corresponded to the mono-nucleosomes containing 
fraction. The MΦ were differentiated from human monocytes in the presence of M-
CSF and used at a density of 0.6   106 per ml of OPTI-MEM 1 supplemented with 
antibiotics. B. The fractions were analysed using a 1.5% agarose gel with samples 
loaded into the wells with a 6X loading dye containing 0.6% SDS (w/v). DNA 
fragments released from the mono-nucleosomes (≈ 150 bp) and di-nucleosomes 
(≈300 bp) were most evident in fractions 5 and 7 respectively. C. Fractions 5 to 12 
contained the 4 histone proteins (*) that typically stained equally with Coomassie 
staining due to their equimolar presence. The presence of these histone proteins were 
confirmed with western blotting done with antibodies against all 4 types (Histones 
H4, H3, H2A and H2B). The western blots with anti-Histone H3 and anti-HMGB1 
(both rabbit polyclonal) were shown above. Proteins were separated with 15% SDS-
PAGE under reducing condition with western blotting done after transfer onto a 
PVDF membrane.   
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In summary, apoptotic supernatant did not exhibit any pro-inflammatory 
activity by itself. It was generally immunosuppressive in nature although late 
apoptotic supernatant did exhibit synergism with LPS with certain batches of 
DCs especially when the supernatant was derived from more ACs. Both pro- 
and anti-inflammatory activities existed in the total apoptotic supernatant. This 
was evident as when the supernatant was fractionated with sucrose gradient 
ultracentrifugation, certain fractions, especially the mono-nucleosomes 
containing ones exhibited pro-inflammatory activity in terms of stimulating 
IL-6 production from MΦ. This finding was consistent with previous report 




Chapter 5 C1 complex role in IFN-α regulation    
 
5.1 IFN-α AND SLE   
IFN-α is a key pathologic cytokine in SLE and the formation of SLE ICs are 
believed to be important in stimulating its release from pDCs found in PBMCs 
(Bave, Alm et al. 2000; Lovgren, Eloranta et al. 2004; Santer, Yoshio et al. 
2009). PDCs appeared to be the main source of this cytokine as pDCs depleted 
PBMCs did not secrete detectable amounts of INF-α upon SLE ICs challenge 
(Santer, Hall et al. 2010). A component in these ICs that appeared to be 
important for the induction of IFN-α secretion by pDCs was HMGB1 (Tian, 
Avalos et al. 2007). Activation of IFN-α through TLR9 was dependent on 
HMGB1 and its interaction with RAGE on pDCs as this activity could be 
inhibited by monoclonal antibodies to HMGB1 and RAGE as well as RAGE-
Fc region chimeric protein.  
Figure 5.1: Predicted C1s cleavage sites on HMGB1 correspond to its TLR4 and 
RAGE receptors interacting regions. The regions that are important in its 
interaction with TLR4 and RAGE are shown in the schematic figure above. R: single 
amino acid code of arginine.  
 
An interesting observation in our study was that the predicted C1s cleavage 
sites at the C-terminal ends of arginine 97 and 163 were found within the 
TLR4 and RAGE binding regions of HMGB1 respectively (Huttunen, Fages et 
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al. 2002; Yang, Hreggvidsdottir et al. 2010) (Figure 5.1). This meant that its 
interactions with these receptors would likely be affected. In the context of 
SLE, the HMGB1 containing SLE ICs interaction with RAGE leading to 
TLR9 activation and the study of how C1 complex might ameliorate this 
activity would be an interesting as well as relevant part of this project.   
 
We hypothesised that C1 complex could reduce the SLE ICs ability to induce 
IFN-α secretion  by cleaving HMGB1 at its RAGE binding region and hence, 
disrupting its interaction with RAGE. In this chapter, the specific aims were: 
1) To develop and optimise an in-vitro assay of SLE ICs induced PBMCs 
IFN-α secretion, 
2) To determine whether C1 complex cleaved HMGB1 from the apoptotic 
U937 cells that were used as a source of autoantigens,  
3) To determine whether C1 complex reduced the IFN-α inducing ability of 
SLE ICs,  
4) To determine whether C1s in C1 complex played a role in reducing SLE-
ICs PBMCs IFN-α secretion, and  
5) To validate the importance of HMGB1 in the SLE ICs in inducing IFN-α 
secretion with the system developed in this project.  
 
There are 2 interfaces that C1 complex can act on the autoantigens and 
DAMPs (Figure 5.2). The first interface is on the surfaces of ACs where C1 
complex can be recruited (Lu, Teh et al. 2008). In this interface, C1q by itself 
plays a role in aiding the clearance of ACs through phagocytosis. In addition, 
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there is evidence that C1s is enzymatically active on the ACs as there is 
deposition of C3b as a result of C1s cleavage of C4 and C2 with the formation 
of C3 convertase (C4bC2a). The second interface will be with the binding of 
C1q to SLE ICs (Reid 1986). These were taken into consideration in the 
design of the in-vitro assays to assess C1 complex interaction with 
autoantigens and DAMPS as well as its effect on SLE ICs activity on PBMCs 
IFN-α secretion.  
Figure 5.2: Potential sites of C1 complex interaction with autoantigens and 
DAMPs. C1q can bind to the surfaces of ACs (.1.) and autoantibodies-autoantigens 
ICs (.2.). C1q will then recruit C1s as C1 complex onto the interfaces that will 
potentially allow them to act on both autoantigens and DAMPs such as HMGB1.   
 
5.2 SLE ICS INDUCED PBMCS IFN-α PRODUCTION  
The first aim was to develop a working in-vitro assay that allowed PBMCs to 
secrete IFN-α in response to SLE ICs. To create the SLE ICs, autoantibodies 
and autoantigens were required. SLE patients were screened for the presence 
of anti-nucleosome antibodies and the sera from 4 patients with the highest 
titers were used as the source of autoantibodies (Figure 5.3). These 4 patients 
were clinically assessed to be in active flare by the attending rheumatologist.   
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The autoantigens were obtained after induction of apoptosis by UVC 
irradiation in the monocytic cell line U937. This cell line was used previously 
by multiple investigators and the autoantigens were obtained differently in 
different studies including induction of apoptosis by different means 
(chemicals, drugs, or UV irradiation) and necrosis from repeated freeze-thaw 
cycles (Bave, Alm et al. 2000; Lovgren, Eloranta et al. 2004; Santer, Yoshio et 
al. 2009; Santer, Hall et al. 2010). The likely reason for it being favoured was 
because it was superior in terms of eliciting a greater IFN-α response from 
PBMCs as compared to other cell lines (Bave, Alm et al. 2000). The U937 
cells used were determined to be free from Mycoplasma contamination using a 
Mycoplasma PCR detection kit. 
 
U937 cells were cultured in RPMI 1640 supplemented with 10% (v/v) FCS, 
100 units/ml Penicillin, 100 μg/ml Streptomycin, and 2 mM L-glutamine. 
Cells were harvested, washed 3 times with 1X PBS and re-suspended in 1X 
PBS with antibiotics similar to the culture medium to a density of 50   106 
cells/ml. Induction of apoptosis was by UVC irradiation (dose of 500 mJ/cm
2
). 
The irradiated U937 cells were cultured for 24 hours prior to the collection of 
the apoptotic supernatant by centrifugation at 500 g for 5 minutes to remove 
cellular debris. Cell death by apoptosis was confirmed by the presence of 
DNA laddering. The ICs were formed by incubating 40% (v/v) of apoptotic 
supernatant with the SLE sera at 10X or 100X dilution at 37°C for 30 minutes. 
The SLE ICs were then added into the PBMCs at 10% (v/v) and the cells 
cultured for a further 24 hours before the supernatant was collected for IFN-α 




Figure 5.3: SLE serum in combination with U937 apoptotic supernatant induced 
IFN-α production by PBMCs. Juvenile SLE patients were screened for the presence 
of anti-nucleosome antibodies. A cut-off of 20 RU/ml was used as at this level, 204 
healthy blood donors that were tested with this kit by the manufacturer were anti-
nucleosomes negative. Sera from 4 patients with the highest titers and clinically 
active diseases were used for this experiment. The ICs were prepared with either a 
10X or 100X dilutions of the sera incubated with 40% (v/v) of U937 apoptotic 
supernatant (AS) in 1X PBS (with antibiotics) for 30 minutes at 37°C. 10 μl of this 
preparation was added into 90 μl of PBMCs in Macrophage-SFM supplemented with 
100 units/ml penicillin and 100 μg/ml streptomycin at 5   106 cells/ml. These 
PBMCs were primed with IFN-αB2 500 U/ml just prior to addition of the stimuli. 
Medium control was without PBMCs but with IFN-αB2. The IFN-αB2 subtype did not 
cross react with the IFN-α ELISA kit used and by itself did not stimulate IFN-α 
production by the PBMCs. Serum, SLE (C), was used subsequently as the source of 
SLE autoantibodies at the dilution of 100X for all subsequent generation of SLE ICs. 
The experiments including the anti-nucleosome ELISA were conducted in duplicates 
and results were presented as mean  SD. SLE (A), (B), (C), and (D) represented 4 




The ICs formed with 100X dilution of serum, SLE (C), had the highest IFN-α 
response and was used as the source of SLE autoantigens for the remaining 
experiments. A high dilution of SLE serum was ideal to minimise the potential 
effect of serum factors that would potentially affect the downstream 
experiments (including complement factors). This serum would eventually be 
at 1000X dilution in the PBMCs culture as the stimuli were added at 10% 
(v/v).  
 
Priming with IFN-α, IFN-α2b subtype (Intron A), was used commonly by 
different investigators in the study of SLE ICs to increase the IFN-α secretion 
(Lovgren, Eloranta et al. 2006; Lood, Gullstrand et al. 2009; Santer, Hall et al. 
2010). This IFN-α subtype, however, would cross react with the ELISA kit 
that was used in the project, according to the manufacturer’s manual 
(VeriKine™ Human IFN-α ELISA Kit. PBL Assay Science. Piscataway, NJ, 
USA.). Another IFN-α subtype, IFN-αB2 (IFN-α8), which would not cross 
react with the ELISA kit was used instead. This cytokine, at 500 U/ml, also 
increased the SLE ICs IFN-α production significantly (Figure 5.4) and by 
itself did not stimulate PBMCs IFN-α production. Also, the IFN-αB2 did not 
exhibit any cross reactivity with the ELISA kit.  
 
The complement proteins found in this particular patient’s serum at the 
dilution used did not appear to affect the SLE ICs IFN-α production (Figure 
5.4). Heat inactivation of the SLE serum at 56°C for 30 minutes in the water 
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bath was done to inactivate the complement factors before being incubated 
with the U937 apoptotic supernatant to form the ICs. There was no statistically 
difference between the heat inactivated and non-heat inactivated serum from 
the same SLE patient.  
 
Figure 5.4: Priming with IFN-αβ2 enhanced subsequent SLE ICs IFN-α 
production. Heat inactivation (HI) (56°C for 30 minutes) was done for an aliquot of 
SLE (C) serum. Subsequently, the ICs were prepared with either HI or non-HI SLE 
(C) serum at 100X dilution incubated with 40% (v/v) of U937 apoptotic supernatant 
(AS) in 1X PBS (with antibiotics) for 30 minutes at 37°C. 10 μl of this preparation 
was added into 90 μl of PBMCs in Macrophage-SFM supplemented with 100 
units/ml penicillin and 100 μg/ml streptomycin at 5   106 cells/ml. The 
concentrations represented in the diagram were the eventual cell culture 
concentrations. These PBMCs were either primed with IFN-αB2 500 U/ml or not 
primed. Priming was just added prior to the addition of the stimuli. Buffer control was 
without PBMCs. The IFN-αβ2 subtype did not cross react with the IFN-α ELISA kit 
used and by itself did not stimulate IFN-α production by the PBMCs. The experiment 
was done in duplicates and results were presented as mean  SD. Statistical analysis 
was done with unpaired student’s t-test (2 tails): n.s.-not significant, * p < 0.05 and ** 
p < 0.01. 
 
In summary, serum from SLE patients had different IFN-α stimulating ability 
in combination with autoantigens. This could be the combination of the 
following factors: 1) different autoantibodies profile, 2) different amount of 
total IgG and 3) varying amount of other factors (known and unknown) that 
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may affect IFN-α production (for example C1q) (Lood, Gullstrand et al. 2009; 
Santer, Hall et al. 2010). For the SLE (C) serum used at the 100X dilution 
during the incubation with U937 apoptotic supernatant, complement factors 
appeared not to affect the IFN-α production. Lastly, although the SLE ICs 
could still result in PBMCs IFN-α production without priming with IFN-αB2, 
priming helped to increase the IFN-α production significantly such that any 
treatment reduction would be more perceivable.     
 
5.3 C1 COMPLEX REDUCED SLE ICS INDUCED PBMCS IFN-α 
SECRETION  
C1 complex reduced PBMCs IFN-α production induced by SLE ICs in a dose 
dependent manner (Figure 5.5 D). In this experiment, the effect of C1 complex 
interacting at the autoantibodies-autoantigens/DAMPs soluble interface was 
examined. C1 complex was added into the U937 apoptotic supernatant at 40% 
(v/v) and SLE serum (SLE (C) Figure 5.3) at 1% (v/v) (100X dilutions) during 
the 30 minutes incubation period at 37°C prior to its addition into the PBMCs. 
10 μl of this preparation was added into 90 μl of PBMCs (primed with IFN-
αB2 500 U/ml) at 8 × 10
6
 cells/ml in macrophage-SFM medium with 100 
units/ml Penicillin and 100 μg/ml Streptomycin. Apoptosis was determined by 
the presence of DNA laddering at 24 hours after UVC irradiation (Figure 5.5 




Figure 5.5: C1 complex reduced PBMCs IFN-α production induced by SLE ICs 
in a dose dependent manner. A. DNA laddering was seen in U937 cells at 24 hours 
after UVC irradiation (1.2% agarose gel visualised with GelGreen). Hence, the 
supernatant used for SLE ICs contained autoantigens from apoptotic U937 cells. B. 
C1 complex cleaved HMGB1 in the apoptotic supernatant (AS). With increasing C1 
complex concentration, there was a decreasing intensity of HMGB1. A faint band, not 
seen in the AS and C1 complex alone lanes, was seen (indicated by the red arrow ←). 
Western blotting was done with a polyclonal anti-HMGB1 antibody after 12.5% 
SDS-PAGE separation under reducing condition and transfer onto a PVDF 
membrane. C. C1s cleavage of His-tagged rHMGB1 resulted in the F1 fragment 
which was similar in size to that seen with C1 complex treatment of U937 AS 
(indicated by the red arrow ←). D. C1 complex reduced PBMCs IFN-α production 
induced by SLE ICs in a dose dependent manner. Concentrations represented that 
found in the cell culture. ELISA was done in duplicates and results were presented as 
mean   SD. Statistical testing with student’s t-test (2- tails): * p <0.05.      
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At a C1 complex concentration of 24 μg/ml, HMGB1 in the U937 apoptotic 
supernatant was cleaved almost completely during the 30 minutes incubation 
at 37°C (Figure 5.5 B). The reaction mixture was chilled to 0°C on ice to stop 
the reaction and the samples processed within the same day for SDS-PAGE. 
The endogenous HMGB1 released from the ACs had an apparent molecular 
weight that was consistent with its predicted weight (24.9 kDa). With C1 
complex treatment at a dose from 3 to 24 μg/ml, a faint band (indicated by the 
red arrow ← in figure 5.5 B) was seen. This was not found in the C1 complex 
alone and apoptotic supernatant alone lanes on western blotting with a rabbit 
polyclonal anti-HMGB1. Hence, this faint band, which could be detected by a 
polyclonal anti-HMGB1 antibody, was a cleaved fragment of HMGB1 as a 
result of the action of C1 complex.  The size of this fragment (red arrow ← in 
figure 5.5 B) was consistent with the F1 fragment from the previous in-vitro 
cleavage study using C1s and His-tagged rHMGB1 from Escherichia coli 
(Figure 5.5 C).          
 
The intensity of HMGB1 in the apoptotic supernatant used to form the SLE 
ICs was inversely correlated to the % inhibition of IFN-α (Figure 5.6 B). The 
reduction of IFN-α production of the C1 complex treated from non-treated 
SLE ICs level was expressed as a percentage over the IFN-α concentration of 
non-treated SLE ICs. Even with almost complete absence of HMGB1 as 
detectable by western blotting in the supernatant treated with 24 μg/ml of C1 
complex, the % inhibition was 79.9 % and not 100%. This meant that other 
factors could be involved. One likely possibility would be the release of 
HMGB1 by pDCs after TLR9 activation (Dumitriu, Baruah et al. 2005). 
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Figure 5.6: The intensity of HMGB1 in the apoptotic supernatant used for SLE 
ICs formation was negatively correlated with the % inhibition of IFN-α. A. 
There was a reduction in the amount of HMGB1 left in the U937 apoptotic 
supernatant (AS) after a 30 minutes incubation at 37°C with C1 complex. The 
reaction mixture consisted of 40% (v/v) AS (obtained at 24 hours after UVC 
irradiation of U937 cells at a density of 50   106 cells/ml) and C1 complex at the 
specified concentrations as shown in the diagram and the volume topped up to 100% 
with 1X PBS. For the SDS-PAGE separation followed by western blot with the rabbit 
polyclonal anti-HMGB1, no SLE serum was added. However, for the stimulation of 
PBMCs, the stimuli were prepared similarly but with 1% (v/v) of SLE serum during 
the 30 minutes incubation at 37°C. Densitometry analysis was done after western 
blotting and expressed as relative HMGB1 density with reference to untreated AS. B. 
Relative HMGB1 intensity was negatively correlated with % inhibition of PBMCs 
IFN-α secretion (r = Pearson’s correlation coefficient).   
  
 
Although, the intensity of HMGB1 was negatively associated with % 
inhibition of PBMCs IFN-α production, it would not necessary meant that the 
relationship was causal as it was possible that that one of the component of C1 
complex (C1q, C1r or C1s) might play a direct role in causing this effect.   
 
5.3.1 C1s as C1 complex reduced SLE ICs PBMC IFN-α production  
C1 is a 790 kDa complex consisting of C1q and a tetramer with 2 copies each 
of C1r (≈83 kDa) and C1s (≈83 kDa) (Cooper 1985; Reid 1986). In this 
section, we investigated the effect of a much higher concentration of C1s alone 
as compared to the C1s present in C1 complex on SLE ICs induced IFN-α 
production. C1s was used in excess as it was previously demonstrated that C1s 
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by itself was not enzymatically as efficient as when it was present as C1 
complex in cleaving rHMGB1 in-vitro (Section 3.3.4). 
 
In 24 μg/ml of C1 complex, there would be approximately 5 μg/ml of C1s (as 
a dimer) based on their molecular weights. At 20 times higher concentration of 
activated C1s (100 μg/ml), C1s alone did not cleave HMGB1 (Figure 5.7 A). 
The incubation of C1 complex and C1s with the U937 apoptotic supernatant 
was carried out for 30 minutes at 37°C. In contrast at 24 μg/ml of C1 complex, 
no residual HMGB1 remained in the apoptotic supernatant after treatment. 
There was no statistical difference in the C1s treated SLE ICs (at 10 μg/ml 
after 10X dilution in the cell culture) as compared to non-treated SLE ICs in 
terms of IFN-α production (Figure 3.7 B). Both C1 complex and activated C1s 
used were serum purified proteins obtained from the same company (Merck 
Millipore (Calbiochem). Billerica, MA, USA). 
 
In the presence of C1s alone, there was no inhibitory effect on SLE ICs 
PBMCs IFN-α production even with increasing concentrations of up to 10 
μg/ml in the cell culture. However, during the 30 minutes incubation, C1s at 
the highest concentration used did not cleave HMGB1 significantly; hence 
whether HMGB1 cleavage would affect SLE ICs PBMCs secretion was still 







Figure 5.7: C1s did not cleave and reduce PBMCs IFN-α production induced by 
SLE ICs (30 minutes incubation). A. C1s did not cleave HMGB1 even at the 
highest concentration of 100 μg/ml. C1 complex and C1s were incubated with the 
apoptotic supernatant (AS) for 30 minutes at 37°C. Western blotting of the reaction 
mixtures was subsequently done with a polyclonal anti-HMGB1 antibody after 12.5% 
SDS-PAGE separation under reducing condition and transfer onto a PVDF 
membrane. B. C1s treatment did not affect SLE ICs induced IFN-α production. A 
similarly prepared C1 complex and C1s treated SLE ICs as in A was done except 
these stimuli had 1% (v/v) SLE serum added to it. 10 μl of this preparation was added 
into 90 μl of PBMCs. Concentrations represented that found in the cell culture. 
ELISA was done in duplicates and results were presented as mean   SD. Statistical 
testing with student’s t-test (2- tails): n.s. -not significant.        
 
To investigate further whether C1s cleavage of HMGB1 in the U937 apoptotic 
supernatant would reduce SLE ICs induced PBMCs IFN-α production, C1-
INH at 100 μg/ml was added concurrently with C1 complex during the SLE 
ICs preparation (Figure 5.8). C1-INH was able to restore the IFN-α inducing 
ability of the C1 complex treated SLE ICs. The restoration was most complete 
for the C1 complex concentration of between 1.2 to 5 μg/ml and partially for 
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10 μg/ml of C1 complex. This result suggested that the reduction of IFN-α 
production was mediated by the proteolytic activity of C1 complex (i.e. C1s).  
 
 
Figure 5.8: C1-INH restored the IFN-α inducing ability of SLE ICs when added 
concurrently with C1 complex. C1-INH was added concurrently (100 μg/ml) with 
C1 complex (12, 25, 50 and 100 μg/ml) during the preparation of SLE ICs with SLE 
serum at 100X dilution and 40% (v/v) of ACs supernatant. These mixtures were 
incubated for 30 minutes at 37°C with the controls. 10 μl of this preparation was 
added into 90 μl of PBMCs (primed at a density of 5   106 cells/ml). Concentrations 
represented that found in the cell culture. ELISA was done in duplicates and results 
were presented as mean   SD. Statistical testing with student’s t-test (2-tails): n.s. -
not significant, * p <0.05 and ** p <0.01.      
   
 
5.3.2 C1r/s with C1q played an important role in reducing SLE ICs PBMC 
IFN-α production  
As C1q had been shown previously to be important in reducing the IFN-α 
inducing effect of SLE ICs, we went on to study whether C1r/s played an 
additional role in enhancing the reduction when it is present as C1 complex 
(Lood, Gullstrand et al. 2009; Santer, Hall et al. 2010). To achieve this 
purpose, an equimolar of C1q alone that was comparable to that found in C1 
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complex was used as a comparator so that the effects of C1q as well as the 
additional presence of C1r/s could be assessed.  
 
 
Figure 5.9: The presence of C1r/s was responsible for the IFN-α inhibitory effect 
of C1 complex. A. 1 μg of purified C1q had an equivalent amount of C1q as 1.7 μg 
of C1 complex. Hence, a ratio concentration of 0.58 of C1q: 1 of C1 complex would 
have equimolar amount of C1q. Proteins were separated by 12.5% SDS-PAGE under 
denaturing condition. The 3 chains of C1q were visualised by Coomassie staining. B. 
C1q treatment of SLE ICs appeared to reduce the IFN-α production with increasing 
C1q concentration but the result was not statistically significant. The presence of 
C1r/C1s in C1 complex appeared to be important in C1 complex IFN-α reduction 
ability with the concentrations used. Equimolar of C1q alone was used in the 
treatment of SLE ICs as compared to C1 complex. 40% (v/v) of AS with SLE serum 
at 100X dilution was treated with C1q (7, 15, 29 and 58 μg/ml) or C1 complex (12, 
25, 50 and 100 μg/ml) for 30 minutes at 37°C. The C1q content of 12 μg/ml of C1 
complex would be comparable to that found in 7 μg/ml of purified C1q. 10 μl of this 
preparation was added into 90 μl of PBMCs at 8 × 106 cells/ml (primed with 500 
U/ml of IFN-αB2). Concentrations represented that found in the cell culture. ELISA 
was done in duplicates and results were presented as mean ± SD. Statistical testing 








With increasing C1q concentration, there was a general trend towards a 
reduction of SLE ICs IFN-α production although this was statistically not 
significant (Figure 5.9B). The additional presence of C1r/s with C1q was able 
to reduce the IFN-α production when compared to equimolar C1q alone. This 
was statistically significant for the C1 complex concentration of 5 and 10 
μg/ml when compared to the corresponding equimolar amount of C1q of 2.9 
and 5.8 μg/ml. This suggested that the presence and activity of C1r/s was 
important in C1 complex ability to reduce SLE ICs induced IFN-α production.  
 
The concentration of C1q used was much lower than that used by Lood and 
coworkers of up to 70 μg/ml where they used a fairly similar in-vitro system of 
primed PBMCs stimulated with SLE ICs (Lood, Gullstrand et al. 2009). It is 
likely that if higher C1q concentration is used in our system, a reduction of 
IFN-α production can be observed. However, the experiment demonstrates the 
ability of C1 complex to be able to reduce the IFN-α production much more 
effective than what C1q can potentially do by itself.  
 
5.4 HMGB1 WAS IMPORTANT IN SLE ICS IFN-α RESPONSE   
In the last part of the chapter, we aimed to validate the importance of HMGB1 
in the SLE ICs in inducing IFN-α secretion with the system developed in this 
project. The importance of HMGB1 in the SLE ICs IFN-α response was 
generated with necrotic cells (mouse embryonic fibroblasts and U937 cells) by 
Tian and his coworkers (Tian, Avalos et al. 2007). It was demonstrated that 
redox status of HMGB1 in apoptotic and necrotic cells were different in Jurkat 
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T cells (Figure 5.10) and it was likely that similar differences would be 
observed in U937 cells.  
 
An apoptotic source of autoantigens was chosen in our project instead of a 
necrotic source due to the current belief of the pathological importance of 
apoptosis as a source of SLE autoantigens (Casciola-Rosen, Anhalt et al. 
1994). Because of the different redox forms of HMGB1 in the 
autoantigens/DAMPs used for the generation of ICs, we aimed to determine if 
HMGB1 was still important in the IFN-α inducing ability of SLE ICs as the 
information was important in our project.    
Figure 5.10: Different redox forms of HMGB1 in necrotic and apoptotic cells. 
Jurkat T cells were induced into apoptosis by UVC irradiation or rendered necrotic by 
repeated freeze thaw cycles. The supernatant was collected from the apoptotic Jurkat 
T cells 24 hours after UVC irradiation and necrotic ACs by centrifugation at 1000 g 
for 5 minutes to remove the cellular debris. The proteins were separated by 12.5% 
SDS-PAGE under both reducing (with DTT) and non-reducing condition. Western 
blotting was subsequently done with a rabbit polyclonal anti-HMGB1 after the 
proteins were transferred onto a PVDF membrane. Two different redox forms of 
HMGB1 were visualised. The oxidised form with an intra-molecular disulphide bond 
between cysteine residues 23 and 45 is known to migrate faster due to a more 
compact conformation (Yang, Lundback et al. 2012). This form was found in the 
apoptotic Jurkat T cells supernatant. The completely reduced form was found in the 
necrotic supernatant. NCs: necrotic cells.       
 
5.4.1 Chicken IgY inhibited the formation of SLE ICs and reduced its IFN-α 
response  
Chicken neutralising anti-HMGB1 IgY and control IgY were purchased from 
the same company (Shino-Test Corporation. Kanagawa, Japan). The IgY 
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isotype was chosen as a neutralising antibody because it would not interact 




Figure 5.11: Anti-HMGB1 and control IgY did not inhibit IFN-α production 
when added concurrently with SLE serum to the apoptotic U937 supernatant. 
Neutralising anti-HMGB1 and control IgY (1, 5, and 10 μg/ml) were added to the 
40% (v/v) U937 apoptotic supernatant (AS) and SLE serum at 100X dilution and 
incubated for 30 minutes at 37°C. 10 μl of this preparation was added into 90 μl of 
PBMCs at 8 × 10
6
 cells/ml (primed). Concentrations represented that found in the cell 
culture. This experiment was a representation of two repeats. IFN-α ELISA was done 
in duplicates and results were presented as mean ± SD. 
 
When both the anti-HMGB1 (neutralising) and control IgY (0.1 to 1 μg/ml) 
were added together with the apoptotic U937 supernatant and SLE serum 
during the 30 minutes incubation at 37°C, no change in IFN-α secretion was 
observed (Figure 5.11). However, when anti-HMGB1 IgY and the control 
antibody (0.1 to 3 μg/ml)  were added to the apoptotic supernatant first and 
pre-incubated for 15 minutes before the SLE serum was added for another 15 
minutes to allow for ICs formation, inhibition of IFN-α production was seen 
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(Figure 5.12). Of interest was the finding that both anti-HMGB1 neutralising 
and control IgY inhibited the IFN-α production, this suggested that the IgY by 
itself had inhibitory activity on SLE ICs induced IFN-α production. In 
addition, this was unlikely due to toxicity of the IgY reagents as 1) both the 
anti-HMGB1 neutralising and control IgY were dissolved in 1X PBS with no 
toxic substances such as sodium azide and, 2) the IgY did not have any 
inhibitory activity when added together with the SLE serum. 
 
The results suggested that the inhibition was competitive in nature (Figure 
5.13). The engagement of pDCs FcγRIIa have been found to be important in 
the mediating the endocytosis of SLE ICs containing RNA leading to eventual 
activation of endosomal TLR7 (Santer, Yoshio et al. 2009). Normal healthy 
purified IgG was found to inhibit the IFN-α production by inhibiting ICs 
binding to FcγRIIa on pDCs thus interrupting the update of autoantigens 
(Wiedeman, Santer et al. 2013). This inhibitory activity could be reproduced 
with the IgG Fc fragments. It was possible that IgY blocked the access of the 
autoantibodies of the IgG isotype to the autoantigens (U937 apoptotic 
supernatant) as suggested by the temporal nature of the inhibition requiring the 
addition of the IgY to the apoptotic supernatant before the SLE serum. And as 
IgY would not bind to human FcγR, the SLE ICs containing the immuno-
stimulatory autoantigens would not be taken up.    
 
 
In summary, it is still uncertain whether HMGB1 is important in our SLE ICs 
in stimulating IFN-α production as the presence of IgY itself was sufficient to 
interrupt its secretion. Hence, rHMGB1 from different sources (prokaryotic 
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and eukaryotic expressed) was subsequently used to determine if exogenously 
added rHMGB1 could enhance the IFN-α production by providing increase 




Figure 5.12: Both anti-HMGB1 and control IgY inhibited IFN-α production 
when added to the apoptotic U937 supernatant prior to the SLE serum. This 
suggested that both IgY acted in a competitive nature against SLE autoantibodies. At 
a similar dose, control IgY appeared to be a more potent inhibitor of IFN-α 
production as compared to the specific anti-HMGB1 antibodies. Neutralising anti-
HMGB1 and control IgY (1, 2, 4, 8 and 30 μg/ml) were added to the 40% (v/v) U937 
apoptotic supernatant (AS) and incubated for 15 minutes at 37°C. SLE serum was 
subsequently added 100X dilution and incubated for another 15 minutes at 37°C. 10 
μl of this preparation was added into 90 μl of PBMCs at 8 × 106 cells/ml (primed). 
Concentrations represented that found in the cell culture. This experiment was a 
representation of two repeats. IFN-α ELISA was done in duplicates and results were 







Figure 5.13: Putative mechanism of action of chicken IgY against SLE ICs 
induced IFN-α production. A. When SLE serum (containing autoantibodies) was 
added together with the chicken IgY, the high affinity SLE autoantibodies (IgG 
isotype) would outcompete the IgY and bind to the autoantigens present in the 
apoptotic U937 supernatant. B. However, when the IgY was added before the 
addition of SLE serum, the IgY would have the competitive advantage and 
opportunity to bind to the autoantigens first and possibly preventing the 
autoantibodies from forming immunogenic ICs with the autoantigens. As IgY lacked 
the ability to bind to human FcγR, the immunogenic autoantigens would not have the 
opportunity to be endocytosed and be presented to endosomal TLRs.          
 
5.4.2 Exogenous HMGB1 reduced the IFN-α production induced by SLE ICs  
Recombinant HMGB1 from different sources (prokaryotic and eukaryotic 
expressed) was used to determine if exogenously added rHMGB1 could 
enhance the IFN-α production by providing increase HMGB1 amount beyond 
its endogenous source from the ACs. In order to prevent the in-vitro system of 
being saturated with excess amount of DAMPs (especially HMGB1) and 
autoantigens, a decrease amount of apoptotic supernatant was used and slight 
increase in amount of SLE serum to prevent the autoantibodies from being 







Figure 5.14: Prokaryotic expressed His-tagged rHMGB1 inhibited SLE ICs 
induced IFN-α production in a dose dependent manner. His-tagged HMGB1 
(His-HMGB1) was added at 10, 50 or 100 μg/ml to the U937 apoptotic 
supernatant at 20% or 40% (v/v) for a 15 minutes incubation at 37°C. 
Subsequently, the reaction mixtures were topped up with SLE serum at 50X 
dilution or corresponding amount of 1X PBS (with antibiotics) for the controls 
for a further 15 minutes incubation at 37°C. 10 μl of this preparation was 
added into 90 μl of PBMCs at 8 × 106 cells/ml (primed). Concentrations 
represented that found in the cell culture. IFN-α ELISA was done in duplicates 
and results were presented as mean ± SD. 
      
 
 
First, the His-tagged rHMGB1 expressed in Escherichia coli (GenScript. 
Piscataway, NJ, USA) was used. The initial predominant concern of using this 
prokaryotic expressed rHMGB1 was the possibility of contamination with 
bacterial CpG ODN that could result in TLR9 activation and IFN-α production 
by itself. However, no stimulation was seen with rHMGB1 alone (Figure 
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5.14). As expected, with a decrease in the apoptotic supernatant to 2% (v/v) 
for the formation of ICs with the SLE serum, the IFN-α level was about half 
that of 4% (v/v) apoptotic supernatant (1172   229 U/ml versus 2324   612 
U/ml: mean    S.D.). Unexpectedly, the His-tagged rHMGB1 inhibited the 
SLE ICs induced IFN-α production in a dose dependent manner for both 
concentrations of apoptotic supernatant used. The addition of exogenous 
rHMGB1 did not increase the IFN-α production of ICs formed with 20% 
apoptotic supernatant and 50X diluted SLE serum.  
 
This experiment was repeated with the use of eukaryotic expressed rHMGB1 
(R&D Systems, Minneapolis, MN, USA) (Figure 5.15). Similar result was 
obtained with the eukaryotic expressed HMGB1. HMGB1 inhibited the IFN-α 
production of SLE ICs. There were three possible explanations to this 
experimental observation. 
1) Toxicity of the reagents.  
2) Direct inhibitory activity of HMGB1 on the PBMCs IFN-α production.  
3) Competition between free un-complexed rHMGB1 (exogenously added) 
and complexed HMGB1 (endogenously present) with partner molecule 
such as nucleosomes (DNA-histones complex).  
 
Toxicity of the reagents was unlikely as 1) both forms of rHMGB1 (with their 
buffers) yielded the same result and 2) HMGB1 was already a constituent 
present endogenously from the apoptotic supernatant. Direct inhibition of IFN-
α production by the exogenously added HMGB1 was possible and not 
excluded. However, direct competition between the free un-complexed 
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rHMGB1 for the binding site of receptor necessary for the IFN-α production 
of HMGB1-partner molecule ICs was also a likely explanation. HMGB1 have 
been shown to form complexes with nucleosomes during apoptotic cell death 
and SLE ICs obtained from lupus patients contained HMGB1 (Urbonaviciute, 
Furnrohr et al. 2008; Wen, Xu et al. 2013).  
 
Figure 5.15: Eukaryotic expressed rHMGB1 inhibited SLE ICs induced IFN-α 
production. Eukaryotic expressed HMGB1 was added at 40 μg/ml to the U937 
apoptotic supernatant (AS) at 40% (v/v) for a 15 minutes incubation at 37°C. 
Subsequently, the reaction mixtures were topped up with SLE serum at 100X dilution 
or corresponding amount of 1X PBS (with antibiotics) for the controls for a further 15 
minutes incubation at 37°C. 10 μl of this preparation was added into 90 μl of PBMCs 
at 8 × 10
6
 cells/ml (primed). Concentrations represented that found in the cell culture. 
IFN-α ELISA was done in duplicates and results were presented as mean ± SD. 
Statistical testing with student’s t-test (2-tails): * p < 0.05.        
 
 
In summary, C1 complex reduces the IFN-α response of PBMCs to SLE ICs 
and this is largely due to its proteolytic activity as inhibition of C1 complex 





Chapter 6 Discussion   
 
6.1 A NOVEL C1S FUNCTION: CLEAVAGE OF HMGB1, AN ALARMIN 
INVOLVED IN BOTH STERILE AND INFECTIVE INFLAMMATION   
In this study, a novel, non-complement function of C1s in cleaving HMGB1, 
an alarmin, was discovered and investigated in detail. Although, this is not the 
first description of a non-complement substrate of C1s, the identification of 
HMGB1 as its proteolytic target is significant, as this alarmin has important 
pathophysiologic contribution to SLE. This discovery may help to explain the 
strong clinical association between rare C1s deficiency in humans and the 
occurrence of juvenile SLE (Pickering, Botto et al. 2000; Lewis and Botto 
2006). This association is not easily explainable by C1s classical role in 
cleaving C4 and C2 during the activation of the classical complement 
pathway. With this new insight of C1s proteolytic cleavage of HMGB1 and 
other putative intracellular proteins, the results of this study may allow us to 
start understanding the mechanism behind C1s protective effect against 
autoimmunity.   
 
C1s, as C1 complex (C1qr2s2), have been shown to cleave both exogenous 
rHMGB1 as well as endogenous HMGB1 released from apoptotic Jurkat 
T/U937 cells in this study. The maximum concentration of C1 complex used 
for the treatment of the apoptotic Jurkat T cells at 5 μg/ml and apoptotic U937 
supernatant at 24 μg/ml is a fraction of the physiological C1 complex 
concentration of around 180 μg/ml in the serum (Reid 1986). Even at this 
comparatively low concentration, the cleavage of HMGB1 occurred efficiently 
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within the 30 minutes incubation period at 37°C (Figures 3.8 and 5.5 for C1 
complex treatment of apoptotic Jurkat T cells and U937 supernatant 
respectively). The efficient cleavage of HMGB1 by C1s requires its presence 
as C1 complex. This was consistent with previous experiment demonstrating 
that the C1 complex had a 7 fold higher efficiency as measured by the Kcat/Km 
value in cleaving a synthetic C4 cleavage site peptide as compared to activated 
C1s alone (O'Brien, Quinsey et al. 2003). Thus, physiologically, C1q not only 
acts to target C1s to the site where complement activation is required, such as 
antibody (IgG/IgM) bound pathogen or surfaces of ACs, but also at the same 
time, increases C1s catalytic efficiency. The cooperative effect of C1q and C1s 
in C1 complex demonstrates a facet of the intricacy of the biological system in 
targeting a proteolytic reaction to the required site where cleavage of a 
substrate can occur in a specific and efficient manner.  
 
The biological consequence of the disruption of this complex is illustrated by 
the rare case report of a male SLE patient with a point mutation that leads to 
an amino acid substitution of glycine by serine at position 63 of the C1q B-
chain (Gly63Ser) (Roumenina, Sene et al. 2011). The binding activity of this 
mutant C1q to Ig, pentraxins, and ACs remained intact and the serum C1s 
level was normal but C1 complex failed to form. Although not assessed 
directly with in-vitro phagocytic assay, the authors assumed that since the 
mutant C1q binding to ACs was normal, it should lead to its clearance as well. 
Hence, they concluded that C1q role in ACs clearance was insufficient to 
confer tolerance by itself. It was then likely that downstream classical 
complement factors C1s, C4 and C2 might play a role. However in their study, 
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C1q’s other biological function such as its ability to immuno-modulate DCs 
function was not studied for this mutant protein.              
   
This observed enzyme-substrate interaction between C1s and HMGB1 
released from ACs is significant and physiologically relevant because of the 
following reasons. 1) C1s is known to be recruited by C1q in conjunction with 
C1r as C1 complex (C1qr2s2) onto the surfaces of ACs with resultant 
complement activation occurring up to the level of C3b deposition (Zwart, 
Ciurana et al. 2004; Ogden, Kowalewski et al. 2005; Quartier, Potter et al. 
2005). 2) ACs are important sources of autoantigens and believed to be an 
important contributor to SLE pathogenesis (Casciola-Rosen, Anhalt et al. 
1994; Munoz, van Bavel et al. 2008). 3) HMGB1 is important in SLE 
pathogenesis and does so by various mechanisms including: a) its effect on 
DCs, b) its adjuvant-like effect when complexed with autoantigens and c) its 
role in the IFN-α axis. DCs and IFN-α are two important pathologic factors in 
SLE (Rahman and Isenberg 2008).  
 
DCs, as professional APCs, are important in its role in presenting antigens 
(both foreign and self-antigens) to T cells so that an adaptive effector response 
can be generated. HMGB1, as reviewed in chapter 1, causes DCs maturation 
with the acquisition of the ability to home in to lymphoid tissues where naïve 
T cells are located. HMGB1 enhances DCs ability to present antigens by 
causing the upregulation of the expression of MHC class II and co-stimulatory 
molecules (CD80, 83 and 86), as well as the secretion of cytokines necessary 
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for Th cells polarisation (such as IL-12p70) (Dumitriu, Baruah et al. 2005; 
Dumitriu, Bianchi et al. 2007; Yang, Chen et al. 2007). This will eventually 
result in a positive effect on T cells proliferation and survival (Messmer, Yang 
et al. 2004; Dumitriu, Baruah et al. 2005; Yang, Chen et al. 2007). 
 
In the case of SLE, it is likely that an inappropriate response in terms of DCs 
presenting autoantigens to and activating autoreactive T cells will be present. 
These autoreactive T cells will then provide the necessary T cell help to the 
autoreactive B cells which will lead to the eventual formation of pathogenic 
high affinity IgG autoantibodies due to the process of affinity maturation and 
isotype switching (Rahman and Isenberg 2008). In addition, HMGB1 appears 
to have an adjuvant-like effect when complexed with autoantigens (such as 
nucleosomes/DNA). Specifically, HMGB1-nucleosomes from apoptotic Jurkat 
T cells have been shown to induce cytokines production (TNF-α and IL-10) 
from Thioglycollate-elicited peritoneal MΦ and formation of autoantibodies of 
the IgG isotype (anti-histones and anti-dsDNA) in C57BL/6 mice in a TLR2 
dependent manner (Urbonaviciute, Furnrohr et al. 2008). In addition, HMGB1 
content of circulating DNA-containing ICs correlated positively with anti-
dsDNA titers in lupus patients and HMGB1 mediated this through the 
TLR2/MyD88 pathway (Wen, Xu et al. 2013).  
 
In regard to its effect on the IFN-α axis,  HMGB1 present in SLE DNA 
containing ICs has been found to be important in inducing PBMCs IFN-α 
production mediated by RAGE (Tian, Avalos et al. 2007). A potential key 
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contribution by IFN-α to disease progression is its ability to induce plasma 
cells differentiation for antibodies formation in conjunction with IFN-β and 
IL-6 (Jego, Palucka et al. 2003). How HMGB1 interacts with TLR2 (whether 
directly or indirectly through a binding partner) is unknown but the region that 
HMGB1 interacts with RAGE is known (Huttunen, Fages et al. 2002). 
 
C1s cleavage of HMGB1 was predicted to disrupt three of its known 
biological functions (Figure 6.1). Of primary interest in SLE will be the 
cleavage at the arginine residue at position 163 which cuts HMGB1 at the 
region known to bind to RAGE (amino acid residue position 150 to 183) 
(Huttunen, Fages et al. 2002). Of secondary interest will be the cleavage at 
arginine residue at position 97 which will disrupt the TLR4 interacting region 
(Li, Kokkola et al. 2003; Yang, Hreggvidsdottir et al. 2010) as well as disrupt 
HMGB1 ability to transfer LPS to CD14 and the subsequent signaling through 
TLR4 (Youn, Oh et al. 2008). However, how this cleavage influences the 
TLR2 mediated production of autoantibodies (Urbonaviciute, Furnrohr et al. 
2008; Wen, Xu et al. 2013) is unclear as the nature of the interaction between 





Figure 6.1: Schematic representation of C1s cleavage sites on HMGB1 and the 
biological functions that it will disrupt. Through bioinformatics prediction and 
subsequent experimental confirmation, C1s cleaved HMGB1 at arginine positions 97 
and 163. These 2 cutting sites would cleave HMGB1 at the region known to interact 
directly with TLR4 and RAGE. In addition, its ability to mediate the transfer of LPS 
to CD14 and subsequent TLR4 signaling would also be affected. There are 3 cysteine 
residues in HMGB1 of which the cysteine residues at position 23 and 45 are known to 
form intra-molecular disulphide bond. This form was found in the apoptotic Jurkat T 
cells supernatant and was cleavable by C1s. The two predicted fragments F1´ and F2´ 
were confirmed with in-vitro cleavage of rHMGB1 demonstrating the existence of 
these fragments.    
 
Using rHMGB1 with an N-terminal FLAG and a C-terminal polyhistidine 
tags, HMGB1 was cleaved at 2 sites consistent with the bioinformatics 
predicted cleavage sites (Figure 6.1). Two fragments, F1 and F2 (both having 
the N-terminal end of HMGB1), were visualised on western blot with a 
monoclonal anti-FLAG antibody (Figure 3.6). No fragment with the C-
terminal polyhistidine tag was seen. It was possible that the smaller fragments 
might have degraded during the 37°C incubation with C1 complex. Thus, this 
precluded the use of N-terminal protein sequencing to demarcate the cleavage 
sites. With the cleavage of prokaryotic expressed rHMGB1 that had an 
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apparent molecular weight similar to that predicted (24.9 kDa), two fragments, 
F1 and F2, were generated that migrated with molecular weights that 
approximated that of the predicted molecular weights of F1´ and F2´ (Figure 
3.7). This provided added strength and evidence that the C1s cleavage sites 
were at the arginine positions 97 and 163 although this was not supported by 
any direct evidence (for example, from N-terminal protein sequencing).     
 
6.1.1. C1s regulation of HMGB1-LPS synergistic effect  
Activated C1s treatment of eukaryotic expressed rHMGB1 obliterated its 
synergistic activity with LPS, experimentally confirming the predicted loss of 
this function from the C1s cleavage sites on HMGB1 (Figure 6.1). This 
provided additional confidence that the cleavage sites on HMGB1 as 
determined by other means (bioinformatics prediction and in-vitro cleavage 
studies) were correct. 
 
C1s was used at 2.75 μg/ml, a relatively low concentration as compared to 
serum level of about 50 μg/ml (Reid 1986). This C1s concentration was 
sufficient to cleave the rHMGB1 at 5 μg/ml after a 24 hours incubation period. 
When C1s and rHMGB1 were incubated at these same concentrations for 24 
hours in the presence of LPS and added at a 50X dilution into monocytes, MΦ 
and DCs cultures, HMGB1 pro-inflammatory synergistic activity with LPS 




Although the use of C1 complex will allow the rHMGB1 to be cleaved more 
efficiently, the effect of C1s cleavage of HMGB1 will not be able to be studied 
in isolation and it is possible that the presence of C1q found in C1 complex 
can confound the results. C1q by itself has been shown to reduce monocytes 
and MΦ cytokines (IL-1β and TNF-α) secretion in response to LPS 
stimulation (Fraser, Laust et al. 2009). This was similarly shown in moDCs 
where the presence of C1q down-regulated the LPS induced secretion of pro-
inflammatory cytokines such as TNF-α and IL-6 (Castellano, Woltman et al. 
2007; Teh, Yeo et al. 2011).  
 
As C1s cleavage of HMGB1 obliterates its synergistic pro-inflammatory effect 
with LPS and C1q has been shown to down-regulate LPS inflammatory 
response by other investigators, it is possible that when these two proteins are 
present as C1 complex, their anti-inflammatory effect against LPS maybe 
more pronounced. This hypothesis is potentially testable in-vitro with the co-
treatment of monocytes, MΦ and DCs with C1 complex or equimolar amount 
of C1q (found in the comparative C1 complex treatment) in the presence of 
LPS.  
 
Although the physiological significance of this phenomenon is currently 
unclear, it is interesting that C1s can cleavage HMGB1 and down-regulate its 
pro-inflammatory synergistic activity with LPS and that both C1s and 
HMGB1 can be produced by MΦ. HMGB1 can be secreted by tissue MΦ in 
response to endotoxin challenge (Wang, Bloom et al. 1999) and in return, it 
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has the ability to enhance LPS pro-inflammatory effect (a positive feedback 
loop) (Youn, Oh et al. 2008). In addition, HMGB1 can also act alone and have 
either a chemoattractant or cytokine inducing activity depending on its redox 
status (Venereau, Casalgrandi et al. 2012; Yang, Lundback et al. 2012). Both 
these activities are important aspects of the innate inflammatory response 
which will allow for the recruitment of leukocytes followed by their induction 
to secrete pro-inflammatory cytokines (Venereau, Casalgrandi et al. 2012). As 
both molecules are produced by MΦ and thus will be found within the same 
microenvironment, it is possible that C1s may have a regulatory activity on 
HMGB1 by cleaving and inactivating some if not all of its biological 
activities.  
 
HMGB1, at the concentrations of 50 to 100 ng/ml, led to the greatest increase 
in cytokines (TNF-α and IL-6) release in combination with LPS for monocytes 
and MΦ. This is clinically relevant as this concentration range of HMGB1 is 
found in patients with severe sepsis. In a prospective cohort of 25 patients with 
severe sepsis (bacteraemia and organ dysfunction), the HMGB1 concentration 
was found to be in the tens of ng/ml level. In addition, there was a statistically 
significant association between mortality and mean HMGB1 level (Survivors’ 
mean HMGB1 25.2 ng/ml versus non-survivors’ mean HMGB1 83.7 ng/ml, p 
< 0.05) (Wang, Bloom et al. 1999). This seems to suggest that HMGB1 can 
act as a prognostic bio-marker and potentially plays a role in sepsis 
pathogenesis. This is supported by mouse sepsis models where antagonism of 
HMGB1 appears to confer a survival advantage (Wang, Bloom et al. 1999; 
Yang, Ochani et al. 2004). In a more recent study, the HMGB1 level was also 
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found to be in the same range at 34 ± 76 ng/ml (mean ± SD) at the 144 hours 
sampling point from disease onset (n=59) (Sunden-Cullberg, Norrby-Teglund 
et al. 2005). 
 
Lastly, in regard to HMGB1 synergism with LPS in eliciting a pro-
inflammatory cytokines response, it is necessary to consider the effect of LBP, 
a protein with similar ability to transfer LPS to CD14 (Wright, Ramos et al. 
1990) . This is an important consideration as biological redundancy may occur 
such that even if in-vivo HMGB1 cleavage by C1s occurs, the outcome may 
not be as expected based on the results from the in-vitro study which 
demonstrates a loss of LPS pro-inflammatory effect with HMGB1. By 
considering this and taking it in right context, it will prevent an erroneous 
conclusion from being made. However, even though HMGB1 and LBP have 
similar ability to bind to LPS and transfer it to CD14 for subsequent TLR4 
activation and signaling, significant differences still exist between them  
(Youn, Oh et al. 2008). LBP is a much larger protein (50 kDa) as compared to 
HMGB1 (24.9 kDa), is synthesised by hepatocytes and found as a serum 
protein (Schumann, Leong et al. 1990). The source of HMGB1 is different and 
is either passively released from primary or secondary necrotic cells or 
actively secreted by immune cells that have encountered PAMPs. Hence, it is 
possible that these 2 proteins may have different roles to play in different 
microenvironments/body compartments and C1s cleavage of HMGB1 may 
only be a significant regulatory process in the tissue fluid spaces where cells 
such as tissue MΦ, which are able to secrete both HMGB1 and C1s, reside.   
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6.1.2. C1 complex cleaved HMGB1 and reduced PBMCs IFN-α secretion 
induced by SLE ICs   
PBMCs IFN-α production induced by SLE ICs was reduced with C1 complex 
in a dose dependent manner and this reduction was positively correlated with 
the loss of HMGB1 in the apoptotic U937 supernatant used as the source of 
autoantigens/DAMPs. A cleaved fragment (≈ 20 kDa) was detected with 
western blotting with a polyclonal anti-HMGB1 antibody in the C1 complex 
treatment U937 supernatant. This fragment was similarly observed with the in-
vitro cleavage of prokaryotic expressed His-tagged rHMGB1 with activated 
C1s (Figure 5.5 C).    
 
The purpose of our study is to determine how C1s may be involved in the 
regulation of the IFN-α axis when it is present as C1 complex and whether 
C1s proteolytic activity may play a role. The hypothesis that C1s may inhibit 
IFN-α production induced by SLE ICs is based on the observation that the 
cleavage site at arginine residue 163 lies within the region of HMGB1 that 
interacts with RAGE and the ability of SLE DNA containing ICs to stimulate 
PBMCs IFN-α production has been shown to be RAGE dependent (Tian, 
Avalos et al. 2007).  
 
Although the C1q component of C1 complex, by itself, has been shown to 
suppress SLE ICs induced IFN-α production, there is still uncertainty on the 
exact inhibitory mechanism involved (Lood, Gullstrand et al. 2009; Santer, 
Hall et al. 2010). Lood and coworkers demonstrated a direct suppressive effect 
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of C1q (70 μg/ml) on SLE ICs induced pDCs IFN-α production (Lood, 
Gullstrand et al. 2009). Contrary to this finding, Santer and colleagues instead 
demonstrated that the incubation of SLE ICs and C1q (50 μg/ml) with isolated 
pDCs resulted in an increase in IFN-α production rather than a suppression 
(Santer, Hall et al. 2010). However, an overall inhibitory IFN-α effect was still 
observed when PBMCs were used and the inhibitory mechanism was not due 
to a direct C1q effect on pDCs. In their study, it was shown that in the 
presence of C1q, SLE ICs were preferentially diverted away from the pDCs 
and sequestered in the early endosomes compartment of monocytes.  
 
In regard to the difference in C1q activity on pDCs SLE ICs induced IFN-α 
production, the most likely cause of this disparity was the difference between 
primed and unprimed pDCs (with the cytokines GM-CSF and IFN-α2b) 
among the other differences in terms of the format and the reagents used by 
these two groups of investigators (Table 6.1). Santer and his group of 
researchers opted not to prime their cells for two reasons that were mentioned 
in their publication. 1) They wanted a system that reflected the baseline state 
of the cells prior to SLE ICs stimulation. 2) In their system, the C1q inhibitory 
effect was more marked on unprimed than prime cells. Conversely, the cells 
used by Lood and coworkers were primed. It is uncertain which state (primed 
or unprimed) will reflect the truth but it is not preposterous to believe that both 
may occur in different clinical situations. For example in some cases, the cells 
maybe IFN-α primed due to an antecedent viral illness that can precede the 
onset of SLE (Rahman and Isenberg 2008).       
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Table 6.1: Experimental differences of in-vitro studies on the effect of C1q on 
SLE ICs induced IFN-α production.   




High dilution of SLE serum 
(1:2000).  
IgG purified from pooled anti-
ribonucleoprotein positive SLE 




Necrotic freeze thawed U937 
cells (1-2% v/v) (5   107/ml in 
Macrophage-SFM Medium). 
 
Necrotic freeze thawed Jurkat T 





PBMCs (5   106/ml) and pDCs 
(1 to 1.5   105/ml) 
 
PDCs purification: negative 
selection with pDCs isolation 
kit (Miltenyi Biotec, Auburn, 









medium supplemented with  
Penicillin (60 μg/ml) and 
Streptomycin (100 μg/ml). 
 
PBMCs (2   106/ml) and pDCs 
(2   105/ml) 
 
PDCs purification: negative 
selection with pDCs isolation kit 





Cytokines: 2 ng/ml GM-CSF 




Medium supplemented with 
Gentamicin (50 μg/ml).  
 
C1q  Up to 50 μg/ml 
 
Up to 70 μg/ml 
     
In our study, there was a negative correlation between the amount of HMGB1 
and % inhibition of IFN-α (Figure 5.6) and the proteolytic activity of C1 
complex was important in the reduction of IFN-α production induced by SLE 
ICs (Figure 5.8). The presence of C1s alone without the proteolytic cleavage 
of HMGB1 did not affect the IFN-α level (Figure 5.7). Although, the reduction 
of IFN-α was due to C1 complex proteolytic activity, it is still uncertain 
whether the direct cleavage of HMGB1 was responsible for the effect or 
secondary to cleavage of other proteins. The role of HMGB1 in SLE ICs 
induced IFN-α production in our in-vitro system has not been determined 
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conclusively as the source of our autoantigens is from UVC induced apoptotic 
U937 cells supernatant while that use by Tian and coworkers is from necrotic 
U937 cells supernatant from freeze-thaw cycles.  
 
In our study, HMGB1 exists in different redox forms in apoptotic and necrotic 
supernatant (Figure 5.10). This may cause HMGB1 to behave in a different 
manner in terms of its role in IFN-α production. Although, the importance of 
HMGB1 in our in-vitro system was assessed with the use of neutralising anti-
HMGB1 IgY antibody, the result was inconclusive as the inhibition of IFN-α 
production appeared to be due to the prevention of the formation of SLE ICs 
by the presence of IgY as the control IgY had a similar inhibitory effect 
(Figure 5.12). However, with the IFN-α inhibitory effect observed with the 
addition of different HMGB1 preparations, it seemed to suggest that HMGB1 
might play a role in our system (Figures 5.14 and 5.15). A possible mechanism 
for this observation is the competitive inhibition between free un-complexed 
rHMGB1 (exogenously added) and complexed HMGB1 (endogenously 
present) with partner molecule such as nucleosomes for the HMGB1 receptor 
that is necessary for its biological activity. This can be proven if reduced 
binding of the SLE ICs to the pDCs in the presence of exogenous HMGB1 can 
be demonstrated experimentally.     
 
In summary, C1 complex reduces the IFN-α response of healthy PBMCs 
(primed with IFN-αB2) to SLE ICs and its proteolytic activity is largely 
responsible for this inhibitory effect. C1 complex cleaves HMGB1 in the 
190 
 
apoptotic supernatant but it is still uncertain whether this is the main 
mechanism of the IFN-α reduction or the cleavage of another protein is 
responsible. The cleavage of HMGB1 may only be an indication of the 
presence of the proteolytic activity of C1 complex. It is also uncertain whether 
HMGB1 derived from ACs is as important in the IFN-α stimulating ability of 
SLE ICs as compared to HMGB1 derived from necrotic cells.  
 
6.2 C1S CLEAVED OTHER INTRACELLULAR PROTEINS INCLUDING 
A KNOWN SLE AUTOANTIGEN    
In addition to HMGB1, other putative protein targets of C1s were found 
through the use of mass spectrometry (Section 3.5). The identity of one of 
them, B23/Nucleophosmin, was validated with western blotting where a loss 
of this protein band in the supernatant was found with C1 complex treatment 
of the apoptotic Jurkat T cells (Figure 3.12). Of interest is that 
B23/Nucleophosmin has been described as an intracellular nucleolus 
autoantigen of SLE (Li, McNeilage et al. 1989). 
 
For the remaining putative targets, the bioinformatics C1s model was used to 
evaluate for potential cleavage sites within them and to determine if these sites 
were accessible or buried. Only sites accessible to C1s with no buried amino 
acid residues will have their PoPS scores reflected in table 6.2. Those with 
potential accessible C1s cleavage sites will be ranked according to their score 
from the highest (1) to the lowest (14). A search of existing literature, using 
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PubMed, was done for those that were ranked to determine if the targets had 
been described as an SLE autoantigens with autoantibodies found in humans.    
 
Two of the potential targets, heat shock protein 90 and ribosomal protein P0, 
stood out (Table 6.2). Autoantibodies to heat shock protein 90 and ribosomal 
protein P0 have been described in up to 50% and 42% of lupus patients 
respectively and both appear to correlate with disease activity (Sherer, 
Gorstein et al. 2004). It will be interesting to determine if the cleavage sites 
predictions on these substrates are true and then investigate whether the 
antigenic sites of these autoantigens are disrupted with C1s cleavage.  
 
The exact significance of the identification of a few autoantigens that are 
potential C1s substrates is unclear at the moment especially when considering 
that there are many SLE autoantibodies described (Sherer, Gorstein et al. 
2004). It is however possible that if the autoantigens that are targeted by SLE 
autoantibodies are of significant association with disease activity, its cleavage 
by C1s maybe important as a protective mechanism to prevent the excessive 





Bands Identified Proteins 
Accession 
numbers 
PoPS scores / 
sequences 
Ranks References (Proteins known as SLE autoantigens) 
A 
 
Elongation factor 2  IPI00186290 33.9 (Arg50-Ala51) 
ASAR-AGET 
9 (Alberdi, Dadone et al. 2001; Arora, Yang et al. 2002) 
Importin subunit beta-1 IPI00001639 Nil  - - 
Isoform 2 of Heat shock protein 
HSP 90-alpha 
IPI00382470 36.8 (Arg367-Val368) 
FVPR-RAPF 
7 (Minota, Koyasu et al. 1988; Conroy, Faulds et al. 1994; 
Conroy, Tucker et al. 1996; Stephanou, Latchman et al. 
1998; Ripley, Isenberg et al. 2001; Kenderov, Minkova et 
al. 2002; Dal Ben, Bisi et al. 2010)  
26S proteasome non-ATPase 
regulatory subunit 2  
IPI00012268 38.6 (Arg72-Pro73) 
SLYR-PALE 
5 Nil  
Transitional endoplasmic 
reticulum ATPase  
IPI00022774 29.4 (Arg745-Ser746) 
FARR-SVSD 
13 Nil  
B Isoform M2 of Pyruvate kinase 
isozymes M1/M2 
IPI00479186 Nil  - - 
T-complex protein 1 subunit eta IPI00018465 39.2 (Arg535-Gly536) 
AAGR-GRGR 
4 Nil  
T-complex protein 1 subunit zeta IPI00027626 33.1 (Arg15-Ala16) 
EVAR-AQAA 
12 * Nil  
T-complex protein 1 subunit alpha IPI00290566 Nil - Nil  
T-complex protein 1 gamma 
isoform C 
IPI00552715 34.3 (Arg20-Lys21) 
ESGR-KVQS 
8 Nil  
59kDa protein IPI00302925 Nil  - - 
T-complex protein 1 subunit delta IPI00302927 43.1 (Arg19-Gly20) 
AGGR-GKGA 
1 Nil 
Table 6.2: Cleavage sites analysis and association as SLE autoantigens for the potential novel C1s substrates identified by mass spectrometry. *, 
similar score with another protein; nil, literature search showed no published information on the protein being an SLE autoantigen; -, not ranked or literature 








PoPS scores / 
sequences 
Ranks References (Proteins known as SLE autoantigens) 
C Isoform alpha-enolase of Alpha-
enolase  
IPI00465248 Nil - - 
Elongation factor 1-alpha 1  IPI00396485 Nil - - 
cDNA FLJ56389, highly similar 
to Elongation factor 1-gamma 
IPI00000875 38.1 (Arg13-Ala14) 
VLRR-ARFA 
6 Nil  
Tubulin alpha-1C chain IPI00218343 Nil - - 
Proteasome 26S non-ATPase 
subunit 11 variant (Fragment) 
IPI00105598 39.9 (Arg90-Ser91) 
RLVR-SLLD 
3 Nil 
60S ribosomal protein L4 IPI00003918 40.7 (Arg291-Ile292) 
DLSR-ILKS 
2 Nil  
Hsc70-interacting protein  IPI00032826 33.1 (Arg250-Ile251) 
IKER-IERV 
12 * Nil 
D Isoform 2 of Nucleophosmin  IPI00220740 33.2 (Arg142-Ser143) 
SGKR-SAPG 
11 (Pfeifle, Anderer et al. 1986; Li, McNeilage et al. 1989) 
Glyceraldehyde-3-phosphate 
dehydrogenase  
IPI00219018 Nil - - 
60S acidic ribosomal protein P0 IPI00008530 34.3 (Arg112-Ala113) 
AAAR-AGAI 
10 (Arnett, Reveille et al. 1996; Isshi and Hirohata 1996; 
Chindalore, Neas et al. 1998; Isshi and Hirohata 1998; 
Reichlin, Broyles et al. 1999; Ghirardello, Doria et al. 2000; 
Tzioufas, Tzortzakis et al. 2000; Toubi and Shoenfeld 
2007) 
Transaldolase  IPI00744692 27.4 (Arg8-Gln9) 
PVKR-QRME 
14 Nil  
Actin, cytoplasmic 1  IPI00021439 Nil  - - 
Table 6.2 (continued).*, similar score with another protein; nil, literature search showed no published information on the protein being an SLE autoantigen; -, 




It will be interesting if C1s cleavage does destroy the immunogenicity of some 
of these autoantigens and preventing them from being available to the 
autoreactive T and B cells as well as preventing the formation of ICs with pre-
existing circulating autoantibodies in lupus patients. However, this remains a 
postulation that has yet been proven. One of these identified proteins, 
transaldose, although not described as an SLE autoantigen, has been described 
to be a significant target of autoantibodies found in multiple sclerosis, another 
autoimmune disease (Banki, Colombo et al. 1994; Colombo, Banki et al. 1997; 
Esposito, Venkatesh et al. 1999; Niland and Perl 2004). 
 
6.3 CLINICAL SIGNIFICANCE OF STUDY  
The results of this study will allow us to view the classical complement serine 
protease C1s in a new light. Classical complement system activation with 
binding of C1 complex (C1qr2s2) to the IgG after deposition of ICs in end-
organs such as the renal basement membrane has been believed to be the cause 
of tissue injury (Rahman and Isenberg 2008). Instead of a solely pathogenic 
role in SLE, the potential protective role of C1s cleavage of HMGB1 and 
autoantigens that may lead to the destruction of its alarmin and immunogenic 
activities respectively, allow us to understand the role that the complement 
system may play in autoimmunity more completely. When considered C1s as 
part of C1 complex, C1s ability to cleave HMGB1 and autoantigens 
potentially can add another layer of protection to the activity of C1q which is 
important for ACs clearance. In the situation where ACs clearance is delayed, 
the importance of C1s ability to cleave and potentially inactivating these 
proteins may increase in importance. This will add on to our current 
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understanding of the clearance (or waste) disposal hypothesis of SLE 
pathogenesis (Walport 2001; Carroll 2004). 
 
6.4 LIMITATIONS OF STUDY  
 
6.4.1 Limitation of bioinformatics C1s protease model 
The major limitation of the C1s protease model is the lack of ability to assign a 
negative value (0 to -5) for the amino acid specificity for each subsite. The 
reason is because of the inherent nature of the randomised phage display 
substrate system where a lack of cleavage just reflects the failure of cleavage 
but will not provide information whether it negatively influenced the cleavage 
(Section 2.1.1). Hence, substrates that have amino acid residues that hinder 
C1s-cleavage site interactions will have a PoPS score that is higher than 
expected. This limits the potential use of the model to screen the human 
proteome as large number of proteins which may have lower PoPS score will 
not be eliminated. It is possible to assign a negative value based on the 
knowledge derived from the crystal structure of C1s catalytic fragment 
(Gaboriaud, Rossi et al. 2000) but this will not have been verified with kinetics 
study with synthetic peptide substrates.  
 
6.4.2 Limitation of in-vitro study of C1 complex on SLE ICs induced PBMCs 
IFN-α secretion     
The use of PBMCs instead of purified pDCs was decided for two reasons. 
First, it would be more physiologically relevant to use a complex mixture 
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consisting of mono-nuclear cells that already existed together in the 
bloodstream and also because the cells might interact with each other 
influencing the eventual response to a stimuli. Interaction between different 
populations of PBMCs was demonstrated in the study by Santer and 
colleagues where the diversion of C1q bound SLE ICs prevented it availability 
to pDCs to cause IFN-α production (Santer, Hall et al. 2010). The second 
reason was practical in nature where the experimental design would be 
simplified with the use of PBMCs and prevented the problem of the low yield 
of pDCs purification from human blood. However, the study is hence limited 
by the inability to study the specific mechanism on how C1 complex may 
affect pDCs IFN-α production directly.  
 
6.5 FUTURE WORK 
6.5.1 Definitive delineation of C1s cleavage sites on HMGB1 
Although the results suggest that the cleavage sites are at arginine at position 
97 and 163, definitive proof of the sites has not been determined. Potentially, 
this can be achieved through the use of site directed mutagenesis to mutate the 
arginine residue at these two positions to glycine in the pre-existing FLAG-
rHMGB1-His construct in the pcDNA 3.1 A mammalian expression vector 
and the mutant protein produced with transient transfection of HEK293T cells 
using the calcium phosphate transfection protocol. The mutant protein, after 
purification, can be subjected to treatment by C1 complex to determine if 




6.5.2 Potential anti-inflammatory role of cleaved HMGB1 fragment from 
amino acid residues 1 to 97  
C1s cleavage of HMGB1 generates a fragment from amino acid residue 
positions 1 to 97. This fragment consists of the A-box and the first 10 amino 
acid residues of B-box. It is known that HMGB1 A-box (from amino acid 
residues position 1 to 85) can antagonise HMGB1 effects in-vitro (murine MΦ 
cell-line, RAW 264.7 cells, TNF-α and IL-1β secretion) and in-vivo (2 models: 
polymicrobial murine sepsis model with caecel ligation with puncturing, and 
LPS injection) (Yang, Ochani et al. 2004). It will be interesting to determine if 
this HMGB1 fragment from amino acids 1 to 97 has the same antagonistic 
effect as A-box alone. To test this, a truncated rHMGB1 from amino acid 
residues 1 to 97 can be produced and added in increasing amount to the full 
length rHMGB1 and LPS in the stimulation of monocytes, MΦ and DCs. If the 
truncated rHMGB1 has antagonistic effect, an increasing suppression of pro-
inflammatory cytokines (TNF-α and IL-6) will be observed with increasing 
amount of the truncated protein.     
 
Information from this additional study will be physiologically interesting as if 
an antagonistic fragment is formed from C1s cleavage, it may enhance the 




6.5.3 What is the effect of C1 complex on both IFN-α primed and unprimed 
pDCs?  
As C1q has a different effect on SLE ICs induced pDCs IFN-α production 
based on the presence or absence of IFN-α and GM-CSF priming. It will be 
interesting to look at the effect of C1 complex on the SLE ICs as a whole in 
these two different in-vitro systems. Priming may reflect a disease onset 
triggered by an antecedent viral infection while a lack of priming may reflect 
the baseline prior to the onset of disease. It is possible that both states may 
exist in different patients/clinical conditions. It is perceivable that the 
additional presence of the proteolytic activity of C1s may alter the C1q bound 
SLE ICs stimulation of pDCs observed by Santer and coworkers in unprimed 
pDCs (Santer, Hall et al. 2010). If this proves to be true, C1 complex may then 
provide two inhibitory mechanisms against SLE ICs induced IFN-α 
production in unprimed PBMCs. One involves the diversion of the SLE ICs to 
monocytes through the action of C1q and prevents the uptake of these 
immuno-stimulatory complexes by pDCs. The second involves the proteolytic 
action of C1s on proteins found within the SLE ICs.    
 
6.5.4 Can other proteolytic targets of C1s be determined more specifically? 
The use of SDS-PAGE separation of proteins to determine novel C1s 
substrates through the loss or reduction in intensity of its band with C1 
complex treatment is limited by its resolving ability. It is possible to replicate 
the experimental setup using C1 complex alone, C1 complex treated apoptotic 
Jurkat T cells supernatant and untreated apoptotic Jurkat T cells supernatant 
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and compare these mixtures after separation through the use of conventional 2-
D gel electrophoresis or 2-D Fluorescence Difference Gel Electrophoresis (2D 
DiGE). The use of this technique will allow us to identify the protein target 
with greater accuracy and specificity. Subsequent spot excision after staining 
can be done so that the identity of the protein whose spot disappears with C1 
treatment can be determined.    
 
6.5.5 Does C4b plays a role in capturing autoantigens for C1 complex 
cleavage?    
Physiologically, many of the C4b molecules are bound near to C1 complex to 
ensure that the formation of C3 convertase (C4bC2a) is located close to the 
site of activation. The binding of C2 to C4b and the cleavage of C2 by 
activated C1 complex are important steps leading to the formation of C3 
convertase. Only C4b bound close to the activator site carrying C1 complex 
will form the C3 convertase (Reid 1986). Hence, the binding of C2 to C4b is 
important for subsequent cleavage of C2 by C1s.  
 
Therefore, it is potentially interesting to look into and determine the protein-
protein interacting sites between C4b and C2 and to investigate if proteins 
other than C2 have similar interacting domains through in-silico analysis. In 
addition, protein-protein interaction studies using pull-down assay with solid 
phase bound C4b can be carried out and the identities of the interacting 
partners determine using mass spectrometry. Interesting hits that are of 
relevance to SLE can then be studied in greater detail. This can include the 
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determination whether cleavage sites of C1s exist in these proteins and are 
cleavable by C1s. If these proteins that interact with C4b are found cleavable 
by C1s, this will mimic the relationship between C4b and C1s where C4b 
binds to C2 to allow its cleavage by C1s in C1 complex.    
 
6.5.6 Does C1 complex cleavage of autoantigens from ACs affect the binding 
by autoantibodies found in SLE patients? 
The discovery of other potential cleavage targets of C1s that are found in the 
apoptotic Jurkat T cells supernatant gives rise to the question whether cleavage 
of these autoantigens affect its binding to autoantibodies. To evaluate for this 
possibility, western blot technique will be used with the lupus patients’ sera as 
a source of autoantibodies. Their binding to proteins found in apoptotic 
supernatant and apoptotic bodies with and without treatment with C1 complex 
(C1qr2s2) will be assessed to look for a loss of binding in the C1 complexed 
treated supernatant signifying a loss of the antigenic sites. This will allow us to 
determine the linear epitopes that are disrupted as the result of this cleavage. 
Specifically, patients’ sera that contained anti-heat shock protein 90, anti-
B23/nucleophosmin and anti-ribosomal protein P0 through screening using an 
ELISA formation with coated purified proteins will be used for this purpose 
once the cleavage of these autoantigens have been determined in-vitro through 
the use of western blot detection with antibodies directed against these 
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